BLUK122-Dijkstra
September 28, 2007
19:12
Trans Fatty Acids
i
BLUK122-Dijkstra
September 28, 2007
19:12
Trans ...
390 downloads
2345 Views
3MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
BLUK122-Dijkstra
September 28, 2007
19:12
Trans Fatty Acids
i
BLUK122-Dijkstra
September 28, 2007
19:12
Trans Fatty Acids Edited by
Albert J. Dijkstra Richard J. Hamilton Wolf Hamm
iii
BLUK122-Dijkstra
September 28, 2007
19:12
C 2008 by Blackwell Publishing Ltd
Blackwell Publishing editorial offices: Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK Tel: +44 (0)1865 776868 Blackwell Publishing Professional, 2121 State Avenue, Ames, Iowa 50014-8300, USA Tel: +1 515 292 0140 Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia Tel: +61 (0)3 8359 1011 The right of the Author to be identified as the Author of this Work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. First published 2008 by Blackwell Publishing Ltd ISBN: 978-1-4051-5691-2 Library of Congress Cataloging-in-Publication Data Trans fatty acids / edited by Albert J. Dijkstra, Richard J. Hamilton, Wolf Hamm. p. ; cm. Includes bibliographical references and index. ISBN: 978-1-4051-5691-2 (hardback : alk. paper) 1. Trans fatty acids. I. Dijkstra, Albert J. II. Hamilton, R. J. (Richard John) III. Hamm, Wolf. [DNLM: 1. Trans Fatty Acids. QU 90 T774 2007] QP752.T63.T82 2007 612.3 97 – dc22 2007032665 A catalogue record for this title is available from the British Library Set in 10/12 pt Times by Aptara Inc., New Delhi, India Printed and bound in Singapore by COS Printers Pte Ltd The publisher’s policy is to use permanent paper from mills that operate a sustainable forestry policy, and which has been manufactured from pulp processed using acid-free and elementary chlorine-free practices. Furthermore, the publisher ensures that the text paper and cover board used have met acceptable environmental accreditation standards. For further information on Blackwell Publishing, visit our website: www.blackwellpublishing.com
iv
BLUK122-Dijkstra
September 28, 2007
19:12
Contents
Contributors Preface
1
Fatty acids: structure, occurrence, nomenclature, biosynthesis and properties Richard J. Hamilton 1.1 1.2
1.3 1.4
1.5
1.6 2
Introduction Fatty acid nomenclature 1.2.1 Saturated acids 1.2.2 Monounsaturated acids 1.2.3 Diunsaturated acids 1.2.4 Triunsaturated acids Occurrence Fatty acid biosynthesis 1.4.1 Saturated fatty acids 1.4.2 Monoenoic fatty acids 1.4.3 Polyunsaturated fatty acids Properties of trans fatty acids 1.5.1 Melting points 1.5.2 Ultraviolet spectra 1.5.3 Infrared spectra 1.5.4 Nuclear magnetic resonance spectroscopy Labelling and legislation
ix xi
1 1 2 2 4 7 7 7 12 12 12 14 15 17 18 20 22 23
Trans fatty acids intake: epidemiology and health implications Geok Lin Khor and Norhaizan Mohd Esa
25
2.1 Introduction 2.2 Food sources of trans fatty acids 2.3 Trans fatty acids intake 2.4 Trans fatty acids in human milk 2.5 Trans fatty acids intake and health implications 2.5.1 Coronary heart disease 2.5.2 Diabetes 2.5.3 Cancer 2.6 Concluding remarks
25 26 30 39 40 40 43 44 45
BLUK122-Dijkstra
vi
3
September 28, 2007
19:12
Contents
Conjugated linoleic acid effects on body composition and clinical biomarkers of disease in animals and man: metabolic and cell mechanisms Klaus W.J. Wahle, Marie Goua, Simona D’Urso and Steven D. Heys 3.1 General introduction: conjugated linoleic acids and health 3.2 Structure, dietary origins and consumption of CLAs in man 3.2.1 Structure 3.2.2 Origins of CLAs in the human diet 3.2.3 Dietary consumption of CLAs in man 3.3 CLAs in cancer prevention and treatment 3.3.1 Epidemiology of dietary fats and cancer risk 3.3.2 CLAs and breast cancer 3.3.3 CLAs and prostate cancer 3.3.4 CLAs in gastrointestinal cancer 3.3.5 CLAs and other cancers (hepatic, pancreatic and dermal) 3.4 Cellular mechanisms of CLAs’ anti-cancer effects 3.4.1 Inhibition of angiogenesis 3.4.2 Attenuation of cancer metastasis 3.4.3 Reduction of cancer cachexia 3.5 Effect of CLAs on body composition and energy metabolism in animals and men 3.5.1 Body composition in animals 3.5.2 Body composition in man 3.5.3 Possible mechanisms underlying reported changes in body composition 3.5.4 Efficacy of different CLA isomers in regulating body composition 3.6 Other reported health benefits of CLAs 3.6.1 Effects on insulin resistance and diabetes 3.6.2 Modulation of immune functions 3.6.3 Effects of CLAs on biomarkers of cardiovascular disease 3.7 Reported adverse health effects of CLAs in vivo and in vitro 3.8 Conclusions
4
54 54 55 55 56 59 59 60 60 62 64 66 67 72 73 74 75 75 76 78 78 79 80 81 87 90 91
Analysis of trans mono- and polyunsaturated fatty acids Jean-Louis S´eb´edio and W.M. Nimal Ratnayake
102
4.1 4.2 4.3 4.4
102 102 106 106 106 111 113
Introduction Isomeric fatty acids in the human diet Gas chromatography and Fourier transform infrared spectroscopy Direct GC analysis 4.4.1 Analysis of monounsaturated isomers 4.4.2 Isomers of linoleic and -linolenic acids 4.4.3 Resolution of eicosenoic and -linolenic acid isomers 4.4.4 Effect of the type of carrier gas and flow rate on cis and trans isomer resolution and fatty acid quantification 4.4.5 Conjugated fatty acids 4.5 Silver nitrate thin-layer and high-performance liquid chromatography separation of cis and trans isomers
114 116 123
BLUK122-Dijkstra
September 28, 2007
19:12
Contents
4.6 4.7 5
Controlling physical and chemical properties of fat blends through their triglyceride compositions Albert J. Dijkstra 5.1 5.2 5.3 5.4
5.5 6
4.5.1 Monounsaturated fatty acid isomers 4.5.2 Conjugated fatty acids Utilisation of pre-fractionation steps prior to chromatographic analysis: the case of dairy fats Conclusion
Introduction Defining triglyceride compositions Melting points and sfc The effect of oil processing on triglyceride groups 5.4.1 Hydrogenation 5.4.2 Fractionation 5.4.3 Interesterification 5.4.4 Other oil treatments Using triglyceride groups in product development
vii
123 125 127 128
132 132 133 135 136 136 138 139 141 143
Trans isomer control in hydrogenation of edible oils Annemarie Beers, Rob Ariaansz and Douglas Okonek
147
6.1
147 147 147 147 148 148 149 149 149 149 150 150 151 151 153 157 158 160 160 162 162 163 169 169 175
6.2
6.3
6.4
6.5
6.6
Introduction 6.1.1 Hydrogenation process 6.1.2 History of hydrogenation 6.1.3 Reasons for hydrogenation Isomerisation 6.2.1 Geometric and positional isomerisation 6.2.2 Controlling isomerisation Reaction mechanism 6.3.1 ‘Half-hydrogenated’ intermediate 6.3.2 Saturation, positional and geometric isomerisation Industrial hydrogenation 6.4.1 Batch process 6.4.2 Reactor types and features 6.4.3 Reaction parameters 6.4.4 Influence of feedstock on trans 6.4.5 Influence of reaction conditions on trans 6.4.6 Influence of catalyst on trans 6.4.7 Influence of reactor design on trans 6.4.8 Trans isomer control New developments in low trans hydrogenation 6.5.1 Alternative reaction conditions 6.5.2 Alternative hydrogenation processes 6.5.3 Hydrogenation additives 6.5.4 Alternate catalysts Summary
BLUK122-Dijkstra
viii
7
9
19:12
Contents
Fractionation and interesterification Wim De Greyt and Albert J. Dijkstra
181
7.1 7.2
181 182 182 183 185 185 187 191 191 192 196 198
7.3
8
September 28, 2007
Introduction Fractionation 7.2.1 Historical 7.2.2 Fat crystallisation theory 7.2.3 Fat crystallisation practice 7.2.4 Separation processes 7.2.5 Fractionation products Interesterificaton 7.3.1 Historical 7.3.2 Interesterification mechanism 7.3.3 Interesterification practice 7.3.4 Interesterification products
Food applications of trans fatty acids John Podmore
203
8.1 Introduction 8.2 Margarine 8.2.1 Table margarine 8.2.2 Cake margarine 8.2.3 Pastry margarine 8.3 Biscuit fats 8.3.1 Dough fats – short dough biscuits 8.3.2 Dough fat – laminated biscuits 8.3.3 Cream filling fat 8.4 Fats for chocolate confectionery 8.5 Fats for sugar confectionery 8.6 Vanaspati 8.7 Synthetic creams 8.7.1 Whipped toppings 8.7.2 Coffee whiteners 8.8 Concluding remarks
203 205 205 208 209 210 210 211 211 211 214 215 216 216 216 217
Food products without trans fatty acids Pernille Gerstenberg Kirkeby
219
9.1 Introduction 9.2 Fat phase 9.3 Margarine and related products 9.4 Manufacturing process 9.5 Optimal processing conditions 9.6 Final remarks
219 219 222 225 230 233
Index The colour plate section follows page 228
235
BLUK122-Dijkstra
September 28, 2007
19:12
Contributors
Rob Ariaansz BASF Nederland B.V. De Meern, The Netherlands Dr Annemarie Beers BASF Nederland B.V. De Meern, The Netherlands Dr Wim De Greyt De Smet Technologies & Services Zaventem, Belgium Dr Albert J. Dijkstra Consultant to the Oils and Fats Industry St Eutrope-de-Born, France Simona D’Urso Department of Zootechnological Sciences and Nutrition Frederico II University of Napoli Naples, Italy Dr Norhaizan Mohd Esa Department of Nutrition and Dietetics Faculty of Medicine and Health Sciences Universiti Putra Malaysia Serdang, Malaysia Pernille Gerstenberg Kirkeby Gerstenberg Schroeder A/S Brondby, Denmark Dr Marie Goua The Robert Gordon University School of Life Sciences Aberdeen, UK Professor Richard J. Hamilton Consultant in Oils and Fats Chemistry Merseyside, UK
Wolf Hamm Harpenden, UK Professor Steven D. Heys Department of Surgical and Nutritional Oncology Medical School, Aberdeen University Aberdeen, UK Professor Geok Lin Khor Department of Nutrition and Dietetics Faculty of Medicine and Health Sciences Universiti Putra Malaysia Serdang, Malaysia Douglas Okonek BASF Catalysts LLC Iselin, NJ, USA John Podmore Consultant to the Oils and Fats Industry Liverpool, UK Dr W.M. Nimal Ratnayake Nutrition Research Division Food Directorate Health Products and Food Branch Health Canada Ottawa, Ontario, Canada Professor Jean-Louis S´eb´edio INRA, Unit´e de Nutrition Humaine Mass Spectrometry Platform Saint Gen`es Champanelle, France Professor Klaus W.J. Wahle The Robert Gordon University School of Life Sciences Aberdeen, UK
BLUK122-Dijkstra
September 28, 2007
19:12
Preface
Over the last several decades, a great deal of work has been carried out on trans fatty acids within a number of interrelated fields, such as nutrition, health, food science and industrial processing. In chapters written by leading experts, this volume offers a clear perspective of the current position of trans fatty acids in commerce and academic research. The book is designed as an aid to researchers and professionals in nutrition and health and those providing analytical services to the food industry. Readers seeking ways to formulate oil blends without trans fatty acids and those wishing to alter the composition of oils and fats by means of interesterification, fractionation and hydrogenation will find a large amount of research described and many applications outlined. They will also find methods of adjusting the formulation of their products and their processing. The book is written in a readerfriendly style, which will permit newcomers to the area to grasp the ways in which the field is progressing. Each chapter contains many of the latest references and significant areas of research. Chapter 1 introduces trans fatty acids and puts them in their proper context in relation to the many other saturated and unsaturated acids found in nature. It shows how trans acids are produced both in industry and by natural biohydrogenation in animals and plants. It outlines some of the properties of trans fatty acids and contrasts them with those of their cis isomers. Chapters 2 and 3 deal with the health implications and the epidemiology of trans fatty acids. Intakes of trans acids in the USA, Central America, Nigeria, Iran, India, China, Hong Kong, New Zealand, Australia, Hungary, the Czech Republic, Poland, Bulgaria and Spain are considered. A number of studies, e.g. the Zutphen Elderly, the Scottish Heart and Health, the Seven Countries, the Nurses Health and the EURAMIC case control, have been referenced. The results are considered without bias and the authors are not afraid to point out where further research is needed to confirm the original conclusions. In the consideration of conjugated linoleic acid (Chapter 3), the authors discuss the synthetic products that can be used for human and animal supplementation. With the realization that not all trans fatty acids have the same biological effect came the realization that it is important to know more than just the total trans fatty acid content in a food. Chapter 4 explains how direct GC, GC-MS, AgNO3 -TLC and HPLC are used to determine the trans fatty acid composition of various food products. Some recommendations for the best analysis of cis/trans monounsaturated fatty acids are given, whilst the need for pre-fractionation in some instances is highlighted. Chapter 5 introduces the concept of triglyceride groups and demonstrates that, for most components used in constituting fat blends, the triglyceride group composition can be calculated. It illustrates how hydrogenation, fractionation and interesterification cause the triglyceride group composition to change and it also highlights how product development can be facilitated by specifying fat blends on the basis of their triglyceride group composition. Chapter 6 provides a wide survey of the industrial hydrogenation process in the field of edible oil processing, its mechanism and how process parameters affect the trans fatty acid
BLUK122-Dijkstra
xii
September 28, 2007
19:12
Preface
content of the hydrogenation product. In addition, the chapter provides insight into the latest developments comprising the use of catalysts other than the usual nickel, the use of additives and unconventional process conditions and their effect on trans fatty acid formation. Chapter 7 deals with major modification processes that do not alter the trans fatty acid content of the oil or fat being processed: fractionation and interesterification. After outlining the basics, examples are provided that illustrate what kind of products suitable for low-trans or trans-free oil blends can be arrived at by these modification processes. The last two chapters are food product oriented and cover both compositional and processing aspects. Chapter 8 reviews products such as various margarines, dough fats and shortenings that still contain trans fatty acids. In Chapter 9, their low-trans or trans-free equivalents are introduced and their processing requirements highlighted. Solutions are provided for dealing with slow crystallisation of low-trans fat blends, which cover both the use of adjuvants and the adaptation of the cooling equipment and its process conditions. We express our thanks to the authors for their excellent contributions that provide fresh insight into this interesting and exciting field of study. We are indebted to our friends and colleagues for their helpful comments and criticisms. Finally, we are grateful for all the help we have received from Blackwell Publishing. Albert J. Dijkstra Richard J. Hamilton Wolf Hamm
BLUK122-Dijkstra
September 25, 2007
1
19:41
Fatty acids: structure, occurrence, nomenclature, biosynthesis and properties
Richard J. Hamilton
1.1
INTRODUCTION
Trans fatty acids have been present in the Western diet for as long as milk and butter have been staple commodities. However, in the last century with the discovery of catalytic hydrogenation by Sabatier and Senderens (Hastert, 1996; Hoffmann, 1989), food technologists came to recognise the improved physical characteristics which trans fatty acids could bestow on food products. The protection of the foodstuffs from the off flavours, which developed when highly unsaturated oils were incorporated into foods, was an added advantage which hydrogenation gave. However, in the last 50 years, studies have been conducted into the effects of increased quantities of trans fatty acids on human health and nutrition. The result has been the requirement for food processors to be able to claim that they have low or no trans fatty acids in their products (Korver and Katan, 2006). To appreciate the reason for this changed consideration, we first need to look at the constituents of oils and fats. As far as the world production is concerned, the major vegetable oils and fats are soya, palm, rape (canola), sunflower, cotton, groundnut, coconut, palm kernel and corn. The major animal fats, by comparison, are butter, tallow, lard and fish. During the year 2005, the production split between the animal and vegetable groups of oils and fats was 78.5% vegetable oils and 21.5% animal fats. In Chapters 8 and 9 on applications, we will see how the two sources of oils and fats are utilised. Oils and fats are made up of:
r r r r
lipids, viz. triacylglycerols (also called triglycerides), diacylglycerols (diglycerides), waxes, phosphoglycerols, sphingolipids, free fatty acids and hydrocarbons; certain vitamins; pigments and antioxidants.
These lipids cover a wide range of different chemical structures but there are two common features. Most lipids are water insoluble and they can all be biosynthetically related to fatty acids. The triacylglycerols account for 90–95% by weight of oils and fats and in many senses are the most important part of these items of commerce. A generalised formula for a triacylglycerol is shown in Fig. 1.1.
BLUK122-Dijkstra
2
September 25, 2007
19:41
Trans Fatty Acids O
H2C
O
R2
C
O
CH
H2C Fig. 1.1
O
C
R1
O
O
C
R3
General formula for a triacylglycerol.
If the fatty acids in this triacylglycerol, R1 COOH, R2 COOH and R3 COOH, are all identical, i.e. R1 = R2 = R3 , the triacylglycerol would be referred to as a monoacid triacylglycerol or a single-acid triacylglycerol. More usually, each triacylglycerol will have two or three different fatty acids. Gunstone (1967) claimed that over 300 fatty acids were known in nature. By the time of a more recent book in 1996, he estimated that there were over 1000 fatty acids (Gunstone, 1996). Thus the diversity of these oils and fats (Gunstone, 2004) is considerable as will be manifested in Chapter 4 on analysis. One simplifying feature is that the major fatty acids, in nature, have an even number of carbon atoms. In addition, there are usually only five to seven major fatty acids in most commercially important oils and fats.
1.2
FATTY ACID NOMENCLATURE
Fatty acid nomenclature is complicated by the fact that many acids were well known before any system of naming them had been determined. Thus the names of oleic, stearic and palmitic acids were well established before any rules were developed.
1.2.1
Saturated acids
Fatty acids are named according to the number of carbon atoms in the chain. In turn, the name of the fatty acids refers back to the name of the saturated hydrocarbon with the same number of carbon atoms. So stearic acid has 18 carbon atoms and is related to the alkane with 18 carbon atoms, i.e. octadecane. To obtain the name of the acid, the ‘e’ is removed from octadecane giving ‘octadecan’ and the ending ‘oic’ is added to indicate the carboxylic acid. Thus, octadecan(e) → octadecan(oic) acid → octadecanoic acid, which is the full and correct name for stearic acid. Whilst it is convenient to use the trivial names, such as oleic and linoleic acid, many of the acids encountered later in our discussions have no simple trivial names. Even the use of formulae, as given in Tables 1.1 and 1.2, is not very quick and easy. An alternative shorthand method has been devised. This system reduces the acid to the minimum statement that is needed to define it.
Chain length 4
6
8
10
12
14
16
18 20 22
4:00
6:00
8:00
10:00
12:00
14:00
16:00
18:00
20:00
22:00
Docosanoic
Eicosanoic
Octadecanoic
Hexadecanoic
Tetradecanoic
Dodecanoic
Decanoic
Behenic
Arachidic
Stearic
Palmitic
Myristic
Lauric
Capric
Caprylic
Caproic
Butyric
Common name
C H2
C H2
C H2
C H2
C H2
C H2
C H2
C H2
H2 C
H2 C
H2 C
H2 C
H2 C
H2 C
H2 C
H2 C
CH3 (CH2)20 COOH
CH3 (CH2)18 COOH
H3C
H3C
H3C
H3C
H3C
H3C
H3C
H3C
Structure
C H2
C H2
C H2
C H2
C H2
C H2
C H2
H2 C
H2 C
H2 C
H2 C
H2 C
H2 C
H2 C
COOH
C H2
C H2
C H2
C H2
C H2
C H2
H2 C
H2 C
H2 C
H2 C
H2 C
H2 C
COOH
C H2
C H2
C H2
C H2
C H2
H2 C
H2 C
H2 C
H2 C
H2 C
COOH
C H2
C H2
C H2
C H2
H2 C
H2 C
H2 C
H2 C
COOH
C H2
C H2
C H2
H2 C
H2 C
H2 C
COOH
C H2
C H2 H2 C
H2 C
COOH
C H2
H2 C
COOH
COOH
September 25, 2007
Octanoic
Hexanoic
Butanoic
Proper name
Structures of saturated fatty acids.
Shorthand notation
Table 1.1
BLUK122-Dijkstra 19:41
Structure, occurrence, nomenclature, biosynthesis and properties 3
BLUK122-Dijkstra
4
September 25, 2007
19:41
Trans Fatty Acids
In the case of stearic acid, first the total number of carbon atoms in the chain is stated, i.e. 18, and then the number of double bonds is given which, in the case of stearic acid, is 0. The shorthand system then inserts a colon between the number of carbon atoms and the number of double bonds and so, for stearic acid, the shorthand is 18:0. Stearic acid is shown in Table 1.1, where the long straight chain is given by the zigzag representation. Some of the main straight-chain saturated fatty acids are also given in Table 1.1.
1.2.2
Monounsaturated acids
Oleic acid is an unsaturated fatty acid that can be represented by the formula shown in Fig. 1.2. Thus oleic acid has 18 carbon atoms, and it has one double bond at position 9 from the carboxyl end. Since oleic acid has 18 carbon atoms and one ethylenic double bond, the name is based on octadecene. In this instance the ‘e’ is removed and the ending for the carboxylic acid group octadecen(e) → octadecen(oic) acid. Thus is added 9-octadecenoic acid. In the case of oleic acid, the double bond is in the cis configuration (also called the Z configuration from the German zusammen, meaning together). Thus to specify oleic acid precisely, the full name would be 9c-octadecenoic acid or 9Z -octadecenoic acid. An isomer of oleic acid is elaidic acid, which has a trans double bond at the 9-position. The shorthand for this acid would therefore be 9t-octadecenoic acid. If the EZ system is to be used, the letter referring to the trans configuration is E, which stands for the German word entgegen, meaning opposite. These two acids are shown in Fig. 1.2. From a chemist’s point of view, the most important part of a fatty acid is the carboxylic acid group. The position of the double bond is therefore quoted with reference to the carboxylic acid group, i.e. 9 in the case of oleic acid. Using the shorthand method oleic acid is 18:1. Since the double bond is at the ninth carbon atom and the configuration of the double bond is cis, the name becomes 9c-18:1. It is also possible to denote the position of the double bond by using the symbol . Oleic acid is described as a 9 acid, whilst petroselinic acid is a 6 acid. Some of the main monounsaturated fatty acids are given in Table 1.2.
O C H Oleic acid
9c-octadecenoic acid
H or
OH
9Z-octadecenoic acid
O C Elaidic acid Fig. 1.2
H H 9t-octadecenoic acid or
Structures of oleic and elaidic acids.
9E-octadecenoic acid
OH
14 14 16 18 18 18 18 22
14:1 5c
14:1 9c
16:1 9c
18:1 6c
18:1 9c
18:1 9t
18:1 11c
22:1 13c
Erucic
Oleic
Petroselenic
Palmitoleic
13c-Docosenoic
Erucic
11c-Octadecenoic Vaccenic acid
9t-Octadecenoic
9c-Octadecenoic
6c-Octadecenoic
9c-Hexadecenoic
Myristoleic
H3C
HC
CH
CH3 (CH2)7 CH=CH (CH2)11 COOH
CH3 (CH2)5 CH=CH (CH2)9 COOH
CH3 (CH2)7 CH=CH (CH2)7 COOH
CH3 (CH2)7 CH=CH (CH2)7 COOH
CH3 (CH2)10 CH=CH (CH2)4 COOH
CH3 (CH2)5 CH=CH (CH2)7 COOH
CH3 (CH2)3 CH=CH (CH2)7 COOH
CH3 (CH2)7 CH=CH (CH2)3 COOH
Structure
C OH
O
September 25, 2007
9c-Tetradecenoic
5c-Tetradecenoic
Common name
Structures of monoenoic acids.
Shorthand Chain Proper notation length name
Table 1.2
BLUK122-Dijkstra 19:41
Structure, occurrence, nomenclature, biosynthesis and properties 5
COOH
-Linolenic acid
-Linolenic acid
Rumenic acid
6c,9c,12c-18:3
9c,12c,15c-18:3
9c,11t-18:2
COOH
September 25, 2007
COOH
COOH
Linoleic acid
9c,12c-18:2
Structure
Name
Shorthand notation
Structures of polyunsaturated acids.
6
Table 1.3
BLUK122-Dijkstra 19:41
Trans Fatty Acids
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties
1.2.3
7
Diunsaturated acids
Linoleic acid is a diunsaturated acid with two double bonds and 18 carbon atoms and is named from the diunsaturated hydrocarbon octadecadiene (Table 1.3). Octadecadien(e) → octadecadien(oic) acid → 9, 12-octadecadienoic acid Again, the stereochemistry of the double bonds is known to be cis and so the correct name for linoleic acid is 9c,12c-octadecadienoic acid, with its shorthand name 9c,12c-18:2. There is another system of numbering the position of the double bond, which came into operation because of the way in which the fatty acid is built up during biosynthesis. In Section 1.4, it will be seen that the starting point for biosynthesis is a two-carbon unit that becomes the methyl end of the final fatty acid. Each time that another two-carbon unit is added to the chain, the name of the new fatty acid would alter and the position of any double bond would also alter with respect to the chemist’s fixed point, i.e. numbering from the carboxyl group. It was recognised that it might be advisable to use a system of nomenclature, which started at the methyl end of the acid chain. This is called the n-x system or the system. Thus linoleic acid is 9c,12c-18:2, where the carboxyl group is the starting point for the numbering. The alternative name for linoleic acid starts the numbering at the methyl end. In this case the double bond is now of six carbon atoms from the methyl group, and the position of the double bond is represented as n-6 or 6. The tells us that we start counting from the methyl end. Linoleic acid would be described as 6,9-18:2 in this alternative system. The notation for monounsaturated acids is given in Table 1.2. Rumenic acid is a conjugated diene fatty acid, 9c,11t-18:2, which is dealt with in Chapter 3.
1.2.4
Triunsaturated acids
The structures of two of the major triunsaturated acids -linolenic acid and -linolenic acid are given in Table 1.3. Their full names are 6c,9c,12c-octadecatrienoic acid and 9c,12c,15coctadecatrienoic acid respectively. The name derived as above from octadeca with the trienoic added shows that there are three ethylenic double bonds. Octadeca(ne) → octadecatrienoic acid → 9c,12c,15c-octadecatrienoic acid
1.3
OCCURRENCE
Of the saturated fatty acids, palmitic acid is the most widely occurring in both animal fats and vegetable oils, whilst stearic acid is found in lesser quantities in vegetable oils. Stearic acid is present in large quantities only in animal tallows and in vegetable fats, such as cacao butter and Borneo tallow. Butyric acid is found in butterfat (also referred to as anhydrous milk fat) produced from cow’s milk. Caprylic, capric and myristic acids are present in coconut and palm kernel oil. Oleic acid is the most widely distributed monounsaturated fatty acid. In some oils it is found in high proportions, ranging from 50 to 80%, e.g. olive, cashew and pistachio.
BLUK122-Dijkstra
8
September 25, 2007
19:41
Trans Fatty Acids 40 35
Percentage
30 25 C16
20
C18
15 10 5 0 5
6
7
8
9
10
11
12
13
14
15
16
Position of double bond Fig. 1.3
Trans isomeric monoene C16 and C18 fatty acids in butter.
Whereas most of the unsaturated fatty acids in nature have a cis double bond, there are some acids that have the trans configuration. We can concern ourselves mainly with trans fatty acids from now on. There are three main sources of trans fatty acids in the human diet; viz., they can be derived from animals or from the plant kingdom, or produced in the processing of oils and fats. In animals, trans fatty acids are derived from dietary lipids. It is believed that biohydrogenation by bacteria in the rumen of the dietary lipids results in a mixture of trans fatty acids. Such fatty acids are found in all ruminant milk fats. Rumenic acid (9c,11t-18:2) is the major conjugated fatty acid in ruminant fats. Rossell (2001) reported the trans content of subcutaneous adipose tissue in beef, sheep and pig to be 1.3–6.6%, 11.0–14.6% and 1.1–1.4% by weight respectively. In the case of farm animals, where the feed may contain trans fatty acids, the animal will metabolise some of the trans fatty acids and place some trans fatty acids in the adipose tissue. Hay and Morrison (1970) showed that amongst the trans isomers in butterfat, the monenoic C16 and monoenoic C18 are the major components (Fig. 1.3). The major isomer for C16 is palmitelaidic acid 9 (32%) and for C18 trans vaccenic acid 11 (36.1%). Trans fatty acids in most vegetable oils are present, if at all, in very minor proportions and in some oils, at the trace level. In the vegetable kingdom, trans fatty acids do occur naturally and sometimes in significant quantities; i.e. there is 6–12% of eleostearic acid 9c,11t,13t-18:3 in cherry oils, which have now been accepted as safe for food oils (Comes et al., 1992). Petroselaidic acid, 6t-18:1, is found along with petroselinic acid in Heracleum nipponicum, Conium maculatum, Phelopterus litoralis, Ligusticum acutifolium, Bupleurum falcatum, Osmorhiza aristata, Conioselinum univittatum, Hedera japonica, Panax schinseng and Aralia elata (Placek, 1963). In the plant kingdom, conjugated triene fatty acids often have one or more trans double bonds, e.g. jacaric acid 8c,10t,12c-18:3, calendic acid 8t,10t,12c-18:3, catalpic acid 9t,11t,13c-18:3, punicic acid 9c,11t,13c-18:3 and -eleostearic acid 9t,11t,13t-18:3. There are also conjugated tetraenoic acids - and -parinaric acids 9c,11t,13t,15c-18:4 and 9t,11t,13t,15t-18:4 respectively. In addition the biosynthetic pathways given in Section 1.3
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties
9
involve trans double bonds even when cis double bonds are being generated. So it can be seen that trans fatty acids occur naturally in both animals and plants. In 1983, Sommerfeld stated that ‘hardened oils do NOT contain trans fatty acids isomers other than those produced by the microflora of ruminants. Therefore claims that trans fatty acids isomers are “synthetic” “non-physiologic” or “unnatural” are unjustified if these words are used to imply “not produced by the living organism” ’. The presence in nature of conjugated linoleic acid double bonds contains trans which is further confirmation of Sommerfeld’s statement. Conjugated linoleic acid is covered in full in Chapter 3. The third source of trans fatty acids in foods is where they are produced in processing. Why was hydrogenation introduced into the oils and fats industry? Initially, it was to remedy a shortage of solid fats. At its simplest, hydrogenation is the addition of two hydrogen atoms across the ethylenic double bond of the fatty acid. It was recognised that the more unsaturated the fatty acid, the more likely it was for the fatty acid to be oxidised, which leads to oxidative rancidity. By removing two double bonds from linolenic acid, a monoenoic acid would be formed, which would resist oxidation better. Triene → diene → monoene → saturated acid
(1.1)
If the hydrogenation could proceed by the route suggested by Equation 1.1, the triene linolenic acid would yield the saturated acid, i.e. stearic acid. However, under industrial conditions, hydrogenation with a nickel catalyst is partial, giving rise to a mixture of products. From the above, it is still not obvious why there should be any trans fatty acid formed. Dijkstra (2002) suggested an amendment to the Horiuti–Polanyi mechanism in which the monoene M forms a semihydrogenated intermediate MH (Eq. 1.2). M + H → MH,
where M represents monoene
(1.2)
Dijkstra explains that the hydrogen concentration is too low for these intermediates to go on to form stearic acid. In turn this allows dissociation to occur as in Eq. 1.3. MH → M + H
(1.3)
When an individual acid, e.g. oleic acid, is considered in these reactions, the changes can be represented as shown in Fig. 1.4. When a fatty acid with a single cis double bond is partially hydrogenated, adsorption to (Step 1) and desorption from (Steps 3–5) the catalyst surface occurs, which produces a mixture of fatty acids. Some of the acids have a trans double bond. It is believed that the adsorption mechanism (Step 1) involves the formation of carbon nickel bonds between the metal catalyst and the carbon atoms of the 9 double bond C9 and C10 to give a structure (a). One hydrogen atom is then transferred (Step 2), probably from a Ni–H atom on the surface of the catalyst near the adsorbed fatty acid, to the carbon atom C9 to give structure (b). If the addition goes further, another hydrogen atom is added, the C Ni bond is broken and the hydrogen adds to C10 , with the formation of stearic acid as a desorption (Step 3).
BLUK122-Dijkstra
10
September 25, 2007
19:41
Trans Fatty Acids H2 C
R
10
H2 C
9
R1
1
H2 10 C
R
H
H
H
Ni
cis 9
H2 C
9
Ni
R1
H
(a)
2 H2 C 10
R
H2 C
9
H2 C
R1 R
H2 C
R1
3 H
Ni
H
H
H
(b)
H H Stearic acid
H
4 R
H
H2C 11
10
R1 R
H
(c)
H
Fig. 1.4
11
H
10 H2C (f) trans 10
R
R1
C H2 +
trans 9
+
R
H
9
H
(e) cis 10
H2 10 C
H2 C
10
9
R1
H
H R1
H2 C
(d) cis 9
Partial hydrogenation of oleic acid, where R1 = (CH2 )7 COOH and R2 = CH3 (CH2 )7 .
The interactions between these species are reversible (Fig. 1.4), with the result that in structure (b) the hydrogen from C9 and the C Ni bond can be eliminated to reform a double bond between C9 and C10 (Step 4). This results in a mixture of cis and trans isomers (c) and (d). It is also possible that when the C Ni bond breaks, the hydrogen which is involved in the elimination comes from the C11 . This will produce a mixture of cis and trans 10 monoenes (e) and (f). The production of the trans isomers can be seen more easily in Fig. 1.5. The cis monoene, in an addition reaction (Step 1), gives the intermediate with two Ni atoms (a). Structure (a) can now react with a hydrogen on a neighbouring nickel atom, as explained above, to form the semihydrogenated intermediate (b) (Step 2); this is the structure MH in Equation 1.2. The elimination of the Ni–H atoms from (b) with the breaking of a C H bond and a Ni H bond results in the reformation of the cis double bond between C9 and C10 (Step 3). This step is a desorption from the catalyst surface.
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties 1R
1
R
H
C R
1
R
1
H 1
H cis
C
H Ni
C
(b)
H 3
(b) R
1
H
C R
R
R
H
2
H
C
H Ni
C
11
R
H
C
H Ni
C
R
H
Ni (a)
cis
2
1R
C R
1R
H
C
4 H
H Ni
C
C
H
H
R Ni
H (b1)
(b)
5
1R
H
H R trans
Fig. 1.5 Partial hydrogenation of oleic acid, where R1 = (CH2 )COOH and R2 = CH3 (CH2 ), showing free rotation at Step 4.
However the semihydrogenated intermediate (b) can undergo free rotation about the C9 to C10 bond (Step 4) when the fatty acid is attached to the metal atom at just one point to give the conformation (b1). When the Ni–H atoms from (b1) are eliminated in a desorption (Step 5), it is a trans isomer which is formed. The oils and fats industry and catalyst manufacturers are working to permit hydrogenation without the production of trans fatty acids (see Chapter 6).
BLUK122-Dijkstra
12
September 25, 2007
19:41
Trans Fatty Acids
As will be explained later in Chapters 5, 7 and 9, industrial processors have reduced the level of trans fatty acid in foodstuffs from this source. In processing, thermally induced geometrical isomerisation can occur as described in Chapter 5.
1.4 1.4.1
FATTY ACID BIOSYNTHESIS Saturated fatty acids
When the pathways for fatty acid synthesis were being elucidated, it was realised that fatty acids were built up from acetic acid units. This finding made it easy to understand why so many naturally occurring acids had an even number of carbon atoms. It was subsequently found that only two carbon atoms of palmitic acid came directly from acetic acid, the carbons at positions 15 and 16 from the carboxyl end. The remainder of the carbon atoms came from malonyl coenzyme (CoA), as in Equation 1.4 (Gurr and James, 1980). CH3 COOH + 7CH2 (COOH)2 → CH3 (CH2 )14 COOH
(1.4)
The synthesis of palmitic acid is carried out by fatty acid synthetase (FAS). In the case of FAS in Escherichia coli, the enzymes involved in individual steps are shown in Fig. 1.6. Malonyl CoA:ACP transacylase (a) activates the malonyl unit, whilst acetyl CoA:ACP transacylase (b) activates the acetic acid unit. The joining of these two activated forms to form a C4 unit is catalysed by 3-ketoacyl-ACP synthetase (c). The ketone group in this C4 unit is then reduced to a hydroxyl group in the presence of 3-ketoacyl-ACP reductase (d). It is in the next step that we see the formation of a trans fatty acid derivative as the hydroxyl group, and a hydrogen is eliminated in the presence of 3-hydroxyacyl-ACP dehydrase (e). The trans fatty acid is not released as such but the double bond is reduced to give a new C4 fatty acid still in the activated form of ACP under the influence of enoyl-ACP reductase (f). These same reactions are performed to convert the C4 up to the normal C16 palmitic acid, with the addition of further six malonyl units. This is the natural end point of this series of reactions, and longer chain length fatty acids depend on elongation reactions using FAS III. From the viewpoint of trans fatty acids, it is important to recognise that the system accepts and utilises trans acids; i.e. trans fatty acids are not unnatural. There are in fact three fatty acid synthetases FAS I, II and III. Type I consists of large molecular mass multifunctional proteins containing covalently bonded acyl carrier proteins (ACP) and is found in animals. Type II consists of individual enzymes that normally act as one complex and are found in bacteria and plants (Gunstone et al., 1994). Type III FAS can elongate already formed fatty acids. The differences in these three synthetases relate to the subunits and the sequence of domains.
1.4.2
Monoenoic fatty acids
In the case of monoenoic acids in E. coli formed by type II FAS, there is a branch point when the chain length reaches ten carbon atoms, in an anaerobic pathway. In Fig. 1.7, it can be seen that when the dehydrase enzyme has worked on -hydroxydecenoyl ACP, the resulting trans2-decenoyl ACP can be elongated as normal and finish as palmitic acid. Alternatively, the dehydration step can lead to cis-3-decanoyl ACP which is then elongated to 9-palmitoleoyl
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties ACP-SH
CoA-SH
O
O H2 C
COOH
13
S
C
H2 C
COOH
CoA
S
C
ACP
(a) ACP-SH
CoA-SH O
O H3C
C
S
H3C
CoA
C
S
ACP
(b) O H3C
C
S
ACP
+ ACP-SH
CO2
O
O COOH
H2 C
S
C
C
H 3C
ACP
O H2 C
C
S
ACP
S
ACP
(c) NADPH + H +
O
O H3C
C
NADP +
H2 C
OH
C
S
ACP
H3C
C H
(d) OH H3C
O H2 C
C H
C
H3C S
ACP
C
H C
(e)
O H2 C
+ H2O
C C
H
S
ACP
O NADPH + H
H3C
O
C
H3C C
S
ACP
O Fig. 1.6
NADP
+
H C
H
+
Partial biosynthetic reactions of FAS.
(f )
H2 C
H2 C
C
S
ACP
BLUK122-Dijkstra
14
September 25, 2007
19:41
Trans Fatty Acids ACP
OH
3-Hydroxydecanoyl ACP
O
O H
H
H H CP A
O
CP A
trans-2-Decenoyl ACP
cis-3-Decenoyl ACP
I or II
I
16:0
9-16:1 II
18:0
11-18:1
Fig. 1.7 Anaerobic pathway of fatty acid biosynthesis in bacteria showing the branching point in the formation of cis vaccenic acid, where I is 3-ketoacyl-ACP synthetase I, and II is 3-ketoacyl-ACP synthetase II.
ACP and then to 11-cis-vaccenyl ACP (the Lipid Library, www.lipidlibrary.co.uk). This results in the n-7 double bond being retained. There are aerobic desaturases that remove two hydrogens from a saturated acyl chain stereospecifically. This is the system which is common in all organisms, where oxygen and a reducing cofactor are needed. The first double bond is usually produced at the 9 carbon atom catalysed by stearoyl–CoA 9 desaturase in plants and algae with the production of oleic acid. Palmitoleic acid is derived in a similar way from palmitic acid. Bacteria, uniquely, are able to produce 10 monoenoic acids. In addition some bacteria can remove a second pair of hydrogen atoms, giving rise to a diunsaturated double bond system, which is not a methylene interrupted one as is found in plants.
1.4.3
Polyunsaturated fatty acids
Mammals can introduce a second double bond to a monounsaturated fatty acid chain, but usually this new double bond cannot be inserted towards the methyl end of the chain.
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties
15
Oleic acid COOH
−2H
COOH
+C2
COOH −2H
COOH Oleic acid family Fig. 1.8
Biosynthetic relationships in the oleic acid family of fatty acids.
A second double bond can be introduced into oleic acid 9c-18:1, with the formation of 6c,9c-18:2 (Fig. 1.8). Addition of a further two carbon atoms under the influence of an elongase converts the C18 chain length to 8c,11c-20:2. If this acid is desaturated, it produces 5c,8c,11c-20:3. Further elongation and desaturation steps will convert this acid to other acids in the oleic acid family which all have the first double bond from the methyl end at the 9-position, i.e n-9 or 9. By contrast, when linoleic acid is subjected to a similar set of desaturation and elongation, the acids that are produced are shown in Fig. 1.9. Linoleic acid is converted to -linolenic acid, i.e. 6c,9c,12c-18:3, which is elongated to 8c,11c,14c-20:3. Further desaturation gives arachidonic acid, i.e. 5c,8c,11c,14c-20:4. Again, it is easy to see in Fig. 1.9 that all these acids in the linoleic acid family have the first double bond from the methyl end at the 6-position, i.e. n-6 or 6. Starting from -linolenic acid, desaturation yields 6c,9c,12c,15c-18:4. Elongation of this acid gives 8c,11c,14c,17c-20:4, and a further desaturation leads to 5c,8c,11c,14c,17c-20:5. This is called eicosapentaenoic acid (67A) which gives the next member of the series, docosapentaenoic acid. This acid in turn loses 2 hydrogen atoms to give docosahexaenoic acid (DHA). Both EPA and DHA are found in fish oils. All of these acids in the linolenic acid family (Fig. 1.10) have the first double bond from the methyl end at the 3-position, i.e. n-3 or 3. These pathways represent the formation of three different families of polyunsaturated fatty acids.
1.5
PROPERTIES OF TRANS FATTY ACIDS
The physical properties of trans fatty acids are different from the corresponding cis isomers.
BLUK122-Dijkstra
16
September 25, 2007
19:41
Trans Fatty Acids Linoleic acid COOH
−2H
CO2H +CH2
CO2H
−2H
CO2H Arachidonic acid Linoleic acid family n-6
Fig. 1.9
Biosynthetic relationships in the linoleic acid (n-6) family of fatty acids. Linolenic acid CO2H
−2H
CO2H +C2
CO2H −2H
COOH Linolenic acid family
Fig. 1.10
n-3
Biosynthetic relationships in the linolenic acid (n-3) family of fatty acids.
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties
17
Table 1.4 Melting points of monoacid triacylglycerols with C18 monounsaturated acids.
1.5.1
Position of the double bond
Cis isomers
Trans isomers
4 5 6 7 8 9 10 11 12 13 14 15
34 14 28 7 24 5 27 10 32 26 44 43
53 41 52 39 49 41 49 43 51 44 58 56
Melting points
In Table 1.4 and Fig. 1.11 we can see that the melting points of the two series are very different with the trans isomers having the higher melting points (Hagemann et al., 1975). It was this higher melting behaviour which made the trans fatty acids so valuable in commerce. These melting characteristics made it possible to produce the desirable properties for a plastic shortening by hydrogenation of cottonseed oil (and subsequently of other oils, e.g. soya bean oil). The polymorphism of trans fatty acid triacylglycerols is indicated in Table 1.5 (Hagemann et al., 1975).
70 60
Melting point
50 40 30 20 10 0
cis trans 4
5
6
7
8
9
10
11
12
13
14
15
DB position
Fig. 1.11 Melting points of C18 triacylglycerols with differing positions of the double bond. DB, double bond; MP, melting point. (Adapted from Hagemann et al., 1975.)
BLUK122-Dijkstra
18
September 25, 2007
19:41
Trans Fatty Acids Table 1.5 Melting points (◦ C) of polymorphs of monoacid triacylglycerols with C18 monounsaturated acids. Position of double bond
Polymorph
Polymorph
5 27 −36 16 −34 15 −20
34 53 5 39 5 41 27 49 32 51 26 44
cis 4 trans 4 cis 7 trans 7 cis 9 trans 9 cis 10 trans 10 cis 12 trans 12 cis 13 trans 13
21 23
Adapted from Hagemann et al., 1975.
These differences in melting point are attributable to the different shapes of the trans fatty acids in comparison with the cis isomers. In Fig. 1.12a, we can see the straight chain of the trans isomer elaidic acid that hardly alters the overall shape compared with a saturated acid, stearic acid, as in Fig. 1.12b. By contrast the cis double bond in Fig. 1.12c inserts a bend in the chain with the result that the molecules do not pack together as well. The melting points of a selection of trans compounds are given in Tables 1.6 and 1.7 (Hagemann et al., 1972; Jackson and Callen, 1951; Markley, 1947).
1.5.2
Ultraviolet spectra
Ultraviolet (UV) spectra are not used very often for the determination of the major fatty acids, because the UV -maximum for the cis unsaturated group is at 176 nm and for the trans double bond at 187 nm. The UV spectrum is much more informative when conjugated double bonds are present in the fatty acid (Hamilton and Cast, 1999). In cyclohexane, -eleostearic acid, 9c,11t,13t-octadecatrienoic acid, has max 262, 272 and 283 nm, as shown in Fig. 1.13, whilst -eleostearic acid, 9t,11t,13t-octadecatrienoic acid, has very similar absorption maxima at max 259, 270 and 281 nm (O’Connor et al., 1947).
Table 1.6 Melting points (◦ C) of the polymorph of selected triacylglycerols. Trielaidin Triolein Tripetroselenin Tripetroselaidin Trierucin Tri-trans-13-docosenoin Adapted from Hagemann et al., 1972.
41 5 28 52 32 58
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties Table 1.7
Melting points of selected cis and trans lipids. Melting point (◦ C)
Lipids Elaidic acid Oleic acid Petroselaidic acid Petroselenic acid Vaccenic acid Methyl elaidate Methyl oleate Methyl petroselaidate Triolein Trielaidin
45.0–45.5 16.3 53.2 33 43.5–44.1 11.5 −5 19.9 5.1 42.2
Adapted from Jackson and Callen, 1951; Markley, 1947.
(a)
(b)
(c) Fig. 1.12
Three-dimensional representations of (a) elaidic acid, (b) stearic acid and (c) oleic acid.
19
BLUK122-Dijkstra
20
September 25, 2007
19:41
Trans Fatty Acids
200
Absorbance
150
A 100
B
50
0 220
250 Wavelength (nm)
300
Fig. 1.13 UV absorption spectra of (A) -eleostearic acid and (B) -eleostearic acid. (Adapted from O’Connor et al., 1947.)
1.5.3
Infrared spectra
The maxima for the cis double bonds are at 1660–1630 and 730–650/cm, and for the trans double bonds at 1680–1670 and 980–865/cm. When the double bonds are in conjugation, we get cis,trans conjugated bonds at 990–980 and 968–950/cm, whilst trans,trans double bonds are at 990–984/cm. For triunsaturated acids, we have a maximum at 989/cm for cis,cis,trans conjugated, at 991/cm for cis,trans,trans conjugated and at 994/cm for trans,trans,trans conjugated (Chapman, 1965). A typical spectrum for trielaidin is shown in Fig. 1.14, with the characteristic band at 980/cm, in contrast with the spectrum for triolein (Feuge et al., 1951).
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties
21
100 Triolein 80 60 40 20 100 Trielaidin Transmission (%)
80 60 40 20 100 Tristearin 80 60 40 20 0
1
3
5
7
9
11
Wavelength (µm)
Fig. 1.14 Infrared absorption spectra of triolein, trielaidin and tristearin in chloroform. (Adapted from Feuge et al., 1951.) Table 1.8 Chemical shifts for the ethylenic carbon atoms in octadecenoic acid isomers by nuclear magnetic resonance. Position of double bond 5 6 7 8 9 10 11 12 13 14 15
Trans 131.98 131.13 130.81 130.67 130.54 130.47 130.43
Cis 128.72 129.49 129.89 130.13 130.23 130.21 130.34
131.44 130.62 130.31 130.17 130.09 130 129.96
130.14 130.39 130.63 131.93
Adapted from Gunstone, 1993.
128.21 129.01 129.45 129.65 129.78 129.83 129.89 129.94 129.9
130.13 129.45
130.16 131.54
129.66 129.39
BLUK122-Dijkstra
22
September 25, 2007
19:41
Trans Fatty Acids
Fourier transform infrared methods have been developed for the measurement of the trans content of oils, as noted by Ismail et al. in 1999.
1.5.4
Nuclear magnetic resonance spectroscopy
Gunstone (1993) has shown that the 13 C spectra of cis and trans fats can be used as a way of analysing partially hydrogenated fats. The values given in Table 1.8 show that there are differences between the cis and trans isomers in cases where the double bond is at C5 through C15 of the octadecenoic acids.
Nutrition facts Serving size 1 cup (228 g) Serving per container 2 Amount per serving Calories 260 Calories from fat 120 % Daily value* Total fat
13 g
20%
5g
25%
Saturated fat Trans fat
30 mg
10%
660 mg
28%
31 g
10%
Dietary fiber
0g
0%
Sugars
5g
Cholesterol Sodium Total carbohydrate
Protein
5g
Vitamin A Calcium
4% 15%
Vitamin C
2%
Iron
4%
*Percent daily values are based on a 2000 caloric diet. Your daily values may be higher or lower depending on your calorie needs:
Calories
2000
3000
Total fat
less than
65 g
Sat fat
less than
20 g
25 g
Cholesterol
less than
200 mg
200 mg
Sodium
less than
2400 mg
2400 mg
Total carbohydrate Dietary fiber
80g
300 g
375 g
26 mg
30 mg
Calories per gram Fat 9
Fig. 1.15
Carbohydrate 4 Protein 4
A United States of America nutrition facts label. (Adapted from Moss, 2006.)
BLUK122-Dijkstra
September 25, 2007
19:41
Structure, occurrence, nomenclature, biosynthesis and properties
1.6
23
LABELLING AND LEGISLATION
The Danish government has issued an order (Order no. 160), which came into operation on 31 March 2003. The order applies to oils and fats, including emulsions with fat as the continuous phase, which, either alone or as part of processed foodstuffs, are intended, or are likely, to be consumed by humans. The order does not apply to the naturally occurring content of trans fatty acids in animal fats or products governed under any other legislation. The order only applies to products sold to the final consumer. It states that it is prohibited to sell oils and fats covered by the order to consumers if they contain a higher level of trans fatty acids defined in the Annex than that quoted in Section 3. Section 3 states that, as from 1 June 2003, the content of trans fatty acids in the oils and fats covered by this order must not exceed 2 g/100 g of oil or fat. In products that are claimed to be ‘free from fatty acids’, the content of trans fatty acids in the finished product shall be less than 1 g/100 g of the individual oil or fat. Such has been the success of the Danish manufacturers/authorities that the level of intake of trans fatty acids from margarines and shortenings has fallen away completely from 4.5 g trans fatty acids per day in 1975, 2.2 g trans fatty acids per day in 1993 through 1.5 g trans fatty acids per day in 1995 to almost zero by 2005 (Leth et al., 2006). From 1 January 2006, the US government amended its regulations on nutrition labelling. This regulation is available on http://vm.cfsan.fda.gov/-Ird/fr991117.html and requires that all foodstuffs or products containing trans fatty acids, e.g. dietary supplements, should have the amount of trans fatty acids stated on the label. A typical example is shown in Fig. 1.15 (Moss, 2006), which is a listing of the grams of trans fat in a serving defined as the sum of all the unsaturated fatty acids that contain one or more isolated (non-conjugated) double bonds in the trans configuration. If the serving contains less than 0.5 g, it is possible to state the content as zero trans (Yurawecz, 2004). In October 2006, the Food navigator.com http://www.foodnavigator.com reported that the Australian government plans to work with industry to reduce trans fatty acids in Australian food.
REFERENCES Chapman, D. (1965) Infrared spectroscopy of lipids. J Am Oil Chem Soc 42 (5), 353–371. Comes, F., Farines, M., Aumelas, A. & Soulie, J. (1992) Fatty acids and triacylglycerols of cherry seed oil. J Am Oil Chem Soc 69, 1224–1227. Dijkstra, A.J. (2002) Hydrogenation and fractionation. In: Fats in Food Technology (ed. K.K. Rajah). Sheffield Food Technology, Sheffield, pp. 123–158. Feuge, R.O., Pepper, M.B., O’Connor, R.T. & Field, E.T. (1951) Modification of vegetable oils. XI The formation of trans isomers during hydrogenation of methyl oleate and triolein. J Am Oil Chem Soc 28, 420–426. Gunstone, F.D. (1967) An Introduction to the Chemistry and Biochemistry of Fatty Acids and Their Glycerides. Chapman and Hall, London. Gunstone, F.D. (1993) Composition of hydrogenated fats by high resolution 13 C nuclear magnetic resonance spectroscopy. J Am Oil Chem Soc 70 (10), 965–970. Gunstone, F.D. (1996) Fatty Acid and Lipid Chemistry. Blackie Academic and Professional, Glasgow. Gunstone, F.D. (2004) The Chemistry of Oils and Fats, Sources, Composition, Properties and Uses. Blackwell Publishing, Oxford. Gunstone, F.D., Harwood, J.L. & Padley, F.B. (1994) The Lipid Handbook. Chapman and Hall, London. Gurr, M.I. & James, A.T. (1980) Lipid Biochemistry, an introduction. Chapman and Hall, London. Hagemann, J.H., Tallent, W.H., Barve, J.A., Ismail, I.A. & Gunstone, F.D. (1975) Polymorphism in singleacid triglycerides of positional and geometric isomers of octadecenoic acid. J Am Oil Chem Soc 52, 204– 207.
BLUK122-Dijkstra
24
September 25, 2007
19:41
Trans Fatty Acids
Hagemann, J.W., Tallent, W.H. & Kolb, K.E. (1972) Differential scanning calorimetry of single acid triglycerides: effect of chain length and unsaturation. J Am Oil Chem Soc 49, 118–123. Hamilton, R.J. & Cast, J. (1999) Spectral Properties of Lipids. Sheffield Academic Press, Sheffield. Hastert, R.C. (1996) Hydrogenation. In: Bailey’s Industrial Oil and Fat Products, Vol. 4 (ed. Y.H. Hui). J. Wiley and Sons, New York, pp. 213–300. Hay, J.D. & Morrison, W.R. (1970) Isomeric monoenoic fatty acids in bovine milk fat. Biochim Biophys Acta 202, 237–243. Hoffmann, G. (1989) Chemistry and Technology of Edible Oils and Fats and Their High Fat Products. Academic Press, London. Ismail, A.A., Nicodemo, A., Sedman, J., van de Voort, F.R. & Holzbaur, I.E. (1999) Infrared spectroscopy of lipids: principles and applications. In: Spectral Properties of Lipids (eds R.J. Hamilton & J. Cast). Sheffield Academic Press, Sheffield, pp. 235–269. Jackson, F.E. & Callan, J.E. (1951) Evaluation of the Twitchell isooleic method: comparison with the infrared trans isooleic method. J Am Oil Chem Soc 28, 61–65. Korver, O. & Katan, M.B. (2006) The elimination of trans fats from spreads: how science helped to turn an industry around. Nutr Rev 64 (6), 275–279. Leth, T., Jensen, H.G., Mikkelsen, A.A. & Bysted, A. (2006) The effect of the regulation on trans fatty acid content in Danish food. Atheroscler Suppl 7, 53–56. Markley, K.S. (1947) Fatty Acids: Their Chemistry and Physical Properties. Interscience Publishers, New York. Moss, J. (2006) Labeling of trans fatty acid content in food, regulations and limits – the FDA view. Atheroscler Suppl 7, 57–59. O’Connor, R.T., Heinzelman, D.C., McKinney, R.S. & Pack, F.C. (1947) The spectrophotometric determination of alpha and beta isomers of eleostearic acid in tung oil. J Am Oil Chem Soc 24, 212–216. Placek, L.L. (1963) A review of petroselenic acid and its derivatives. J Am Oil Chem Soc 40, 319–329. Rossell, J.B. (2001) Oils and Fats, Volume 2 Animal Carcass Fats. Leatherhead Publishing, Leatherhead. Sommerfeld, M. (1983) Trans unsaturated fatty acids in natural products and processed foods. Prog Lipid Res 22 (3), 221–233. Yurawecz, M.P. (2004) FDA requires mandatory labeling of trans fat. Inform 15 (3), 184–185.
BLUK122-Dijkstra
2
September 25, 2007
19:43
Trans fatty acids intake: epidemiology and health implications
Geok Lin Khor and Norhaizan Mohd Esa
2.1
INTRODUCTION
The benefits of the functional roles of dietary fat in providing calorie density to the diet as a source of essential fatty acids and as a vehicle for fat-soluble vitamins, nutrients and antioxidants for the human body are long established. However, concerns for the ill-health effects of high intake levels of total fats and saturated fats are also well recognised. Epidemiological and experimental studies have demonstrated the links between high intake levels of saturated fats, elevated serum cholesterol levels, risk of atherosclerosis and coronary heart disease (CHD) mortality. In the light of the evidence, controlling the intake of dietary cholesterol, saturated fat and total fat has become a key dietary guideline in many countries. Heightened concerns for the deleterious effects of saturated fat intake have spurred interest in vegetable oils that are low in saturated fat. Total consumption of vegetable oils worldwide increased over twofolds from about 60 million tonnes in 1985 to over 130 million tonnes in 2005, and the level is projected to exceed 150 million tonnes by 2010 (Fig. 2.1). Averagely, global consumption of vegetable oils grew at an annual rate of 4.2% over the past decade. In terms of consumption per capita, countries of the European Community and United States are the largest consumers of vegetable oils accounting for approximately one-third of world consumption, with intake levels of approximately 50 kg/capita (Jank, 2006). Brazil and Japan are also large consumers at 20–25 kg/capita followed by China and India at 10–20 kg/capita (Fig. 2.2). The remarkable increase in vegetable oils consumption in recent decades may be attributed to rapid growth in population in developing countries and expanding economies in both developing and developed countries. Soya bean oil was the major edible vegetable oil in use globally, but after 2000, palm oil has taken the lead, owing to its relatively lower price per volume basis. The predicted global growth in palm oil usage is likely to continue through to 2016 (Drummond, 2005) (Fig. 2.3). In the food industry, vegetable oils are hydrogenated in the presence of metal catalysts and hydrogen to produce solid or semi-solid fats. As a result of this process termed partial hydrogenation, the double bonds in unsaturated fatty acids are reduced and some double bonds are converted from their normal cis configuration to the trans isomer. Vegetable oil is also partially hydrogenated to remove some fatty acids, such as linolenic and linoleic acid, which easily oxidise causing fat to go rancid with time. Partial hydrogenation of vegetable oils (PHVO) brings about desirable physical and chemical characteristics to foods cooked in PHVO, giving them distinctive flavour, crispness, creaminess, plasticity and oxidation stability.
BLUK122-Dijkstra
26
September 25, 2007
19:43
Trans Fatty Acids 200
Million tonnes
4% volume growth per year 150 100 50 0 1985 Fig. 2.1
1990
1995
2000
2005
2010
Worldwide vegetable oils consumption. (From Jank, 2006.)
EU-15 USA Brazil Japan World China India 0 Fig. 2.2
10
20
30
40
50
60
World per capita consumption of vegetable oils (in kg/capita). (From Jank, 2006.)
% of total fat
30 25 20 15 10 5 0
1976/1980
1986/1990
1999/2000
2000/2010
2016/2020
Period Soybean Fig. 2.3
2.2
Palm/palm kernel
Rape seed/canola
Sunflower seed
Trends in global edible oil production. (From Drummond, 2005; Gunstone, 2002.)
FOOD SOURCES OF TRANS FATTY ACIDS
Partially hydrogenated vegetable oil containing trans fatty acids (TFA) is used widely in the food industry, for reasons including its low cost compared with other fats, and ability to prolong the shelf-life of products and impart desirable characteristics to the food. For example, PHVO are extensively used to cook French fries and fast food, as well as in the preparation
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications Animal products (21%)
27
Cakes, cookies, pies and bread (40%)
Candy (1%) Breakfast cereal (1%) Salad dressing (3%) Shortening (4%) Potato chips (5%) Fried potatoes (8%)
Margarine (17%)
Fig. 2.4 Trans fats in US food supply. (From Perryman and Stone, 2006. Data based on FDA’s economic analysis for the final TFA labelling rule, ‘Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims’ (11 July 2003).)
of baked products. In this way, foods containing industrially produced hydrogenated fats and oils contribute the major share of TFA to the diet. Dairy products and ruminant meats also contribute a small proportion of the dietary TFA (generally making up 2–6% of the fat content in dairy products and ruminant meats). These ‘natural’ TFA are formed as a result of the normal process of bacterial transformation of unsaturated fatty acids in the rumen (biohydrogenation). A small quantity of TAF is also found in poultry and pork fat through the feed. The predominant trans isomer in ruminant fat is vaccenic acid (11t-18:1), while in PHVO, elaidic acids (9t-C18:1) and its isomer 10t-18:1) are the major TFA. Data on food sources of TFA are mainly for North American and European countries. Figure 2.4 shows the proportions of TFA found in various food categories in the United States. The major sources of TFA are baked products comprising cakes, biscuits, pies and bread (40%) followed by animal products (21%) and margarine (17%) (Perryman and Stone, 2006). Snack foods, principally fried potatoes and potato chips, contribute 13%, while another 7% comes from salad dressing and shortening. Overall, approximately 80% of the food items containing partially hydrogenated oils constitute the major sources of TFA intake. A similar pattern prevails in Canada where food items containing PHVO are found predominantly in baked and fried foods, such as crackers, cookies, doughnuts, muffins, croissants, French fries and breaded foods (Health Canada, 2006). These food items were also found to be the main sources of TFA of a group of pregnant women (Elias and Innis, 2002). Among these women, bakery foods contributed 33% of the TFA consumed, fast foods 13%, bread 10%, snacks 10% and margarines/shortenings 8%. In the European multicentre TRANSFAIR Study undertaken in 1995–1996, samples of foods contributing to 95% total fat intake in 14 countries were analysed centrally for TFA content (Hulshof et al., 1999; Institute of Food Science and Technology (IFST), 2004). Among the hydrogenated products, oils and fats are the main contributors (35%) followed by biscuits and cakes (16.5%) (Table 2.1). As for the biohydrogenated products, dairy products provide 18.8%
BLUK122-Dijkstra
28
September 25, 2007
19:43
Trans Fatty Acids Table 2.1 Contributions (%) of various foods to trans fatty acids intake in the TRANSFAIR Study. Milk and cheese Butter Eggs Meat and meat products Oils and fats Biscuits and cakes Savoury pies Chips and French fries Others Total
18.8 5.9 0.9 10.3 35.5 16.5 3.5 4.5 4.1
Natural Natural Natural Natural Mainly resulting from hydrogenation Mainly resulting from hydrogenation Mainly resulting from hydrogenation Mainly resulting from hydrogenation Mainly resulting from hydrogenation
100.0
From IFST, 2004.
of the total TFA, while meat and meat products contribute 10.3% and butter another 5.9%. Overall, approximately, two-thirds of TFA in European diets are from foods with PHVO, while the remaining one-third is from natural food sources. Thus, in general, Europeans consume a lower proportion of TFA from PHVO compared with North Americans (∼80%). The TFA content in commonly consumed food items is available in databases such as those from the US (US Department of Agriculture (USDA) Nutrient Data Laboratory, 2007), Canada (Health Canada, 2006) and Denmark (Stender and Dyerberg, 2003). Among the natural products in the US market, the TFA content of ground beef, butter and whole milk are 1 g/100 g, 2–7 g/100 g and 0.07 g/100 g respectively (expressed as grams per 100 grams food). In contrast, the TFA content in shortenings, margarines/spreads and bread/cake products are relatively higher at 10–33 g/100 g, 3–26 g/100 g and 0.1–10.0 g/100 g respectively. Stick margarine typically contains a higher amount of TFA compared with the softer (tub) margarines (Table 2.2). Commercially baked products, e.g. pies and cookies, provide significant amounts of TFA. Table 2.2
Trans fatty acids in selected foods.
Food (ingredients) Stick margarines Tub margarines Shortening (blend of sunflower, soya bean and cottonseed oil) Apple pies Brownies (hydrogenated soya bean and cottonseed oil, and butter oil) Coffee cake (soya bean oil, margarine and shortening) Noodles and oriental prepared food (hydrogenated soya bean oil, cottonseed oil and chicken fat) Noodles and oriental prepared food (palm oil) Potato chips (sunflower oil) Potato chips (vegetable oil) Peanut butter, creamy (hydrogenated vegetable oil and soya bean oil) Adapted from Health Canada, 2006.
Total fat (g/100 g of food)
Trans fatty acid (g/100 g of fat)
70–72 61–73 100
40 ± 4 20 ± 5 0.6
11–12 19–27
29–33 24–25
17
0.9
21
39
22 30 32–40 48–56
0 0.6 0.5–2.7 0–0.2
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications Table 2.3
29
Wide variability in the trans fatty acids content of foods. Mean (range)
Food description (number of samples) White bread (n = 8) Whole-wheat bread (n = 8) Crackers (n = 14) Breakfast cereals (n = 11) Cake mixes (n = 3) Cookies (n = 19) Potato chips (n = 6) Doughnuts (n = 13) Sauces and gravy (n = 16) French fries (n = 16) Hard margarine (n = 14) Soft margarine (n = 14)
Trans fatty acid (% total fat in food)
Trans fatty acid (g/100 g food)
18.5 (1.3–34.9) 15.6 (1.0–36.3) 40.3 (23.5–51.3) 4.2 (0.2–24.3) 29.6 (28.7–30.1) 23.0 (1.4–45.7) 5.9 (0.4–25.3) 29.6 (3.9–42.7) 33.2 (1.7–60.3) 37.7 (4.9–56.9) 39.8 (31.1–44.6) 16.8 (1.1–44.4)
0.4 (0.0–1.0) 0.5 (0.0–1.3) 6.4 (0.7–12.9) 0.1 (0.0–1.1) 2.3 (1.4–2.8) 3.5 (0.3–8.1) 1.4 (0.1–5.7) 3.9 (0.5–7.8) 3.6 (0.0–23.1) 2.1 (0.2–3.7) 39.8 (31.1–44.6) 16.8 (1.1–44.4)
Adapted from Innis et al., 1999.
Depending on the type of vegetable oil(s) used, the TFA content in the food may vary considerably, as shown in Table 2.3 for oriental noodles and potato chips. The wide variability of TFA in the same food category was clearly delineated by Innis et al. (1999). For example, 16 bread samples in the US were found to have levels of TFA, ranging from 1% to over 30% of total fat (Table 2.4). Fourteen samples of crackers of different brands contained 23.5–51.3% Table 2.4
Variability of trans fatty acids content in foods depends on the fat added.
Fat added White bread, commercially prepared Partially hydrogenated soya bean oil, mono- and diglycerides and butter Partially hydrogenated soya bean oil and mono- and diglycerides Partially hydrogenated soya bean oil and mono- and diglycerides from hydrogenated vegetable oil and butter Partially hydrogenated vegetable shortening (may contain soya bean oil and/or cottonseed oil, butter and mono- and diglycerides) Margarine, tub Liquid and partially hydrogenated corn oil, canola oil and mono- and diglycerides Partially hydrogenated soya bean oil, mono- and diglycerides and lecithin Liquid sunflower oil and partially hydrogenated soya bean oil Partially hydrogenated corn oil, mono- and diglycerides and soy lecithin From USDA Nutrient Data Laboratory, 2007.
TFA Total fat Total TFA (% total (g/100 g food) (g/100 g food) fatty acid) 5.2
0.71
15.61
1.4
0.11
9.24
6.3
1.39
25.46
4.5
0.82
21.02
67.5
11.30
17.5
70.1
11.29
16.9
56.6
8.06
14.9
40.3
3.05
7.9
BLUK122-Dijkstra
30
September 25, 2007
19:43
Trans Fatty Acids
of total fat as TFA. Likewise, potato chips of different brands were found to have a wide range of TFA (0.4–25.3%). The wide variability of TFA content in commercially prepared white bread depends upon whether the bread is made from PHVO (e.g. soya bean oil or cottonseed oil) mixed with other oils and fats. Accordingly, the TFA content of white bread may vary from 0.11 to 1.39 g/100 g bread (Table 2.4). Similarly for the manufacture of tub margarine, the amount of TFA differs from 3.05 to 11.30 g/100 g, depending on the vegetable oil used (partially hydrogenated or liquid form of corn oil, canola oil, soya bean oil and sunflower oil). While some foods, like cake mixes and hard margarines, have a narrow range of TFA content, the wide variation within a food category indicates that the use of average values for TFA content would be of limited value (Innis et al., 1999).
2.3
TRANS FATTY ACIDS INTAKE
Various methods are used to estimate TFA at the population level. These include market share data, laboratory analysis of typical composite diets, food consumption data and the use of biomarkers, such as human milk, red blood cell membranes and adipose tissue (CraigSchmidt, 2006). Assessing intakes of TFA by conventional methods of dietary assessment is fraught with challenges because few national food composition databases include TFA content of foods, especially indigenous foods. An indirect approach to estimate population level of TFA intake is to use food availability data in the country’s fats and oils supply. ‘The availability of food for human use represents disappearance of food into the marketing system, and food disappearance measures food supplies for consumption through all outlets – at home and away from home’ (US Department of Agriculture and Center for Nutrition Policy and Promotion). While generally food disappearance data tend to overestimate consumption, the disappearance trends do provide researchers with relative changes in fats and oils consumption. For example, the US food supply data showed that vegetable oils availability in the market had risen from 35 to 68 g/capita/day between 1965 and 2003, an increase of nearly 100% (Fig. 2.5). In 2003, 81.3% of total edible fats and oils consumed comprised vegetable oils, having increased from 56.7% in 1965. This increase has been attributed to the rapid expansion of the food industry, particularly fast food outlets and restaurants and their extensive use of fried foods. Demand for convenient ready-to-eat food, including processed foods and food prepared away from home, is evident worldwide in tandem with increases in household income, resulting in lifestyle shifts in favour of higher intake of away-from-home food. In the United States, such dietary behaviour shifts have been extensively documented, partly out of concern for its growing obesity problem (Kennedy et al., 1999; Nielsen et al., 2002; Popkin et al., 2001). Data on non-pregnant adults aged 18 and older from nationally representative surveys, including the Nationwide Food Consumption Survey (NFCS) and the Continuing Survey of Food Intake by Individuals (CSFII), showed a reduction in the proportion of fat consumed from foods identified as major sources of saturated fat – red meat, butter, whole milk and eggs (Fig. 2.6). At the same time, there has been an increased trend in away-from-home food, leading to marked increases in fat intake from foods such as pizza, French fries, Mexican dishes, cheeseburgers and Chinese dishes. This dietary shift has led to a marked reduction in the ratio of visible fat (e.g. meat fat and butter) to invisible fat (French fries and pizza). The latter involves the use of vegetable oils extensively, as they are an important ingredient in processed food and food prepared in food service outlets.
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
31
% 50
g/person/day 180
45
160
40
140
35
120
30
100
25
80
20
60
15 10
40
5
20 0
0 1965
1970
1975
1980
1985
1990
1995
% veg oils of total fat
g fat from plant and animal products
g fat from animal products
g vegetable oils
2000
2003
g fat from plant products
Fig. 2.5 Trends in the availability of fat from plant and animal products in the United States between 1965 and 2003. (From FAO Food Balance Sheets, 1965–2003.)
40 35
Percentage
30 25 1965
20
1995
15 10 5 0
Me
at
ir Da
ye
gg
s A
e dd
df
ats
De
sse
rts
a Bre
dc
a ere
lp
ast
Ve
a
ge
ta
s ble
fru
its M
d ixe
dis
he
s
Ot
he
rs
Fig. 2.6 Changes (%) in the proportion of total fat contributed by major food groups between 1965 and 1995 in the United States. Data on non-pregnant adults aged 18 and older from two nationally representative surveys, namely the 1965 Nationwide Food Consumption Survey (NFCS 65) and the 1994– 1996 Continuing Survey of Food Intake by Individuals (CSFII 96). Meat: beef, pork and poultry; added fats: butter, margarine and salad dressing; mixed dishes: grain-based with beef, e.g. beef burrito; mixed dishes: grain-based without beef, e.g. pasta with tomato sauce, cheese pizza, macaroni and cheese; others: beverages and seafood. (Reproduced from Popkin et al. (2001), Copyright Elsevier 2001.)
BLUK122-Dijkstra
32
September 25, 2007
19:43
Trans Fatty Acids
In the 1980s, the average intake of TFA of the US population was estimated at approximately 8 g/day/capita, with 85% coming from foods containing partially hydrogenated oils and the rest from meat and dairy products. This figure was based on analytical data by Enig et al. (1983), Slover et al. (1985) and the USDA production and sales figures (Tarrago-Trani et al., 2006). In fact, based on food supply or food disappearance data, the mean intake levels were reportedly as high as 13.3 ± 1.1 g/day/capita (Enig et al., 1990). Also, based on food supply data, Hunter and Applewhite (1991) reported 7.6 and 8.1 g/day/capita for 1984 and 1989 respectively. By the 1990s, however, the mean consumption level of TFA in the US was reported at relatively lower levels. Based on food intake data from the 1989 to 1991 USDA CSFII and the 1995 USDA database of TFA content of selected foods, Allison et al. (1999) estimated mean consumption level of about 5.3 g/day/capita (Table 2.5). The Minnesota Heart Study, as an ongoing observational epidemiological study commencing in 1980–1982, has provided evidence in support of a declining trend in the consumption of TFA in the US. For men, the intake level fell from 8.4 g/day in 1980–1982 to 6.4 g/day in 1995–1997, while the corresponding figures for the women were 5.4 and 4.7 g/day respectively (Harnack et al., 2003). The large prospective Nurses Health Study also reported a decrease trend in TFA consumption, dropping from 2.2% to 1.6% of total fats between 1980 and 1998 (Oh et al., 2005). The decline is a consequence of a reduction in the degree of hydrogenation to retain more of the original polyunsaturated fats (Ascherio and Willet, 1997). Further reduction in TFA consumption on per capita basis may be expected in the US, following the Food and Drug Administration (FDA) imposing the regulation that requires TFA to be declared in the nutrition label of conventional food and dietary supplements. Enforced on 1 January 2006, foods and dietary supplements that contain more than 0.5 g of TFA per serving are required to make the declaration, while servings containing less than 0.5 g of TFA shall be expressed as zero (FDA, 2003). In Canada, the level of TFA intake was described as ‘one of the highest in the world’ in the mid-1990s (Health Canada, 2006). Estimations placed the level at 8.4 g/day/person (Ratnayake et al., 1998) and at 5.9–7.2 g/day/person based on the 1991 nutrition surveys in Nova Scotia and Quebec (Ratnayake, 2002). The study on Canadian pregnant women by Elias and Innis (2002) recorded average intake of TFA of 3.8 ± 0.3 g/day and 3.4 ± 0.3 g/day in the second and third trimester, respectively. These intake levels are comparable to that of non-pregnant women in the US (Allison et al., 1999; Ascherio et al., 1994), indicating that the TFA intake level in Canada has declined from the high levels in the mid-1990s. The decline has been attributed to mandatory nutrition labelling and greater consumer awareness, encouraging food manufacturers to reduce or eliminate TFA from many processed foods sold in grocery stores (Health Canada, 2006). For example, almost all bread products and salad dressings are now free of TFA. Nonetheless, while ‘significant progress has also been achieved in certain food categories such as French fries and snack foods, many other foods – including some varieties of baked goods, oriental noodles, snack puddings, liquid coffee whiteners, microwave popcorn, toaster pastries, hard margarines and shortenings – still contain high amounts of trans fats’ (Health Canada, 2006). Consequently, the Trans Fat Task Force has recommended to the Canadian government that for all vegetable oils and soft, spreadable (tub-type) margarines for sale to consumers or for use as an ingredient in the preparation of foods on-site, the total TFA content be limited by regulation to 2% of total fat content. For all other foods, the Trans Fat Task Force recommended that the total TFA content be limited by regulation to 5% of total fat content. This limit does not apply to food products for which the fat originates exclusively
Oh et al. (2005)
USA
Hunter and Applewhite (1991) Enig et al. (1990) Van den Reek et al. (1986)
Ascherio et al. (1996) Ascherio et al. (1994) Willet et al. (1993) Troisi et al. (1992)
Garland et al. (1998)
Allison et al. (1999)
Availability data/food supply Analysis of weighed diets for 7 days; 8 girls aged 12–15 yr
FFQ semi-quantitative; the Normative Aging Study; 748 men aged 43–78 yr Market sizes and shares data
24-h recall for 3 days; 1989–1991 CSFII; 11 258 aged 3 yr and above FFQ semi-quantitative+diet records; 140 women 40–65 yr from Nurses Health Study FFQ; Health Professionals Follow-up Study; 43 757 men 40–75 yr FFQ semi-quantitative; 282 men and women
Semi-quantitative FFQ; Nurses Health Study 78 778 women aged 30–55 yr FFQ semi-quantitative; Nurses Health Study (NHS 498) women aged 44–70 yr; NHSII 473 women aged 32–50 yr 24-h recall; Minnesota Heart Survey 3766 men and 4183 women aged 25–74 yr
Method of estimate; subjects
13.3 ± 1.1 3.14 ± 0.26
1984: 7.6 1989: 8.1
3.4 ± 1.2
Men: 4.4 ± 2.3 Women: 3.6 ± 2.2
First to fifth quintile: 1.5–4.3
2.8 ± 1.3
Men 1980–1982: 8.4 1995–1997: 6.4 Women 1980–1982: 5.4 1995–1997: 4.7 5.3 ± 0.08
gram
First to fifth quintile: 0.8–1.6 Men: 1.5 Women: 1.7 2.2
2.6 ± 0.02
% total energy
6.53 ± 0.42
Men: 4.3 Women: 4.8
4.7 ± 1.4
7.4 ± 0.06
(Continued )
1980– 1998: 2.2% reduced to 1.6% 4.7 range: 1.5–9.2
% total fat
Mean intake (per day per capita)
September 25, 2007
Harnack et al. (2003)
Mozaffarian et al. (2004a)
Reference
Estimated per capita intake of trans fatty acids in various countries.
Country
Table 2.5
BLUK122-Dijkstra 19:43
Epidemiology and health implications 33
Iceland Holland Belgium Norway UK Denmark Sweden France Germany Finland Spain Italy Portugal Greece Denmark Stender and Dyerberg (2003) Holland Oomen et al. (2001) Finland Pietinen et al. (1997) Zutphen Elderly Study; FFQ; 667 men 64–84 yr ATBC Cancer Prevention Study; diet history; 21 930 men 50–69 yr follow-up from 1985–1988 till 1993
TRANSFAIR Study: food records+food analysis of 1300 foods from 14 countries in 1995–1996; men and women 19–64 yr 19–64 yr 18–63 yr 19–64 yr 0–75+ yr 19–64 yr 19–64 yr 19–64 yr 19–64 yr 25–84 yr 0–70+ yr 1–80 yr 38 yr 23–64 yr
FFQ semi-quantitative; 60 pregnant women Laboratory analysis food composites; 1991 Nova Scotia and Quebec nutrition surveys
Method of estimate; subjects
5.4 4.3 4.1 4.0 2.8 2.6 2.6 2.3 2.2 2.1 2.1 1.6 1.6 1.4 1994: 2.5 2000: 1–2 1985: 10.9 ± 6.3 1995: 4.4 ± 1.7 2.0
1985: 4.3% 1995: 1.9% 0.95
2.0 1.6 1.4 1.5 1.3 1.0 1.1 1.2 0.8 0.9 0.7 0.5 0.6 0.6
Second and third trimester: 1.3 ± 0.1 3.0
Second trimester: 3.8 ± 0.3 Third trimester: 3.4 ± 0.3 5.9–7.2
8.4
% total energy
gram
% total fat
Mean intake (per day per capita)
September 25, 2007
Europe
Elias and Innis (2002) Ratnayake (2002)
Canada
Ratnayake et al. (1998) Stender and Dyerberg (2003)
Reference
(Continued)
34
Country
Table 2.5
BLUK122-Dijkstra 19:43
Trans Fatty Acids
Men: 7.1 ± 3.1 Women: 6.4 ± 2.9 1968: 4.9 1975: 3.0 Men: 6.0 Women: 5.0 174 men and women (control group); FFQ 3.0 Calculation based on assumptions for Men: 6.4 trans fats content in foods Women: 4.4 5.0 Life in New Zealand survey Men: 5.4 Women: 3.4 Food content in foods and nutrition 1.56 consumption profiles
Semi-quantitative FFQ; mean age: men (99) 57 yr and women (101) 62 yr 3-day food records; 275 male and female Urban male: 4.96 ± 0.82 adolescents 12–18 yr and female: 4.75 ± 0.68 Rural male: 4.04 ± 0.78 and female: 4.35 ± 0.67
Baylin et al. (2005)
0.7
1.17 ± 0.4 Men: 2.5 Women: 2.1 — 1.9 both sexes
Men: 2.7 ± 2.9 Women: 3.3 ± 3.0 1968: 14.1 1975: 13.6
2.2 ± 0.3
1968: 5.0 1975: 5.1
FFQ stands for Food Frequency Questionaire used to assess frequency of intake of food items over a specified period e.g. in past month, how often did you eat bread?
Costa Rica
Monge-Rojas et al. (2005)
328 Japanese-Brazilians aged 40–79 yr
Rural men: 4.1 ± 0.8 and women: 3.2 ± 0.6 Urban men: 12.2 ± 2.5 and women: 9.4 ± 1.8 1993: men 4.7 and women 5.1 2000: men 3.3 and women 3.4 —
Bertolino et al. (2006)
Food records; 1769 rural 1806 urban men and women 25–64 yr
Brazil
India
Semma (2002); Okamoto et al. (1999) Singh et al. (1996)
FFQ semi-quantitative; 10 359 men and women 40–59 yr in 1984–1986 Analysis of diets
September 25, 2007
Japan
Bolton-Smith et al. (1995) Sweden Akesson et al. (1981) Germany Heckers et al. (1979) Australia Clifton et al. (2004) Noakes and Nestel (1994) New Zealand Eyres (2000) Wilson et al. (1990)
Scotland
BLUK122-Dijkstra 19:43
Epidemiology and health implications 35
BLUK122-Dijkstra
36
September 25, 2007
19:43
Trans Fatty Acids
from ruminant meat or dairy products. These regulations are recommended to be finalised by June 2008 (Health Canada, 2006). In Europe, the TRANSFAIR Study showed considerable variations in the levels of TFA intake among adults in the 14 countries studied (Stender and Dyerberg, 2003). On average, the values ranged from the lowest at 1.4 g/day/capita in Greece to the highest at 5.4 g/day/capita in Iceland (Table 2.5). In general, the Mediterranean countries appeared to have the lowest average intake levels (below 3 g/day/capita). In contrast, countries such as Iceland, Holland and Belgium showed mean consumption levels exceeding 4 g/day/capita, which was comparable to intake levels in North America. Trans fatty acids consumption in Europe used to be higher than the levels reported in the TRANFAIR Study. In Sweden, Akesson et al. (1981) reported intake of 4.9 g/day/capita in 1968 and 3.0 g/day/capita in 1975, compared with 2.6 g/day/capita reported in the TRANSFAIR Study. In Germany in the 1970s, men and women were estimated to consume 6 and 5 g TFA daily respectively (Heckers et al., 1979), in contrast to the TRANSFAIR figure of 2.2 g/day/capita. Scotland in 1984–1986 had mean total TFA intakes of 7.1 ± 3.1 and 6.4 ± 2.9 g/day for men and women respectively (Bolton-Smith et al., 1995), compared with the TRANSFAIR finding of 2.8 g/day/capita for United Kingdom. Finland seems to have maintained its intake level at about 2 g/day/capita since the 1980s. The Alpha-Tocopherol, BetaCarotene (ATBC) Cancer Prevention Study reported TFA consumption of 2.0 g/day/capita or 0.95% energy on average, compared with the TRANSFAIR intake level of 2.1 g/day/capita. Besides margarine, there are no other important sources of TFA in the Finnish diet (Pietinen et al., 1997). Since the TRANSFAIR Study, the TFA levels in industrially produced foods in some European countries have decreased markedly. In the Netherlands, a major reduction in TFA content of retail foods has been achieved through efforts of industry with minimal government intervention. Societal pressure also helps to reduce the TFA content of fast foods. The French fries sold in a popular franchise in the Netherlands now have less than 4% trans and 24% saturates, as opposed to 21% trans and 21% saturates in the USA. This illustrates the feasibility of reducing TFA in fast foods without increasing saturates (Katan, 2006). In the context of declining intake of TFA, Denmark is a noteworthy case. The average daily intake of industrially produced TFA in Denmark in 1994 was approximately 2.5 g/person and has since fallen primarily as a result of a reduction in the TFA content of table margarines produced in Denmark (Stender and Dyerberg, 2003). Nonetheless, owing to the import of products with a high PHVO content and since ‘population groups with eating habits including frequent consumption of fast food, French fries, microwave popcorn, chocolate bars and the like have daily intakes of industrially produced TFA well above average levels in the general population, the Danish Nutrition Council has recommended that industrially produced TFA should not be used in food, and the use of industrially produced TFA in food should be phased out as soon as possible’ (Stender and Dyerberg, 2003). Since 1 January 2004, Denmark has set an upper limit on the percentage of industrially produced TFA in foods, limiting TFA from sources other than meats and dairy products, to a maximum of 2% of total fat in each food item. The content of TFA in Danish food has been monitored for the last 30 years. In margarines and shortenings, the content of TFA has substantially declined, e.g. from levels in 1995, in which only 42% of the samples were free of industrially produced TFA (less than 1%) whereas 88% were free in 1999 (Stender and Dyerberg, 2003). In 2005, an investigation of a broad range of food showed that the TFA content had been reduced or removed from the products with high TFA content originally, like French fries, microwave popcorn and various bakery
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
37
products. Hence, industrially produced TFA is no longer a significant component of the diet in Denmark (Leth et al., 2006). An evaluation was also undertaken to assess the potential exposure of consumers by analysing popular foods in Denmark and in 25 other countries (Stender et al., 2006). ‘Fiftyfive servings of French fries and chicken nuggets, 87 packages of microwave popcorn, and 393 samples of biscuits/cakes/wafers with “partially hydrogenated vegetable fat” listed high on the food label were bought between November 2004 and February 2006’. A ‘high trans menu’ was defined as a large-size serving of French fries and nuggets, 100 g of microwave popcorn and 100 g of biscuits/wafers/cakes. The amounts of TFA in a ‘high trans menu’ was 30 g in 2001 in Denmark but was reduced to less than 1 g in 2005. By contrast, a ‘high trans menu’ provided more than 20 g in 17 out of 18 countries, with Hungary, Czech Republic, Poland, Bulgaria and USA, ranking highest with 42, 40, 38, 37 and 36 g respectively. Information on intake of TFA in Australia and New Zealand is rather limited. Through the Food Standards Australia and New Zealand’s dietary modeling work, it is estimated that Australians obtain only 0.6% of their daily energy from trans fatty acids and New Zealanders only 0.7% (Food Standards Australia and New Zealand, 2007). Previous intakes were estimated at higher levels. According to a review by Booker and Mann (2005), mean TFA intakes were estimated as 6.4 g/day or 2.5% total energy for men and 4.4 g/day or 2.1% total energy for women based on simulated Australian diets collected in 1987 and estimated amounts of trans fats in the food consumed (Noakes and Nestel, 1994). Among Australians, beef and dairy fat are the major sources of trans vaccenic acid (11t-18:1), whereas margarine is the main source of elaidic acid (9t-18:1). However, since mid-1996 when trans-enriched margarines were no longer available in the supermarket, animal sources of TFA are now the major contributor to the dietary intake of TFA (Clifton et al., 2004). In New Zealand, a survey in 1989/1990 estimated intakes of TFA as 5.4 g/day for men and 3.4 g/day for women. Data accrued from studies conducted in Adelaide between 1995 and 1997 recorded dietary intake of TFA as 3.0 g/day/capita or 1.17 ± 0.4% of energy (Clifton et al., 2004). Skeaff and Gowans (2006) compared TFA intake between butter users (mean 25.8 ± 12.9% of dietary fat) and margarine users (20.4 ± 10.5%) in New Zealand, using plasma phospholipids as an indirect biomarker of TFA intake. Butter users were estimated as consuming 4 g/day of TFA. Presently, the Australia New Zealand Food Standards Code does not require food manufacturers to label the TFA content unless they make a nutrition claim about cholesterol, saturated or unsaturated fats or TFA. However, voluntary labelling is permitted, and many edible oil spread manufacturers in Australia and New Zealand have chosen to voluntarily label their products (Food Standards Australia New Zealand, 2005). Margarines with no TFA are available in New Zealand, and major brands of margarines in Australia also are trans free. Asian countries generally have lower dietary fat intake than Western countries, whose total fat intakes are approximately 35–40% of total energy. However, the situation is rapidly changing in tandem with expanding economy in recent decades. China is a noteworthy example. Consumption of vegetable oils on a per capita basis increased by 440% between 1970 and 1999. China was self-sufficient in vegetable oil production until about 1985 and since then has to rely on importing vegetable oils, including palm oil from Malaysia, which soared from 114, 000 tonnes in 1980 to 1.4 million tonnes in 1993–1994. This rapid increase in utilisation of vegetables oils is reflected in China’s dietary fat intake, which rose from 15.9% of total energy in 1982 to 29.5% by 2003 (Food and Agricultural Organization (FAO) Food Balance Sheets, 1965–2003).
BLUK122-Dijkstra
38
September 25, 2007
19:43
Trans Fatty Acids
Table 2.6
Mean content of trans fatty acids in human milk (g/100 g fatty acids).
Country
Reference
n
Mean ± SD (range)
Canada
Friesen and Innis (2006)
87
Nov 2004–Mar 2005: 6.2 ± 0.48 Apr 2005–Aug 2005: 5.3 ±0.49 Sept 2005–Jan 2006: 4.6 ± 0.32 7.1 ± 0.32 (2.2–18.7) 7.2 ± 3.0 (0.1–17.2)
Innis and King (1999) Chen et al. (1995)
103 198
USA
Mosley et al. (2005) Aitchison et al. (1977)
81 11
Poland
Mojska et al. (2003)
Czechoslovakia
Wiererov´ a et al. (2002)
35
4.22 ± 1.87
France
Chardigny et al. (1995)
10
∼ 2% (1.2–3.0)
Spain
Boatella et al. (1993)
38
∼ 1%
Germany
Koletzko et al. (1988)
15
4.4 (2.2–6.0)
Iran
Bahrami and Rahimi (2005)
52
11.3 ± 3.4
Hong Kong
Chen et al. (1997)
51
0.88 ± 0.61
China
Chen et al. (1997)
33
0.22 ± 0.06
100
7.0 ± 2.3 (2.5–13.8) (2.68–5.43) 2.36–2.77 depends: season, week of lactation
Consumption data on TFA in Asian countries is sparse. In Japan, based on the determination of the TFA content in commercially available foods and food consumption surveys, the daily intake of TFA was estimated to be 1.56 g/capita or 0.7% of total energy (Okamoto et al., 1999; Semma, 2002). In India, the major source of TFA is ‘vanaspati’, which is ghee made from PHVO. Vanaspati has a high TFA content and is used in confectionery, bakery and ready-to-eat foods. Ghee may also be prepared from milk or butter (clarified butter), and as such, it contains a high proportion of short- to medium-chain saturated fatty acids. Ghee prepared from milk or butter is traditionally more affordable to the urban affluent and middle-income groups, being more expensive than vanaspati made from vegetable oils (Ghafoorunissa, 1996). Vanaspati use, however, has risen rapidly in urban areas, as various socio-economic groups are drawn to the cities, for example, to seek opportunities in employment and education. Based on the amount of vanaspati consumed, Indian adults in urban areas were found to consume three times higher TFA (9–12 g/day/capita) than those in rural areas (3–4 g/day/capita) (Singh et al., 1996). High consumption of ghee was one of the risk factors, besides tobacco use, raised fasting glucose, high cholesterol and paternal history of cardiovascular disease, for risk of non-fatal myocardial infarction (MI) in Pakistan (Ismail et al., 2004). Compared with studies on TFA intakes in the adult population, the literature on consumption of TFA among the younger age groups is more meagre. The study by Monge-Rojas et al. (2005) among Costa Ricans aged 12–18 years showed significant urban/rural differences. Urban males and females had intake levels at nearly 5 g/day compared with just over 4 g/day among the rural subjects (Table 2.5). The authors attributed the higher TFA intake in urban areas to greater consumption of partially hydrogenated soya bean oil, whereas the rural subjects consume primarily palm shortening, which is more affordable to the lower income rural population. Overall, the TFA intake of the Costa Rican adolescents can be deemed as rather high. Adolescents in the United States are consuming even higher levels of TFA. Allison
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
39
et al. (1999) found that boys and girls aged 12–19 years consume 7.1 ± 0.4 g/day and 5.1 ± 0.2 g/day respectively, or almost 2.8% of total energy. These findings, albeit limited, present a matter of health concern, as they not only revealed that the diet of the younger age group is high in TFA, but also that a significant proportion of the source of the trans fats is red meat and dairy products, which are also major sources of saturated fat. High consumption of trans and saturated fats is known to induce atherogenic changes to plasma lipids and run the risk of CHD.
2.4
TRANS FATTY ACIDS IN HUMAN MILK
Women’s dietary intake influences the fatty acid composition of breast milk (Chappell et al., 1985). When the diet is calorie deficient, the milk’s fatty acid pattern reflects that of the adipose tissue, but when calories are adequate for energy needs, the diet becomes the main influence. Also, a high carbohydrate intake, which is typical of the diet of women from low-income households, leads to preferential synthesis of lauric acid (12:0) and myristic acid (14:0), with a concomitant decrease in oleic acid (18:1) and stearic acid (18:0). As for TFA in human milk, most of it is directly influenced by the mother’s recent dietary intake. Accordingly, the TFA level in human milk is generally higher in North America than in Europe (Table 2.6). In Canada and United States, the mean concentrations of TFA in human milk are found to exceed 7% of total fatty acids content, with values ranging from 0.1 to 17%, compared with mean levels of 1–4% among European countries. However, it is reported that milk TFA concentration in Canada has been decreasing from 7.1% in 1998 to 4.6% in 2006 (Friesen and Innis, 2006). The decline was attributed to a decrease in consumption of TFA among women, following the introduction of labelling regulations on trans fats in food. The decline may also be due to a decrease in the use of partially hydrogenated fats and oils in foods in Canada. In Asian countries (Hong Kong and China), levels of milk TFA are low, at below 1% (Table 2.6). Similarly, the mean TFA content in breast milk of African women (Nigeria) was found to be below 1%, as reported by Koletzko et al. (1991) and Mosley et al. (2005). A high level of TFA (11.3%) in human milk was reported in Iran, and this was attributed to high consumption of partially hydrogenated vegetable oils that contain high trans fat content (up to 38%) (Bahrami and Rahimi, 2005). The significance of the presence of TFA in breast milk is that it has been implicated in the ‘displacement’ of essential fatty acids in the milk. Studies showed that the percentage of milk TFA is inversely related to the percentages of milk linoleic acid (LA; 18:2, n-6) and -linolenic acid (ALA; 18:3, n-3), and these proportions are reflected in the endogenous lipids of the breast-fed infants (Chen et al., 1995; Innis and King, 1999; Ohrigge et al., 1982). Studies also revealed a significant reverse association between TFA content and arachidonic acid (AA; 20:4, n-6) and docosahexaenoic acid (DHA; 22:6, n-3) in infants’ cord blood lipids (Desci et al., 2001). It is thus suggested that TFA are involved in the inhibition of the desaturation of LA and ALA to AA and DHA. Both AA and DHA are crucial for fetal and infant growth and central system development (Carlson et al., 1997). DHA is also required in visual and neural function and neurotransmitter metabolism. Thus, ‘TFA may have adverse effects on growth and development through interfering with essential fatty acid metabolism, direct effects on membrane structures or metabolism, or secondary to reducing the intakes of the cis essential fatty acids in either mother or child’ (Innis, 2006). Maternal dietary TFA may also compromise foetal physical development since Koletzko (1992) showed that TFA can cross the placenta, and significant correlation was also shown
BLUK122-Dijkstra
40
September 25, 2007
19:43
Trans Fatty Acids
between the concentration of trans 18:1 in maternal plasma and foetal tissue (Hornstra, 2000). Nonetheless, Carlson et al. (1997) called for caution in interpreting possible association found between TFA exposure and fetal growth because of influence of complex confounding factors. Another potential adverse health effect arising from maternal intake of high amounts of TFA is the resultant reduction in milk fat, thus rendering breast milk to be less energy dense for the exclusively breast-fed infants. The potent inhibitor of milk fat synthesis found in cows was trans-10,cis-12-conjugated linoleic acid (CLA), which is formed as a result of biodehydrogenation of LA (Baumgard et al., 2000). 10t-18:1 has also been implicated in reducing milk fat synthesis (Bauman et al., 2004). In humans, results are inconsistent and reduced fat in milk was found in leaner, but not obese, women (Anderson et al., 2005). The authors suggested that women with smaller fat stores may have less substrate to mobilise and utilise as milk fat.
2.5 2.5.1
TRANS FATTY ACIDS INTAKE AND HEALTH IMPLICATIONS Coronary heart disease
The effects of TFA on serum lipids are well recognised since the experimental evidence demonstrated by Mensink and Katan (1990) and others (Nestel, 1994; Sundram et al., 1997). Epidemiological investigations that showed support for the metabolic evidence of dietary TFA increasing the risk of CHD include the Seven Countries Study and the Nurses Health Study. The Seven Countries Study, one of the earliest prospective cohort studies, found a strong positive association between TFA and CHD mortality risk (Kromhout et al., 1995). Based on 25 years of mortality data (between baseline in 1958–1964 and 1987–1988) on ∼13 000 middle-aged men constituting 16 cohorts in Europe, United States and Japan, the results of these cross-cultural analyses suggested that TFA, as well as dietary saturated fat and cholesterol, were important determinants of differences in population rates of CHD death. In the Nurses Health Study on ∼80 000 US women aged 30–55 years, those in the highest quintile of TFA intake from PHVO at baseline (median intake of 3.2% of total energy) had a 35% higher risk of CHD than women in the lowest quintile (median 1.3% of total energy) (Ascherio and Willet, 1997; Oh et al., 2005). In addition, the Nurses Health Study revealed that TFA derived from vegetable oils increase the risk of CHD, whereas the naturally occurring TFA of animal origin do not and may decrease CHD risk (Willet et al., 1993). The highest intake of vegetable TFA was associated with a 78% increase in the risk of CHD (RR 1.78), while the highest intake of animal TFA had a 41% reduction in the risk (RR 0.59). In a case-control study on 239 patients from the Boston area (Ascherio et al. 1994), the highest quintile of TFA intake was associated with a doubling of the risk of first MI. In the Netherlands, the Zutphen Elderly Study on 667 Dutch men aged 64–84 years showed that TFA intake at baseline was positively associated with the 10-year risk of CHD (Oomen et al., 2001). After adjustment for confounding factors (age, energy intake, body mass index, smoking, use of vitamin supplements and intake of alcohol, specific types of fat, dietary cholesterol and fibre), the relative risk amounted to 1.28 (95% CI 1.01–1.61). Based on a meta-analysis of four large prospective cohort studies in the US and Europe (Nurses Health Study, Health Professionals Follow-up Study, ATBC Cancer Prevention Study and Zutphen Elderly Study), Oomen et al. (2001) estimated that a 2% increase in energy intake from TFA
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
41
was associated with a 25% increase in the incidence of CHD. In the ATBC Cancer Prevention Study on ∼22 000 male smokers aged 50–69 years in Finland, after about 6 years from 1985– 1988, men in the top quintile of TFA intake (median 6.2 g/day) were found to have a relative risk for CHD at 1.39, as compared with men in the lowest quintile intake (median 1.3 g/day) (Pietinen et al., 1997). There are however some other large prospective studies that failed to find unequivocally significant associations between TFA intake and CHD risk. The Scottish Heart Health Study on ∼11 000 men and women aged 40–59 years found that the odds ratios for CHD in the quintile with the highest intake of total and commercially derived TFA were elevated, but not significantly so when compared with the quintile having the lowest intake (1.26 in women and 1.08 in men). The authors concluded that their results did not ‘support a major effect of dietary TFA from commercial hydrogenation on CHD risk in Scottish men’. In the Health Professionals Follow-up Study on ∼44 000 US men aged 40–75 years (Ascherio et al., 1996), the subjects completed food-frequency questionnaires every 2 years between 1986 and 1992. The authors found that the incidence of MI and fatal CHD was not significantly associated with TFA intake after adjustment for dietary fibre. In another follow-up study on a cohort of ∼52 000 male health professionals, no significant association between TFA intake and risk of stroke was found (He et al., 2003). The EURAMIC case-control study on 671 men with acute MI in eight European countries also did not find a significant overall association between the 18:1 TFA content in adipose tissue and the risk of first MI (Aro et al., 1995). No significant association between TFA intake and risk of MI was found. (Multivariate OR comparing the top versus the bottom quartile was 0.97.) Mozaffarian et al. (2006) suggested that by excluding the two centres in Spain in the EURAMIC Study, where CHD rates are very low and extremely low trans levels, the odds ratio in the third and fourth quartile increased to 1.53 (95% CI 1.02, 2.28) and 1.44 (0.94, 2.20) respectively. It was also suggested that in Spain, unlike in the other countries, most dietary TFA were from animal sources and this factor might have interaction with other dietary factors, or confounding factors, by unmeasured or poorly measured covariates. Using adipose tissue TFA as a biomarker of dietary intake, a study on British men with sudden death showed an odds ratio of 0.4 for the highest quintile of adipose tissue TFA (Roberts et al., 1995). However, it is suggested that the result may not be conclusive owing to its small sample size (n = 66), and it was observed that its 95% confidence interval figures for the highest TFA intake quintile (0.85, 2.84) were comparable to those in the Nurses Health Study (Ascherio and Willet, 1997). In Norway, Pedersen et al. (2000) also found adipose tissue content of TFA to be significantly higher in patients (n = 100) with first MI than in controls (n = 98) aged 45–75 years. The odds ratio for risk of MI between the fifth and first quintile of adipose tissue TFA was 2.81. The adipose tissue has been found to be a suitable biomarker of dietary intake of TFA, total polyunsaturated fatty acids, as well as n-3 and n-6 cis polyunsaturated fatty acids (Baylin et al., 2002; Garland et al., 1998; London et al., 1991). As the half-lives of fatty acids in adipose tissues are estimated to exceed 2 years, the adipose tissue is considered a stable and long-term store of fat. In this way, adipose tissue fatty acids provide an alternative approach that precludes recall bias to questionnaire-derived indices of long-term intake for trans and polyunsaturated fatty acids. The latter also suffers from ‘the problem of determining brand name usage of margarines, savoury snacks, and baked goods over time and would be limited by the fact that food composition has dramatically changed in recent history in this regard, making it almost impossible to estimate the aggregate of intakes over a number of years (Kohlmeier et al., 1997).
BLUK122-Dijkstra
42
September 25, 2007
19:43
Trans Fatty Acids
In Costa Rica, Colon-Ramos et al. (2006) reported a substantial change in adipose tissue TFA before 2000 and after. Before 2000, Baylin et al. (2003) reported a significant association between total adipose tissue TFA with risk of MI among Costa Rican adults. After adjusting for established risk factors and other confounders, the odds ratio for the highest quintile of total adipose tissue TFA was 2.94, compared with the lowest quintile. This association was attributed mainly to 18:2 TFA that were abundant in both adipose tissue and partially hydrogenated soya bean oil, margarines and baked products popular among Costa Ricans. However, following industrial modification leading to a reduction in the TFA content in the food supply, the association of TFA intake and MI was no longer significant during the study in 2000–2003 (Colon-Ramos et al., 2006). In Australia, a similar decrease in adipose tissue TFA was found following the removal of a major vegetable source of TFA in 1996 (Clifton et al., 2004). Prior to that, in the casecontrol study involving 209 cases, subjects in the highest quintile of TFA intake had an odds ratio of first MI of 2.25 (95% CI 1.16–4.32), compared with the lowest quintile intake. This positive association between levels of trans fat in adipose tissue and the risk of non-fatal MI was mitigated with the elimination of TFA from margarines. The Costa Rica and Australian studies provided evidence, based on adipose tissue TFA, that when the trans fats levels in the food supply are eliminated or substantially reduced, the association between TFA intake and development of CHD is no longer significant. Recent evidence has elucidated the biological mechanism exerted by TFA on the risk of CHD beyond changes on the lipid profile alone (Willet, 2006). Metabolic studies have revealed a positive association between dietary TFA and markers of systemic inflammation in women from the Nurses Health Study (Mozaffarian et al., 2004a) and patients with heart failure (Mozaffarian et al., 2004b). Higher intakes of TFA were associated with significant increase in the activity of the tumour necrosis factor (TNF) system among those with higher body mass index (Mozaffarian et al., 2006). Higher intake of TFA raised the concentrations of soluble TNF- receptors 1 and 2 (sTNF-R1 and sTNF-R2), interleukin-6 and C-reactive protein, all of which are known to be elevated in disease states such as CHD, diabetes and heart failure. The inflammatory effects of TFA are as damaging as those caused by saturated fats (Baer et al., 2004). In addition, higher intake of TFA was positively related to plasma concentrations of biomarkers of endothelial dysfunction, including soluble intercellular and vascular cell adhesion molecules (sICAM-1 and sVCAM-1) and E-selectin (Lopez-Garcia et al., 2005). Substitution of TFA for saturated fatty acids was also found to impair endothelial function, leading to a decrease in brachial artery flow-mediated vasodilatation by 29%, compared with intake of saturated fatty acids (de Roos et al., 2001). Thus, higher TFA intake promotes systemic inflammation and endothelial dysfunction, both of which play an integral part in the development and exacerbation of atherosclerotic lesions. As for the implication of high intake of TFA in elevating the level of Lp(a), an independent risk factor for the development of CHD, some studies have found a positive association (Almendingen et al., 1995; Lichtenstein et al., 1999; Mensink et al., 1992) but not others (Judd et al., 1998; Louheranta et al., 1999; Tholstrup and Samman, 2004). The latter investigated the effect of stearic, palmitic, oleic, trans-18:1 and linoleic acid on postprandial plasma Lp(a) on 16 young, healthy man and found pronounced increase in Lp(a) concentration after intake of all the test fats. However, trans fat did not change Lp(a) concentration during the study period. Intake of TFA contributes to a reduction in the size of low-density lipoprotein (LDL) particles, which confers an independent risk to CHD, since small and dense particles are more atherogenic than larger, less dense LDL particles (Lamarche et al., 2001). In a randomised
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
43
trial including 18 men and 18 women, consumption for 35 days of diets with different amounts of TFA (0.6, 9.4, 13.6 and 26.1 g) showed that LDL particle size decreased significantly in a dose-dependent fashion with increasing amounts of dietary TFA. Cholesterol concentrations in large and medium-sized LDL particles also increased proportionately to the amount of TFA in the diet (Mauger et al., 2003). Lemaitre et al. (2002) examined the role of TFA intake with sudden cardiac death, which is usually due to ventricular fibrillation and can occur as a first manifestation of heart disease. While the effects of free fatty acids in cardiac arrhythmias have been studied for more than 30 years (Katz, 2002), the link between TFA intake, TFA levels in erythrocyte membranes and sudden cardiac death is less well elucidated. Different trans isomers were found to exert their effects differently. High levels of trans 18:2 (cis-9, trans-12 and trans-9, cis-12 isomers of LA) in red blood cell membranes were found to be associated with markedly higher risk of sudden cardiac death than cell membrane levels of trans 18:1 (trans isomers of oleic acid), the major TFA in foods (Lemaitre et al., 2006). The author called for further studies to investigate the possible effects of trans 18:2 on arrhythmia, and meanwhile it would be prudent to limit dietary intake of trans 18:2. The majority of studies that examined the association between TFA intake and CHD risk have focused on industrially produced TFA, especially PHVO. TFA from partially hydrogenated fish oil (PHFO) has also been found to be as potent as butterfat, and significantly more potent than partially hydrogenated soya bean oil in raising plasma total and LDL-cholesterol levels in a study in Norway (Almendingen et al., 1995). In addition, Muller et al. (1998) also reported that, after 2 weeks of consuming a margarine based on PHFO, the LDL-cholesterol concentrations and the LDL:HDL ratios of subjects were 19% and 12.6% respectively, higher than those who consumed margarine based on vegetable oils. Cantwell et al. (2006) compared the postprandial effects of three solid fats (PHFO, lard and palm oil) on lipid and lipoprotein levels in eight normocholesterolaemic males. Consumption of all three high-fat test meals resulted in pronounced postprandial lipaemia, which is known to be associated with adverse metabolic events. Since TFA is known to interfere with cell membrane function, studies have been conducted to examine the effects of TFA on insulin sensitivity and consequently diabetes risk.
2.5.2
Diabetes
Compared with the evidence linking saturated fatty acids to the impairment of insulin sensitivity when substituted for unsaturated fatty acids, data relating TFA intake with diabetes risk is scanty, as reviewed by Ris´erus (2006). While there are studies that supported a positive association of TFA intake having adverse effects on insulin sensitivity, there are also studies that failed to do so. In the large prospective Nurses Health Study on ∼85 000 US female nurses who were followed for 16 years, Salmeron et al. (2001) found that while polyunsaturated fatty acid intake was associated with a substantial reduction in diabetes risk, TFA and dietary cholesterol were associated with increased risk. The authors estimated that ‘replacing 5% of energy from saturated fatty acid with energy from polyunsaturated fatty acid was associated with a 35% lower risk and that replacing 2% of energy from TFA with polyunsaturated fatty acid was associated with a 40% lower risk’. Based on the findings, it was suggested that in the US, given that the average intake of TFA from PHVO was ∼3% of energy, the incidence of type 2 diabetes could be reduced by ∼40% if these oils were consumed in their original, unhydrogenated form (Salmeron et al., 2001). Such findings have serious implications for the country food supply and questions were raised about the study’s method of analyses of
BLUK122-Dijkstra
44
September 25, 2007
19:43
Trans Fatty Acids
TFA intake. For example, the results could have been influenced by industrial changes in the TFA content of foods during the study period and wide variations that prevailed among foods in the same category. In contrast to the positive finding in the Nurses Health Study, others did not find consumption of TFA significantly associated with diabetes risk. These include the prospective studies on male health professionals (Meyer et al., 2001; Van Dam et al., 2002) and randomised crossover studies (Louheranta et al., 1999; Lovejoy et al., 2002). As pointed out by Ris´erus (2006), the literature suggests that TFA ‘has no significant effect on insulin sensitivity in lean healthy subjects’.
2.5.3
Cancer
The relationship between dietary fat and risk of cancer has been the subject of copious research studies worldwide. In epidemiological studies, cancers of the breast, colon, rectum and prostate are the common types of cancers that have been extensively investigated in relation to fat intake. Most of these studies examined the association of intakes of total fat and individual categories of fat with cancer risk, such as saturated fats, polyunsaturated fats and monounsaturated fats. There are relatively fewer studies that examined the relationship from the perspective of specific fatty acids intake, such as the essential fatty acids and omega-3 polyunsaturated fatty acids in the light of the critical roles these fatty acids play in human health. The literature on the association between TFA intake and risk of cancer is meagre, although in the past decade or so, increasingly more epidemiological studies have emerged, reflecting growing concerns for the adverse health effects arising from TFA intake. Early experimental animal studies dating back to the 1940s and international correlational observations provided support for a positive association between fat intake and development of cancer. The national recommendation by the US Committee on Diet, Nutrition and Cancer (Committee on Diet, Nutrition and Cancer, 1982) for consumption of saturated and unsaturated fats to be less than 30% of total calories in the diet constitutes an important influence on dietary guidelines of many countries. In relations to breast cancer, an extensive review by Lee and Lin (2000) of studies conducted in the 1980s and 1990s showed conflicting results for dietary fat as a risk factor. A pooled analysis of combined data from seven prospective studies in four countries found no significant association between total dietary fat intake and the risk of breast cancer (Hunter et al., 1996). There was no reduction in risk even among women whose energy intake from fat was less than 20% of total energy intake. Evidence from large cohort studies, including the Nurses Health Study and the Health Professionals Follow-up Study, did not support a positive association (Willet, 2001). In examining TFA intake and breast cancer risk, the data are equivocal. During a 14-year follow-up of the Nurses Health Study, there was no evidence of a significant association between intake of TFA and risk of breast cancer (Holmes et al., 1999). The authors reported that in multivariate models, the relative risk (95% CI) for a 1% increase in energy from TFA, the values were 0.92 (0.86–0.98). In the Nurses Health Study II, Cho et al. (2003) also did not find TFA intake to be significantly related to breast cancer risk, the multivariate relative risk for fifth and first quintile intake being 0.96, 95% CI (0.70, 1.31). In contrast, the EURAMIC Study in several European countries and Israel found that cancers of the breast and colon were associated negatively with cis monounsaturated fatty acids and positively with TFA, based on mean fatty acid composition of adipose tissue samples
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
45
(Bakker et al., 1997; Kohlmeier et al., 1997). A critique of the latter study was that it failed to take into account confounding risk factors for colorectal cancer (Nkondjock et al., 2003b). In relation to colorectal cancer, the overall evidence seems to indicate a lack of consistent positive association between intake of TFA and risk of colorectal cancer (Table 2.7). Among cohort studies, the Women’s Health Study on about 40 000 US women found that total fat intake was not related to colorectal cancer risk, neither were intakes of individual fat types nor major fatty acids including TFA (Lin et al., 2004). However, they found a positive association for fried foods away from home (e.g. French fries, fried chicken and fried fish; RR = 1.86 between fifth and first quintile intake). This result warrants further research to ascertain whether it is the presence of TFA, or acrylamide, a mutagenic chemical, in the brown surface of many heated food products, or other dietary factors that resulted in the positive association. Also, no strong association was established for TFA intake and risk of colorectal cancer among some recent case-control studies conducted in the US and Canada (Lin et al., 2004; Nkondjock et al., 2003a). As for risk of prostate cancer, there is some evidence that dietary fat is associated with increased prostate cancer risk and that specific fatty acids may have unique effects on prostate cancer risk; e.g. omega-6 fatty acids generally promote and omega-3 fatty acids generally prevent tumourigenesis (Bartsch et al., 1999). As for TFA intake, epidemiological evidence from a recent study on about 15 000 US physicians reported that plasma levels of TFA were associated with increased risk of developing prostate cancer, which were specific to organconfined and non-aggressive tumours (Chavarro et al., 2006). The -Carotene and Retinol Efficacy Trial (CARET), a randomised trial of supplemental -carotene and retinol for the prevention of lung cancer among 18 314 heavy smokers and asbestos-exposed workers, began in 1985 and ended prematurely in 1996 when it was determined that the supplements increased risks of lung cancer, cardiovascular disease and total mortality but had no effects on prostate cancer incidence or mortality (King et al., 2005). The authors found consistent trends for increasing prostate cancer risk with higher serum levels of C18 but not C16 trans fatty acids. Table 2.7 summarises the main finding from some epidemiological studies relating TFA intake and risk of cancer of the breast, colon, rectum and prostate undertaken in recent decades. Lack of consistent results from epidemiological studies may be due to several factors, including methodological issues, e.g. dietary assessment tools used (food-frequency questionnaire versus dietary records), and errors in estimating the TFA content, as few countries have the database for TFA content in foods. In the light of conflicting results, more rigorous studies are warranted. In the meantime, one could adopt the stand of the Danish Nutrition Council, which made the conclusion that ‘there was no evidence that dietary levels of trans fatty acids had any carcinogenic effect. Studies published since 1994 do not warrant revising this conclusion, but provide a basis for continued watchfulness of this possibility’ (Stender and Dyerberg, 2003).
2.6
CONCLUDING REMARKS
Epidemiological studies have shown a positive association between the intake of TFA and the risk of CHD and possibly diabetes, primarily accounted for by industrially produced TFA. TFA exerts its adverse effects on blood lipids, including increasing LDL-cholesterol concentration, decreasing the concentrations of HDL-cholesterol, lipoprotein(a) and triglycerides,
BLUK122-Dijkstra
46
September 25, 2007
19:43
Trans Fatty Acids
Table 2.7
Human studies relating trans fatty acids intake and risk of cancer.
Reference Colorectal cancer Lin et al. (2004)
Nkondjock et al. (2003a) Slattery et al. (2001) McKelvey et al. (1999)
Breast cancer Cho et al. (2003)
Voorrips et al. (2002)
Byrne et al. (2002)
Holmes et al. (1999) Kohlmeier et al. (1997)
Bakker et al. (1997) Petrek et al. (1997)
London et al. (1993)
Study setting; subjects; dietary assessment method US; Women’s Health Study began in 1993, 39 876 health professionals aged above 45 yr; semi-quantitative FFQ* French-Canadians; case (n = 402) – control (n = 668) aged 35–79 yr; FFQ US; case (n = 1993) – control (n = 2410) study; diet history 519 cases of colorectal adenomatous polyps and 551 controls aged 50–74 yr; FFQ by food groups containing PHVO
Findings Intake of TFA, total fat and major fatty acids not significantly associated with colorectal cancer risk; positive significant association found for intake of fried foods away from home TFA intake was not significantly associated with risk of colorectal cancer Weak association in women but not in men between TFA intake and colorectal cancer; OR = 1.5; 95% CI (1.0, 2.0) No significant association between adenomas and food groups that contain PHVO, namely sweetened baked goods, candy bars, French fries/chips and margarines/dressings
US Nurses Health Study II; 90 655 premenopausal women aged 26–46 yr; 1991–1999
TFA intake not significantly related to breast cancer risk; multivariate RR for fifth and first quintile 0.96; 95% CI (0.70, 1.31) The Netherlands Cohort Study on Diet Higher incidence of breast cancer with and Cancer; 62 573 postmenopausal higher intake of TFA; multivariate RR for women aged 55–69 began 1986; highest compared with lowest quintile: TRANSFAIR FFQ; 6.3 yr follow-up of 1.30; 95% CI (0.93, 1.80) cases US Nurses Health Study; 44 697 No significant increased rate of breast postmenopausal subjects without cancer with greater intake of TFA, total benign breast disease from 1980 to dietary fat and fat subtypes 1994; semi-quantitative FFQ US Nurses Health Study; 88 795 women No evidence of association between intake in 1980 follow-up for 14 yr; of total fat, TFA and other specific major semi-quantitative FFQ types of fat, and risk of breast cancer EURAMIC Study of five European cities; Positive association between adipose stores 698 postmenopausal cases primary of TFA and occurrence of breast cancer; breast cancer aged 50–74 yr; TFA covariate-adjusted RR between 75th and from gluteal fat biopsies 25th percentiles of total adipose TFA was 1.40; 95% CI (1.02, 1.93) Ecological study in 11 centres from 8 Cancers of the breast and colon associated European countries (EURAMIC Study); positively with TFA and negatively with adipose fatty acids cis monounsaturated fatty acids US 161 women with T1NO breast Odds of having positive lymph nodes cancer followed up for mean 7.3 yr; significantly lower with higher proportion adipose tissue breast and abdomen of TFA OR = 0.24, 95% CI (0.07, 0.77) aspirated Case-control postmenopausal women No major association between risk of 380 cases stage I or II breast cancer, breast cancer or proliferative benign 176 proliferative benign breast breast cancer and adipose tissue TFA cancer and 397 control; aspirates of and any categories of polyunsaturated subcutaneous fat from buttocks fatty acids (Continued)
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications Table 2.7
(Continued)
Reference
Study setting; subjects; dietary assessment method
Prostate cancer Chavarro et al. (2006)
US physicians case-control study; n =∼ 15 000; blood samples
King et al. (2005)
Hodge et al. (2004) Bakker et al. (1997)
47
US; CARET Study; 272 prostate cancer cases and 426 control; serum fatty acids methyl esters Australia; case (n = 858) – control (n = 905) aged <70 yr; FFQ
Findings Blood levels of TFA associated with increased risk of developing prostate cancer, specific to organ-confined and non-aggressive tumours Higher levels of serum C18 but not C16 TFA increased risk of prostate cancer
Margarine intake positively associated with prostate cancer OR = 1.3, 95% CI (1.0, 1.7) Ecological study in 11 centres from 8 No significant association between C18 European countries (EURAMIC Study); TFA and prostate cancer adipose fatty acids
*FFQ, food-frequency questionnaire.
reducing LDL-cholesterol particle size, impairing endothelial function, as well as promoting insulin resistance and thrombosis (Lopez-Garcia et al., 2005; Ris´erus, 2006). The average impact of TFA-induced changes in the LDL:HDL ratio correspond to tens of thousands premature deaths in the US alone (Ascherio, 2006). On a per-calorie basis, trans fat is said to increase CHD risk more than any other macronutrient (Mozaffarian et al., 2006). The adverse effect of TFA on metabolism of the essential fatty acids (all-cis) n-6 and n-3 fatty acids is a matter of concern. Findings of inverse associations between TFA and the essential n-6 and n-3 fatty acids, and TFA inhibition of AA biosynthesis in infants and young children indicate potential adverse effects of TFA on the normal child growth and development (Desci and Koletzko, 1995; Elias and Innis, 2001). Recent evidence provided support for less favourable neurologic development in neonates with high TFA in the umbilicus vein (Bouwstra et al., 2006). In the light of the vast evidence on the damaging health effects of TFA intake, legislations and modifications by the food industry have brought about substantial reduction of industrially produced TFA in the food supply in several countries. The Danish experience demonstrated that reduction in TFA exposure at the individual level can be brought about without noticeable effect on availability, price and quality of the affected foods (Stender et al., 2006). In Costa Rica, it was indirect international influence that has led to a TFA reduction in the food supply and, consequently, to a reduction in the risk of non-fatal MI (Colon-Ramos et al., 2006). As a result of these developments, dairy and meat have become the major remaining source of TFA in Europe. The question whether these ruminant TFA have the same effect on CHD risk as industrial TFA has not been settled (Katan, 2006). Jakobsen et al. (2006) called for controlled metabolic studies of the effect of intake of total and specific ruminant TFA on CHD risk. Procuring accurate estimates of TFA intake is fraught with challenges, including the fact that TFA content of foods is often not available in food composition tables. Alternative approaches have been used to assess TFA exposure, and these include measuring the TFA content in human milk, adipose tissue, plasma phospholipids and erythrocyte membranes.
BLUK122-Dijkstra
48
September 25, 2007
19:43
Trans Fatty Acids
Studies on relating TFA intakes to disease risk need to be mindful of the influence of other components in the diet, as well as lifestyle factors that may impinge on the diet–disease interaction.
REFERENCES Aitchison, J.M., Dunkley, W.L., Canolty, N.L. & Smith, L.M. (1977) Influence of diet on trans fatty acids in human milk. Am J Clin Nutr 30, 2006–2015. Akesson, B., Johansson, B.M., Svensson, M. & Ockerman, P.A. (1981) Content of trans-octadecenoic acid in vegetarian and normal diets in Sweden, analyzed by the duplicate portion technique. Am J Clin Nutr 34, 2517–2520. Allison, D.B., Egan, S.K., Barraj, L.M. et al. (1999) Estimated intakes of trans fatty and other fatty acids in the US population. J Am Diet Assoc 99, 166–174. Almendingen, K., Jordal, O., Kierulf, P., Sandstad, B. & Pederson, J.I. (1995) Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil and butter on serum lipoproteins and Lp(a) in men. J Lipid Res 36, 1370–1384. Anderson, N.K., Beerman, K.A., McGuire, M.A. et al. (2005) Dietary fat type influences total milk fat content in lean women. J Nutr 135, 416–421. Aro, A., Kardinaal, A.F.M., Salminen, I. et al. (1995) Adipose tissue isomeric trans fatty acids and risk of myocardial infarction in nine countries: the EURAMIC study. Lancet 345, 273–278. Ascherio, A. (2006) Trans fatty acids and blood lipids. Atheroscler Suppl 7, 25–27. Ascherio, A., Hennekens, C.H., Buring, J.E. et al. (1994) Trans-fatty acids intake and risk of myocardial infarction. Circulation 89, 94–101. Ascherio, A., Rimm, E.B., Giovannucci, E.L. et al. (1996) Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States. BMJ 313, 84–90. Ascherio, A. & Willet, W.C. (1997) Health effects of trans fatty acids. Am J Clin Nutr 66 (suppl), 1006S– 1010S. Baer, D.J., Judd, J.T., Clevidence, B.A. & Tracy, R.P. (2004) Dietary fatty acids affect plasma markers of inflammation in health men fed controlled diets: a randomized crossover study. Am J Clin Nutr 79, 969–973. Bahrami, G. & Rahimi, Z. (2005) Fatty acid composition of human milk in Western Iran. Eur J Clin Nutr 59, 494–497. Bakker, N., van’t Veer, P. & Zock, P.L. (1997) Adipose fatty acids and cancers of the breast, prostate and colon: an ecological study. Int J Cancer 72, 587–591. Bartsch, H., Nair, J. & Owen, R.W. (1999) Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers, Cardiogenesis 30, 2209–2218. Bauman, D.E., Perfield, J.W. & Lock, A.L. (2004) Effect of trans fatty acids on milk fat and their impact on human health. http://animal.cals.arizona.edu. Accessed 17 October 2006. Baumgard, L.H., Corl, B.A., Dwyer, D.A., Saebo, A. & Bauman, D.E. (2000) Identification of the conjugated linoleic acid isomer that inhibits milk fat synthesis. Am J Physiol 278, R179–R184. Baylin, A., Kabagambe, E.K., Ascherio, A., Spiegelman, D. & Campos, H. (2003) High 18:2 trans-fatty acids in adipose tissue are associated with increased risk of nonfatal acute myocardial infarction in Costa Rican adults. J Nutr 133, 1186–1191. Baylin, A., Kabagambe, E.K., Siles, X. & Campos, H. (2002) Adipose tissue biomarkers of fatty acid intake. Am J Clin Nutr 76, 750–757. Baylin, A., Mi Kyung, K., Donovan-Palmer, A. et al. (2005) Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. Am J Epidemiol 162, 373–381. Bertolino, C.N., Castro, T.G., Sartorelli, D.S., Ferreira, S.R. & Cardosa, M.A. (2006) Dietary trans fatty acid intake and serum lipid profile in Japanese-Brazilians in Bauru, Sao Paulo, Brazil. Cad Saude Publica 22, 357–364. Boatella, J., Rafecas, M., Codnoy, R. et al. (1993) Trans fatty acid content of human milk in Spain. J Pediatr Gastroenterol Nutr 16, 432–434. Bolton-Smith, C., Woodward, M., Fenton, S., McCluskey, M.K. & Brown, C.A. (1995) Trans fatty acids in the Scottish diet. Br J Nutr 74, 661–670.
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
49
Booker, C. & Mann, J. (2005) The relationship between saturated and trans unsaturated fatty acids and LDL-cholesterol and coronary heart disease. A review undertaken for Food Standards Australia New Zealand, Edgar National Centre for Diabetes Research, University of Otago, New Zealand. www.foodstandrds.gov.au. Accessed on 11 October 2006. Bouwstra, H., Dijck-Brouwer, J., Decsi, T. et al. (2006) Neurologic condition of healthy term infants at 18 months: positive association with venous umbilical DHA status and negative association with umbilical trans fatty acids. Pediatr Res 60, 334–339. Byrne, C., Rockett, H. & Holmes, M.D. (2002) Dietary fat, fat subtypes, and breast cancer risk: lack of an association among postmenopausal women with no history of benign breast disease. Cancer Epidemiol Biomarkers Prev 11, 261–265. Cantwell, M.M., Flynn, M.A.T. & Gibney, M.J. (2006) Acute postprandial effect of hydrogenated fish oil, palm oil and lard on plasma cholesterol, triacylglycerol and non-esterified fatty acid metabolism in normocholesterolemic males. Br J Nutr 95, 787–794. Carlson, S.E., Clandinin, M.T., Cook, H.W., Emken, E.A. & Filer, L.J. (1997) Trans fatty acids: infant and fetal development. Am J Clin Nutr 66, 715S–736S. Chappell, J.E., Clandinin, M.T. & Kearney-Volpe, C. (1985) Trans fatty acids in human milk lipids: influence of maternal diet and weight loss. Am J Clin Nutr 42, 49–56. Chardigny, J.M., Wolff, R.L., Mager, E. et al. (1995) Trans mono- and polyunsaturated fatty acids in human milk. Eur J Clin Nutr 49, 523–531. Chavarro, J., Stampfer, M.J., Campos, H. et al. (2006) A prospective study of blood trans fatty acid levels and risk of prostate cancer. In: Proceedings of the American Association for Cancer Research, Vol. 47, Abstract #4004, 943, Washington DC April 1-5, 2006. Chen, Z.Y., Kwan, K.Y., Tong, K.K. et al. (1997) Breast milk fatty acid composition: a comparative study between Hong Kong and Chongqing Chinese. Lipids 32, 1061–1067. Chen, Z.Y., Pelletier, G., Hollywood, R. & Ratnayake, W.M.N. (1995) Trans fatty acid isomers in Canadian human milk. Lipids 30, 15–21. Cho, E., Spiegelman, D., Hunter, D.J. et al. (2003) Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst 95, 1079–1085. Clifton, P.M., Keogh, J.B. & Noakes, M. (2004) Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J Nutr 134, 874–879. Colon-Ramos, U., Baylin, A. & Campos, H. (2006) The relation between trans fatty acids levels and increased risk of myocardial infarction does not hold at lower levels of trans fatty acids in the Costa Rican food supply. J Nutr 136, 2887–2892. Committee on Diet, Nutrition and Cancer (1982) Assembly of Life Sciences, and National Research Council. In: Diet, Nutrition, and Cancer. National Academic Press, Washington. Craig-Schmidt, M.C. (2006) World-wide consumption of trans fatty acids. Atheroscler Suppl 7, 1–4. de Roos, N.M., Bots, M.L. & Katan, M.B. (2001) Replacement of dietary saturated fatty acids by trans fatty acids lowers serum HDL cholesterol and impairs endothelial function in health men and women. Arterioscler Thromb Vasc Biol 21, 1233–1237. Desci, T., Burus, I., Moln´ar, S., Minda, H. & Veitl, V. (2001) Inverse association between trans isomeric and long-chain polyunsaturated fatty acids in cord blood lipids of full-term infants. Am J Clin Nutr 74, 364–368. Desci, T. & Koletzko, B. (1995) Trans fatty acids impair linoleic acid metabolism in children? Ann Nutr Metab 39, 36–41. Drummond, L. (2005) Deep Frying in New Zealand – A Review and Technology Update. National Heart Foundation of New Zealand’s Food and Nutrition Working Group, Auckland, New Zealand. Elias, S.A. & Innis, S.M. (2002) Bakery food are the major dietary source of trans-fatty acids among pregnant women with diets providing 30 percent energy from fat. J Am Diet Assoc 102, 46–51. Elias, S.L. & Innis, S.M. (2001) Infant plasma trans, n-6, and n-3 fatty acids and conjugated linoleic acids are related to maternal plasma fatty acids, length of gestation, and birth weight and length. Am J Clin Nutr 73, 807–814. Enig, M.G., Atal, S., Keeney, M. & Sampugna, J. (1990) Isometric trans fatty acids in the U.S. diet. J Am Coll Nutr 9, 471–486. Enig, M.G., Pallansch, L.A., Sampugna, J. & Keeney, M. (1983) Fatty acid composition of the fat in selected food items with emphasis on trans components. J Am Oil Chem Soc 60, 1788–1795. Eyres, L. (2000) Fats, fatty acids and cholesterol. NZ Food J 29, 143–146.
BLUK122-Dijkstra
50
September 25, 2007
19:43
Trans Fatty Acids
Food and Agriculture Organization (FAO) Food Balance Sheets for 1965–2003. http://www.fao.org/es/ess/ faostat/foodsecurity/Files/FoodConsumptionFoodGroups en.xls.Accessed 14 June 2007. Food and Agriculture Organization (FAO) (2006) Food Outlook Global Market Analysis, 1 June 2006 issue. http://www.fao.org/docrep/009/J7927e/J7927e00.htm. Accessed 14 June 2007. Food and Drug Administration (FDA) (2003) Federal Register 21 CFR Part 101 Part III. In: Food Labeling; Trans Fatty Acids in Nutrition Labeling; Final Rule and Proposed Rule, Vol. 68, no. 133. Department of Health and Human Services, United States. Food Standards Australia New Zealand (FSANZ) (2005) Trans Fatty Acids. http;//www.foodstandards.gov. au/newsroom/factsheets2007/transfattyacidsmay203552.cfm. Accessed 14 June 2007. Friesen, R. & Innis, S.M. (2006) Trans fatty acids in human milk in Canada declined with the introduction of trans fat food labeling. J Nutr 136, 2558–2561. Garland, M., Sacks, F.M., Colditz, G.A. et al. (1998) The relation between dietary intake and adipose tissue composition of selected fatty acids in US women. Am J Clin Nutr 67, 25–30. Ghafoorunissa R.V. (1996) Fats in Indian diets and their nutritional and health implications. Lipids 31, S287–S291. Gunstone, F.D. (2002) Production and trade of vegetable oils. In: Vegetable Oils in Food Technology (ed. F.D. Gunstone). CRC Press, Oxford, 1–17. Harnack, L., Lee, S., Schakel, S.F. et al. (2003) Trends in the trans fatty acid composition of the diet in a metropolitan area: the Minnesota Heart Survey. J Am Diet Assoc 103, 1160–1166. He, K., Merchant, A., Rimm, E.B., Rosner, B.A., Stampfer, M.J. & Willet, W.C. (2003) Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. BMJ 327, 777–382. Health Canada (2006) TRANSforming the food supply. Report of the Trans Fat Task Force submitted to the Minister of Health, June 2006. www.hc-sc.gc.ca. Accessed 4 April 2007. Heckers, H., Melcher, F.W. & Dittmar, K. (1979) Zum t¨aglichen Verzehr trans-isomerer Fetts¨auren. Eine Kalkulation unter Zugrundelegung der Zusammensetzung handels¨ublicher Fette und verschiedener menschlicher Depotfette. Fette Seifen Anstrichm 81, 217–226. Hodge, A.M., English, D.R., McCredie, M.R. et al. (2004) Foods, nutrients and prostate cancer. Cancer Causes Control 15, 11–20. Holmes, M.D., Hunter, D.J., Colditz, G.A. et al. (1999) Association of dietary intake of fat and fatty acids with risk of breast cancer. J Am Med Assoc 281, 914–920. Hornstra, G. (2000) Essential fatty acids in mothers and their neonates. Am J Clin Nutr 71 (suppl), 1262S– 1269S. Hulshof, K.F.A.M., van Erp-Baart, M.A., Anttolainen, M. et al. (1999) Intake of fatty acids in Western Europe with emphasis on trans fatty acids: the TRANSFAIR study. Eur J Clin Nutr 53, 143–157. Hunter, D.J., Spiegelman, D., Adami, H.O. et al. (1996) Cohort studies of fat intake and the risk of breast cancer – a pooled analysis. N Engl J Med 334, 356–361. Hunter, J.E. & Applewhite, T.H. (1991) Reassessment of trans fatty acid availability in the US diet. Am J Clin Nutr 54, 363–369. Innis, S.M. (2006) Trans fatty acids intakes during pregnancy, infancy and early childhood. Atheroscler Suppl 7, 17–20. Innis, S.M., Green, T.J. & Halsey, T.K. (1999) Variability in the trans fatty acid content of foods within a food category: implications for estimation of dietary trans fatty acid intakes. J Am Coll Nutr 18, 255–260. Innis, S.M. & King, D.J. (1999) Trans fatty acids in human milk are inversely associated with concentrations of essential all-cis n-6 and n-3 fatty acids and determine trans, but not n-6 and n-3 fatty acids in plasma lipids of breast-fed infants. Am J Clin Nutr 70, 383–390. Institute of Food Science and Technology (IFST) (2004) Information Sheet on Trans Fatty Acids, 12 pp. http://www.Ifst.org. Accessed 12 September 2006. Ismail, J., Jafar, T.H., Jafary, F.H. et al. (2004) Risk factors for non-fatal myocardial infarction in young South Asian adults. Heart 90, 259–263. Jakobsen, M.U., Bysted, A., Niels, A.L. et al. (2006) Intake of ruminant trans fatty acids and risk of coronary heart disease. Atheroscler Suppl 7, 9–11. Jank, M.S. (2006) Soybeans. Expansion of production, consumption and trade barriers. Presented at the 2nd Round Table on Responsible Soy, Assuncion, Paraquay. Judd, J.T., Baer, D.J., Clevidence, B.A. et al. (1998) Effects of margarine compared with those of butter on blood lipid profiles related to cardiovascular risk factors in normolipemic adults fed controlled diet. Am J Clin Nutr 68, 768–777.
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
51
Katan, M.B. (2006) Regulation of trans fats: the gap, the Polder, and McDonald’s French fries. Atheroscler Suppl 7, 63–66. Katz, A.M. (2002) Trans-fatty acids and sudden cardiac death. Circulation 105, 669–671. Kennedy, E.T., Bowman, S.A. & Powell, R. (1999) Dietary-fat intake in the US population. J Am Coll Nutr 18, 207–212. King, I.B., Kristal, A.R., Schaffer, S., Thornquist, M. & Goodman, G.E. (2005) Serum trans-fatty acids are associated with risk of prostate cancer in -Carotene and Retinal Efficacy Trial. Cancer Epidemiol, Biomarkers Prev 14, 988–992. Kohlmeier, L., Simonsen, N., van’t Veer, P. et al. (1997) Adipose tissue trans fatty acids and breast cancer in the European Community Multicenter Study on antioxidants, myocardial infarction, and breast cancer. Cancer Epidemiol Biomarkers Prev 6, 705–710. Koletzko, B. (1992) Trans fatty acids may impair biosynthesis on long-chain polyunsaturates and growth in man. Acta Paediatr 81, 301–306. Koletzko, B., Mrotzek, M. & Bremer, H.J. (1988) Fatty acid composition of mature human milk in Germany. Am J Clin Nutr 47, 954–959. Koletzko, B., Thiel, I. & Abiodun, P.O. (1991) Fatty acid composition of mature human milk in Nigeria. Z Ernahrungswiss 30, 289–297. Kromhout, D., Menotti, A., Bloemberg, B. et al. (1995) Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary artery disease: the Seven Countries Study. Prev Med 24, 308– 315. Lamarche, B., St-Pierre, A.C., Ruel, I.L. et al. (2001) A prospective, population-based study of low density lipoprotein particles size as a risk factor for ischemic heart disease in men. Can J Cardiol 17, 859–865. Lee, M.M. & Lin, S.S. (2000) Dietary fat and breast cancer. Annu Rev Nutr 20, 221–248. Lemaitre, R.N., King, I.B., Mozaffarian, D., Sootodehnia, N. & Siscovick, D.S. (2006) Trans-fatty acids and sudden cardiac death. Atheroscler Suppl 7, 13–15. Lemaitre, R.N., King, I.B., Trivellore, E. et al. (2002) Cell membrane trans-fatty acids and the risk of primary cardiac arrest. Circulation 105, 697–701. Leth, T., Jensen, H.G., Mikkelsen, A.A. & Anette, B. (2006) The effect of the regulation on trans fatty acid content in Danish food. Atheroscler Suppl 7, 53–56. Lichtenstein, A.H., Ausman, L.M., Jalbert, S.M. & Schaefer, E.J. (1999) Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 340, 1933–1940. Lin, J., Zhang, S.M., Cook, N.R., Lee, I.M. & Buring, J.E. (2004) Dietary fat and fatty acids and risk of colorectal cancer in women. Am J Epidemiol 160, 1011–1022. London, S.J., Sacks, F.M., Caesar, J. et al. (1991) Fatty acid composition of subcutaneous adipose tissue and diet in postmenopausal US women. Am J Clin Nutr 54, 340–345. London, S.J., Sacks, F.M., Stampfer, M.J. et al. (1993) Fatty acid composition of the subcutaneous adipose tissue and risk of proliferative benign breast disease and breast cancer. J Natl Cancer Inst 85, 785–793. Lopez-Garcia, E., Schulze, M.B., Meigs, J.B. et al. (2005) Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 135, 562–566. Louheranta, A.M., Turpeinen, A.K. Vidgren, H.M., Schwab, U.S. & Uusitupa, M.I. (1999) A high-trans fatty acid diet and insulin sensitivity in young health women. Metabolism 48, 870–875. Lovejoy, J.C., Smith, S.R. & Champagne, C.M. (2002) Effects of diets enriched in saturated (palmitic), monounsaturated (oleic), or trans (elaidic) fatty acids on insulin sensitivity and substrate oxidation in healthy adults. Diab Care 25, 1283–1288. Mauger, J., Lichtenstein, A.H., Ausman, L.M. et al. (2003) Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr 78, 370–375. McKelvey, W., Greenland, S., Chen, M.J. et al. (1999) A case-control study of colorectal adenomatous polyps and consumption of foods containing partially hydrogenated oils. Cancer Epidemiol Biomarkers Prev 8, 519–524. Mensink, R.P. & Katan, M.B. (1990) Effect of dietary trans fatty acids on high-density and low-density lipoprotein levels in healthy subjects. N Engl J Med 323, 439–445. Mensink, R.P., Zock, P.L., Katan, M.B. & Hornstra, G. (1992) Effect of dietary cis and trans fatty acids on serum lipoprotein(a) levels in humans. J Lipid Res 33, 1493–1501. Meyer, K.A., Kushi, L.H., Jacobs, D.R., Jr, & Folsom, A.R. (2001) Dietary fat and incidence of type 2 diabetes in older Iowa women. Diab Care 24, 1528–1535. Mojska, H., Socha, P., Socha, J. et al. (2003) Trans fatty acids in human milk in Poland and their association with breastfeeding mothers’ diets. Acta Paediatr 92, 1381–1387.
BLUK122-Dijkstra
52
September 25, 2007
19:43
Trans Fatty Acids
Monge-Rojas, R., Campos, H. & Rojas, X.F. (2005) Saturated and cis- and trans-unsaturated fatty acids intake in rural and urban Costa Rican adolescents. J Am Coll Nutr 24, 286–293. Mosley, E.E., Wright, A.L., McGuire, M.K. & McGuire, M.A. (2005) Trans fatty acids in milk produced by women in the United States. Am J Clin Nutr 82, 1292–1297. Mozaffarian, D., Katan, M.B., Ascherio, A., Stamper, M.J. & Willet, W.C. (2006) Trans fatty acids and cardiovascular disease. N Engl J Med 354, 1601–1613. Mozaffarian, D., Pischon, T., Hankinson, S.E. et al. (2004a) Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 79, 606–612. Mozaffarian, D., Rimm, E.B., King, I.B. et al. (2004b) Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr 80, 1521–1525. Muller, H., Jordal, O., Seljeflot, I. et al. (1998) Effect on plasma lipids and lipoproteins of replacing partially hydrogenated fish oil with vegetable fat in margarine. Br J Nutr 80, 243–251. Nestel, P.J. (1994) Effect of trans fatty acids on serum lipoprotein levels in man. In: Fatty Acids and Lipids: Biological Aspects (eds C. Galli, A.P. Simopoulos & E. Tremoli). World Review Nutrition Dietetics, Karger, Basel, Switzerland, pp. 187–189. Nielsen, S.J., Siega-Riz, M. & Popkin, B.M. (2002) Trends in energy intake in U.S. between 1977 and 1996: similar shifts seen across age groups. Obes Res 10, 370–378. Nkondjock, A., Shatenstein, B., Maisonneuve, P. & Ghadirin P. (2003a) Assessment of risk associated with specific fatty acids and colorectal cancer among French-Canadians in Montreal: a case-control study. Int J Epidemiol 32, 200–209. Nkondjock, A., Shatenstein, B., Maisonneuve, P. & Ghadirian, P. (2003b) Specific fatty acids and human colorectal cancer: an overview. Cancer Detect Prev 27, 55–66. Noakes, M. & Nestel, P. (1994) Trans fatty acids in the Australian diet. Food Aust 46, 124–129. Oh, K., Hu, F.B., Manson, J.E. et al. (2005) Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the Nurses’ Health Study. Am J Epidemiol 161, 672–679. Ohrigge, J.B., Gulley, R.M. & Emken, E.A. (1982) Occurrence of octadecenoic fatty acid isomers from hydrogenated fats in human tissue lipid classes. Lipids 17, 521–557. Okamoto, T., Matsuzaki, H., Maruyama, T., Niiya, I. & Sugano, M. (1999) Trans-fatty acid content hydrogenated oils and estimated intake. J Jpn Oil Chem Soc 48, 1411–1414. Oomen, C.M., Ocke, M.C., Freskens, E.J. et al. (2001) Association between trans fatty acid intake and 10years risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet 357, 746–751. Pedersen, J.I., Ringstad, J., Almendingen, K. et al. (2000) Adipose tissue fatty acids and risk of myocardial infarction: a case-control study. Eur J Clin Nutr 54, 618–625. Perryman, S. & Stone, M. (2006) Trans fats . . . new labels. www.fshn.cahs.colostate.edu. Accessed 9 October 2006. Petrek, J.A., Hudgins, L.C., Ho, M., Bajorunas, D.R. & Hirsch, J. (1997) Fatty acid composition of adipose tissue, an indication of dietary fatty acids, and breast cancer prognosis. J Clin Oncol 15, 1377–1384. Pietinen, P., Ascherio, A., Korhonen, P. et al. (1997) Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. Am J Epidemiol 145, 876–887. Popkin, B.M., Siega-Riz, A.M., Haines, P.S. & Jahns, L. (2001) Where’s the fat? Trends in the U.S. diets 1965–1996. Prev Med 32, 245–254. Ratnayake, W.M.N. (2002) Dietary fat, coronary heart disease, serum cholesterol and quality of fat of the Canadian diet. Presented at the 17th Annual Meeting of the Canadian Section of AOCS on Advances in Nutraceuticals, Toronto. Ratnayake, W.M.N., Pelletier, G., Hollywood, R., Bacler, S. & Leyte, D. (1998) Trans fatty acids in Canadian margarines: recent trends. J Am Oil Chem Soc 75, 1587–1594. Ris´erus, U. (2006) Trans fatty acids and insulin resistance. Atheroscler Suppl 7, 37–39. Roberts, T.L., Wood, D.A., Riemersma, R.A., Gallagher, P.J. & Lampe, F.C. (1995) Trans isomers of oleic and linoleic acids in adipose tissue and sudden cardiac death. Lancet 345, 278–282. Salmeron, J., Hu, F.B., Manson, J.E. et al. (2001) Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 73, 1019–1026. Semma, M. (2002) Trans fatty acids: properties, benefits and risks. J Health Sci 48, 7–13. Singh, R.B., Niaz, M.A., Ghosh, S. et al. (1996) Association of trans fatty acids (vegetable ghee) and clarified butter (Indian ghee) intake with higher risk of coronary artery disease in rural and urban population with low fat consumption. Int J Cardiol 56, 289–298.
BLUK122-Dijkstra
September 25, 2007
19:43
Epidemiology and health implications
53
Skeaff, C.M. & Gowans, S. (2006) Home use of margarine is an important determinant of plasma trans fatty acid status: a biomarker study. Br J Nutr 96, 377–383. Slattery, M.L., Benson, J., Ma, K.N., Shaffer, D. & Potter, J.D. (2001) Trans fatty acids and colon cancer. Nutr Cancer 39, 170–175. Slover, H.T., Thompson, R.H., Davis, C.S. & Merola, G.V. (1985) Lipids in margarines and margarine-like foods. J Am Oil Chem Soc 62, 775–786. Stender, S. & Dyerberg, J. (2003) The influence of trans fatty acids on health. A report of the Danish Nutrition Council. www.ernaeringsraadet.dk. Accessed 15 September 2006. Stender, S., Dyerberg, J., Bysted, A., Leth, T. & Astrup, A. (2006) A trans journey. Atheroscler Suppl 7, 47–52. Sundram, K., Ismail, A., Hayes, K.C., Jeyemalar, R. & Pathmanathan, R. (1997) Trans (elaidic) fatty acids adversely affect the lipoprotein profile relative to specific saturated fatty acids in humans. J Nutr 127 (suppl), 514S–520S. Tarrago-Trani, M.T., Phillips, K.M., Lemar, L.E. & Holden, J.M. (2006) New and existing oils and fats used in products with reduced trans-fatty acid content. J Am Diet Assoc 106, 867–880. Tholstrup, T. & Samman, S. (2004) Postprandial lipoprotein (a) is affected differently by specific individual dietary fatty acids in healthy young men. J Nutr 134, 2550–2555. Troisi, R., Willet, W.C. & Weiss, S.T. (1992) Trans-fatty acid intake in relation to serum lipid concentrations in adult men. Am J Clin Nutr 56,1019–1024. United States Department of Agriculture (USDA) Center for Nutrition Policy and Promotion (CNPP). Nutrient Content of U.S Food Supply Report 1909–2000. http;//www.cnpp.usda.gov/publications/foodsupply/ FoodSupply1909-2000.pdf. Accessed 14 June 2007. United States Department of Agriculture (USDA) Nutrient Data Laboratory. Fat and Fatty Acid Content of Selected Foods Containing Trans Fatty Acids. http://www.nal.usda.gov. Accessed 5 April 2007. Van Dam, R.M., Rimm, E.B., Willett, W.C., Stampfer, M.J. & Hu, F.B. (2002) Dietary patterns and risk for type 2 diabetes mellitus in US men. Ann Int Med 136, 201–209. Van den Reek, M.M., Craig-Schmidt, M.C., Weete, J.D. & Clark, A.F. (1986) Fat in the diets of adolescent girls with emphasis on isomeric fatty acids. Am J Clin Nutr 43, 530–537. Voorrips, L.E., Brants, H.A.M., Kardinaal, A.F.M., Hiddink, G.J. & van den Brandt, P.A. (2002) Intake of conjugated linoleic acid, fat, and other fatty acids in relation to postmenopausal breast cancer: the Netherlands Cohort Study on Diet and Cancer. Am J Clin Nutr 76, 873–882. Wiererov´a, P.D., B´ılkov´a, D., Rambouskov´a, J. & Andel, M. (2002) Trans fatty acids in subcutaneous fat of pregnant women and in human milk in the Czech Republic. Ann NY Acad Sci 967, 544–547. Willett, W.C. (2001) Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarker Prev 10, 3–8. Willet, W.C. (2006) Trans fatty acids and cardiovascular disease. Atheroscler Suppl, 7, 5–8. Willet, W.C., Stampfer, M.J., Manson, J.E. et al. (1993) Intake of trans fatty acids and risk of coronary heart disease among women. Lancet 341 (8845), 581–585. Wilson, N., Russell, D., Paulin, J. et al. (1990) Life in New Zealand Summary Report. University of Otago, Dunedin.
BLUK122-Dijkstra
3
September 25, 2007
20:0
Conjugated linoleic acid effects on body composition and clinical biomarkers of disease in animals and man: metabolic and cell mechanisms
Klaus W.J. Wahle, Marie Goua, Simona D’Urso and Steven D. Heys 3.1
GENERAL INTRODUCTION: CONJUGATED LINOLEIC ACIDS AND HEALTH
Conjugated linoleic acids (CLAs) are fatty acids that are found naturally in foods derived from ruminant animals and they are mainly trans fatty acids; cis,cis conjugated double bonds also occur in extremely low concentrations in nature. CLAs were first reported by Pariza and his group whilst investigating the carcinogenic components of grilled beef (Pariza and Hargreaves, 1985). Surprisingly, since trans fatty acids are generally regarded as detrimental to health, these modified dienoic trans fatty acids derived from the parent linoleic acid (18:2n-6) were found to have anti-cancer rather than pro-cancer properties. Since these early observations, a multiplicity of purported beneficial as well as detrimental effects of CLAs on health have been reported. These have focused mainly on their effects, through dietary inclusion, in animal models of human diseases or through addition to various types of animal and human cells in culture. Different CLAs are reported to be anti-cancer, anti-atherogenic, anti-adipogenic, anti-diabetogenic and/or anti-inflammatory (see Table 3.1). They also appear to elicit both beneficial and detrimental regulatory effects, or be without effect, on immune function, lipid and eicosanoid metabolism, cytokine and immunoglobulin production. They can also modulate the expression of a number of important genes, either directly by activating specific fatty acid response elements in their reporter regions or through regulation of the expression of specific transcription factors involved in the many metabolic processes they affect (see below). The majority of studies with CLAs have been carried out using chemically synthesised products that contain a mixture of cis and trans isomers, either as capsules or added to certain foods (see below). More recent studies report using individual, highly purified isomers of either cis-9, trans-11 and/or trans-10, cis-12 in animals (mainly mice). A small number of studies also report using these purified isomers individually in dietary supplementation in man. The findings contrast with the earlier findings using CLA mixtures and suggest that individual isomers of CLA have distinct effects on whole-body physiology and cell mechanisms. The trans-10, cis-12 isomer appears to elicit detrimental effects on health, mainly through increased peroxidative processes (see Bhattacharya et al., 2006; Ledoux and Laloux, 2006; Park and Pariza, 2007; Salas-Salvado et al., 2006; Tricon et al., 2005; Wahle et al., 2004; below). These observations need to be assessed critically and further substantiated before they can be regarded as fact. It is intriguing to consider why no detrimental effects are observed when the uncommon trans-10, cis-12 isomer is given as a supplement with varying proportions of the more common cis-9, trans-11 isomer? Also, why can a mixture of two isomers elicit effects that are different from those observed with
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects Table 3.1
55
Some reported general health benefits ascribed to consumption of CLAs.
r
Anti-cancer
r
Inhibit tumour growth/metastasis Inhibit cell proliferation Inhibit angiogenesis Elicit pro-apoptotic conditions
Anti-atherosclerotic
r
Reduce plaque formation Reduce adhesion molecule expression Inhibit cytokine production Inhibit angiogenesis Elicit plaque regression
Anti-obesity
r
Reduce fat deposition Reduce insulin resistance/diabetes Increase adipocyte apoptosis Inhibit lipoprotein lipase activity
Modulation of immune functions
Inhibit inflammatory cytokines Inhibit inflammatory eicosanoids Modulate immunoglobulin formation Regulate TH 1/TH 2 reactions
individual isomers? Furthermore, why do mice generally, but not always, respond differently, often opposingly, to other animal species, including humans? This chapter on CLAs attempts to unravel some of the conflicting data relating to CLAs and their putative beneficial and detrimental effects on human health, albeit through the surrogate use of animal models and cell cultures. Nutritional intervention studies on healthy volunteers and a variety of patients are still insufficient to provide an unequivocal perspective of the beneficial or detrimental effects of these intriguing fatty acids. This chapter is not all-encompassing, but somewhat subjective and eclectic in scope. Hopefully, it will present a balanced picture by highlighting some of the recent positive as well as negative data reported for these fatty acids in relation to various aspects of human health. It is hoped that it will provide a platform for further debate whilst seeking some form of current consensus relating to the safety and health aspects of various types of CLAs. Readers are referred to a number of excellent recent reviews (Bhattacharya et al., 2006; Ledoux and Laloux, 2006; Park and Pariza, 2007; Tricon et al., 2005; Wahle et al., 2004) for fuller details and to the website of the University of Wisconsin, Madison, which provides the most recent updates on all published material relating to CLAs (http://www.wisc.edu/fri/clarefs.htm).
3.2 3.2.1
STRUCTURE, DIETARY ORIGINS AND CONSUMPTION OF CLAs IN MAN Structure
CLAs, as their name implies, consist of a series of positional and geometric isomers of linoleic acid (cis-9, cis-12-18:2n-6), where one or both of the double bonds are in either the cis or the trans configuration at different positions along the acyl chain. The term conjugation in this context means that the double bonds are separated by a simple carbon–carbon linkage rather than by the usual methylene (CH2 ) group (Fig. 3.1). A number of cis,cis; cis,trans; trans,cis and trans,trans isomers with the double bonds at various locations along the acyl chain,
BLUK122-Dijkstra
56
September 25, 2007
20:0
Trans Fatty Acids 9
12 Linoleic acid
11
cis-9,trans-11 CLA
trans-10,cis-12 CLA Fig. 3.1
12
9
10
COOH
COOH
COOH
Structure of the parent omega-6 fatty acid linoleic acid and its two main conjugated derivatives.
from C6 to C15 but predominantly in positions 8–10, 9–11, 10–12 and 11–13, have been identified by various chemical reductive, chromatographic and spectroscopic techniques. These methods are described in Chapter 4, and readers are also referred to some excellent reviews on this subject (Adlof, 2003; Christie, 2003; Dobson 2003). CLAs are conjugated isomers of the dienoic, 18-carbon linoleic acid. Other polyunsaturated fatty acids (PUFAs) with longer carbon chains and two or more double bonds can also be utilised as substrates for biohydrogenation, catalytic, chemical hydrogenation or chain elongation and desaturation processes resulting in 18-carbon or possibly, 19-carbon trienoic and even 20- and 22-carbon tetraenoic, pentaenoic and hexadecanoic fatty acids, with conjugated cis,trans; trans,cis; cis,cis or trans,trans double bonds (Banni et al., 2004; Ringseis et al., 2006; Tsuzuki et al., 2006). The latter can be formed by chain elongation and further desaturation of the dienoic or trienoic precursors in mammalian tissues (Banni et al., 2004). Although not as extensively studied as CLAs, some of these less usual isomers appear to have metabolic effects similar to those of the CLAs and will not be discussed here.
3.2.2
Origins of CLAs in the human diet
PUFAs, other than CLAs, with a conjugated double bond system and with more than two double bonds, occur naturally in nature in various seed oils but their biological activity has to date not been extensively investigated when compared with data available for CLAs. Similarly, a variety of conjugated fatty acid isomers of longer chain length than CLAs (e.g. C19 and C20 ) have been identified as derivatives of long-chain PUFA metabolism in mammalian systems (Banni et al., 2004). These fatty acids, although intriguing, will not be discussed in this chapter. Suffice it to say that preliminary evidence suggests that the C19 conjugated non adecenoic acid (CNA –19:2) in some instances has similar properties to that of CLA (K.W.J. Wahle, unpublished findings). The major natural sources of CLAs are the body tissues, predominantly the fat tissues, of ruminant animals or those with ruminant-like, fermentative digestive processes, like wallabies and kangaroos. Consequently, the main food source of CLAs in the Western diet is from meat and dairy products derived from cattle, sheep, goats and deer. The rumen of these animals is a large anaerobic fermentation vat that contains a variety of microbes capable of biohydrogenating, either alone or in concert, the ingested PUFAs derived from forages and
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
57
other PUFA-containing feed sources, natural or otherwise (e.g. added grain or fish and plant oils) (mainly, 18:2n-6 and 18:3n-3 in plant oils and 20:4n-6, 20:5n-3 and 22:6n-3 in fish oils). This chapter will focus mainly on CLAs derived from plant oils. The initial process in the biohydrogenation of dietary linoleic acid results in the production of the cis-9, trans-11 isomer, as a result of the isomerisation and transposition of the delta-12 double bond to produce the conjugated, non-methylene interrupted double bond. This is the most abundant natural isomer present in ruminant tissue fats (over 90% of total CLA) and has been termed rumenic acid (RA) (McGuire et al., 1999b; Parodi, 1997, 2003). Further hydrogenation of RA produces trans-11-18:1 vaccenic acid (TVA), which is the major trans monounsaturated fatty acid present in the fats of ruminant food products (milk, yoghurt, cheese, butter and meats). Other isomers of trans monoenes are also formed but in small quantities (McGuire et al., 1999b; Parodi, 1997, 2003). This contrasts with partial hydrogenation of feed PUFA in the ramen that predominantly produces the trans-9-18:1 isomer, elaidic acid (McGuire et al., 1999b; Parodi, 1997, 2003). Biohydrogenation processes are invariably incomplete, otherwise only saturated fatty acids would flow from the rumen for absorption and tissue incorporation instead of the mix of RA, TVA, minor isomers and saturated products. The high relative proportion of RA in cows’ milk (2–52 mg/g fat depending on diet) cannot be derived entirely from the modest level of RA flowing from the rumen that is absorbed into blood for distribution to tissues, particularly adipose and mammary. It has been estimated that circa 70% of RA in milkfat is derived from TVA by the activity of delta-9 desaturase (SCD1) in endoplasmic reticulum of the mammary tissue and possibly other tissue cells (e.g. adipocytes) (Grinari and Bauman, 1999). This is interesting because both the precursor TVA and the product RA of the 9-desaturation reaction can inhibit the activity of the SCD1 enzyme in cow mammary tissue microsomes (Baumgard et al., 2002; K.W.J. Wahle and J.M. Elliot, unpublished observations). Apparently, this is not the case when TVA, trans-10, trans-12-18:2 or trans-10-18:1 is infused into cow mammary glands (Lock et al., 2007, Perfield et al., 2006). Presumably, the precursor-product concentrations are kept sufficiently low to allow the reaction to proceed in the in vivo situation or the mammary enzyme undergoes compensatory induction. This has been suggested but requires substantiation (Lock et al., 2007; Wahle et al., 2004). Human tissues are also capable of desaturating TVA to form cis-9, trans-11 CLA, indicating that TVA in cow’s milk can be converted to the bioactive CLA isomer in man (Kuhnt et al., 2006; Moseley et al., 2006). As mentioned above, a wide spectrum of minor geometrical and positional isomers of CLA is produced during rumen biohydrogenation by bacterial isomerases. These range from trans-6, trans-8-18:2 to trans-13, trans-15-18:2, with a number of cis,trans; trans,cis and cis,cis positional isomers in between these extreme positions on the acyl chain (McGuire et al., 1999b; Parodi, 1997, 2003). It is not known if these minor components elicit beneficial or detrimental cell metabolism or function. The predominant isomer in milk and other dairy products is the cis-9, trans-11-18:2, with only minor, but significant, proportions of trans-10, cis-12-18:2 (McGuire et al., 1999b; Parodi, 1997, 2003). This contrasts with synthetic, commercial preparations of CLA where proportions of the two main isomers are usually equal. The chemical method for synthesis will allow the production of a variety of CLAs with different ratios of the two isomers in the end product (McGuire et al., 1999b; Parodi 1997, 2003; Saebo, 2003). There are numerous, recent and not so recent, publications describing ways to enhance the TVA and CLA content of cow’s milk in order to obtain a food product with perceived added health benefits. Detailed appraisal of this literature is beyond the scope of this chapter. Interested readers are referred to a number of excellent reviews on the subject (Bhattacharya et al., 2006; Chilliard et al., 2001; Collomb et al., 2006; Gulati et al., 2000; McGuire et al.,
BLUK122-Dijkstra
58
September 25, 2007
20:0
Trans Fatty Acids
1999b; Parodi, 1997, 2003; Parrish, 2003; Saebo, 2003; Stanton et al., 2003; Tricon et al., 2005; Wahle et al., 2004) and, for the most recent information, to the website mentioned above. It is apparent that a cow’s diet has a major impact on the concentrations of TVA and CLA in its rumen and eventually in its milkfat. Fresh pasture rather than concentrates (grain) elicit the highest natural levels of these fatty acids in milk and alpine pastures yield greater concentrations than lowland pastures (McGuire et al., 1999b; Parodi, 1997, 2003). Reasons for this are not clear. The greatest concentrations of CLA (and TVA) in cows’ milk are obtained when supplemental oils, particularly fish oil, are added to their diets. This increases the PUFA concentration that is available for biohydrogenation. Such feeding regimes do affect the rumen microbial populations and generally result in lowering of the milkfat (Chilliard et al., 2001; Collomb et al., 2006; Gulati et al., 2000; Parodi, 1997; Parrish, 2003; Stanton et al., 2003). Genetic variations in the ability of different cows to produce high levels of CLA in their milk occur. This may be due to individual differences in the expression of mammary SCD1 activity that is responsible for the TVA conversion in the gland (Chilliard et al., 2001; Collomb et al., 2006; Gulati et al., 2000; Parrish, 2003; Stanton et al., 2003). As mentioned previously, this could reflect a greater genetic capability for induction of the enzyme in the face of substrate and product inhibition or an innate ability to regulate or compartmentalise the inhibitor concentrations in the tissues. Genetic selection programmes could produce animals with optimum capacities for CLA production. Genetic engineering is also capable of enhancing the expression of various desaturases in mammalian tissues, including the plant-derived desaturases responsible for synthesising long-chain omega-3 PUFA (Kang, 2005) whereby the requirement for dietary long-chain omega-3 PUFA for optimum health in monogastric mammals is precluded. Intriguingly, the highest natural levels of CLA observed to date in nature occur in wallaby milk (Parodi, 1997). The reason for this is unclear at present but may reflect the animal’s diet. Perhaps, the high intake of CLAs in Australian populations is due to consumption of foods derived from kangaroo and wallaby! The CLA content of other dairy products like cheese and yoghurt is largely dependent on the CLA content of the milk they are derived from since processing appears to have either no or only a little effect on the final content of CLA in these products (McGuire et al., 1999b; Parodi, 1997, 2003). Meat from ruminant animals, particularly the fat associated with meat, is also an important source of CLA, contributing in the region of 25–30% of the total intake in Western populations (McGuire et al., 1999b; Parodi, 1997, 2003). The content of CLA in fish and food products derived from fish is negligible in relation to dairy products, ranging from 0.1 to 0.9 mg/g fat in the common marine foods (McGuire et al., 1999b; Parodi, 1997, 2003). Fatty acids with conjugated double bonds do occur in various seed oils from a number of plant species (e.g. columbinic acid from columbine, a trienoic fatty acid with a trans double bond in the delta-5 position trans-5, cis-9, cis-12-18:3). CLA is not found in vegetable oils used in the food chain. Small amounts of CLA (0.1–0.7 mg/g oil) can be produced during the heating, bleaching and deodorising in the refining process for edible oils (Saebo, 2003). Partial hydrogenated edible oils, used in the production of margarines and shortenings until recently, contain a wide spectrum of cis and trans isomers, including TVA and CLA. In the 1990s, metabolic and epidemiological studies indicated that dietary trans fatty acids in hydrogenated oils could be detrimental to human health with particularly adverse effects on the risk of coronary heart disease. These adverse effects were originally thought to relate largely to the induction of high-risk lipoprotein profiles (increased total and LDL-cholesterol and decreased HDL-cholesterol) and attenuation of cell-regulatory eicosanoid synthesis (Hwang
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
59
and Kinsella, 1979; Katan et al., 1995). The edible-oil industry responded to these criticisms and developed methods that virtually eliminated partially hydrogenated isomers from its products so that modern table margarines and shortenings contain negligible quantities of trans acids, including TVA and CLA (Wahle, 1994; Wahle and James, 1993).
3.2.3
Dietary consumption of CLAs in man
The methods used to estimate the daily intake of CLA in human populations range from large dietary surveys to more detailed dietary assessments of small population subgroups, employing dietary records over periods from 24 h to 7 days to retrospective food-frequency questionnaires or various combinations of these methods (Fritsche et al., 1999; Parodi, 2003). These methods have inherent deficiencies, particularly the long-term, retrospective foodfrequency questionnaire with obvious errors due to unreliable recall and variations between individuals. Despite these shortcomings and the lack of reliable figures for CLA content of more than a small sample of food (Ledoux and Laloux, 2006; S´eb´edio et al., 1999), data have been published from different countries relating to estimated daily CLA intakes that range from negligible in non-dairy and meat-eating populations to circa 1500 mg in Australian populations (Fritsche et al., 1999; Parodi, 2003). The average CLA intake in the US has been estimated at between 52 and 137 mg/day for men and women; in the UK it is about 400–600 mg/day and in German men and women, about 430 and 350 mg/day, respectively. Interestingly, intakes in women are generally lower than those in men, which is possibly a result of their lower dairy fat consumption (McGuire et al., 1999a,b; Parodi, 1997, 2003). The average intake of CLA probably does not reflect the absolute amounts of CLA available to an individual because of endogenous conversion of TVA in dairy products to CLA via the SCD1 enzyme, as mentioned above. It has been estimated that circa 20% of TVA could be converted to CLA in situ (Bauman and Griinari, 2003; Turpeinen et al., 2002). This could increase the CLA available to people on an average UK diet to between 600 and 800 mg/day. Achieving an intake of CLA in the region of 3–6 g/day, which appears to be the level at which benefits on health can be expected, is difficult with present natural, unfortified foods and can occur only by increasing the CLA concentration in milk, and consequently in dairy products, through manipulation of the cow’s feed (see above) or through ingestion of CLAenriched oils as capsules or fortified foods. The latter approach is using natural components in pharmaceutical dosages to derive specific health benefits, like a reduction in inflammation or tumour growth (i.e. as nutraceuticals or functional foods). The food industry is particularly interested in the development of a variety of such functional foods, using different forms of bioactive fatty acids like omega-3 and omega-6 LCPUFAs and CLAs.
3.3
CLAs IN CANCER PREVENTION AND TREATMENT
The first published observations relating to the beneficial effects of CLAs were as anti-cancer agents derived from grilled minced beef by Pariza’s group (Pariza and Hargreaves, 1985). The objective of their research was the identification of pro-carcinogens in the meat, and serendipity indeed to discover lipid compounds that have the opposite effect. Since these initial observations, a wealth of data, mainly in animal models of various cancers and cancer cell cultures, have accumulated that support an anti-cancer role of these interesting fatty acids. Findings range from effects on the growth and metastasis of tumours in animals with chemically induced or implanted human tumours to the influence on the regulation of specific
BLUK122-Dijkstra
60
September 25, 2007
20:0
Trans Fatty Acids
cell signalling mechanisms and expression of oncogenes involved in cell cycling and apoptosis in various cancer cell lines. A small number of studies have attempted to establish if there was an association between CLA intake and a decreased risk or incidence of breast cancer (Bhattacharya et al., 2006; Park and Pariza, 2007; Tricon et al., 2005; Wahle et al., 2004). The following section will present a critical appraisal of the recent, relevant publications and concepts. Again, the data included are not exhaustive.
3.3.1
Epidemiology of dietary fats and cancer risk
Over the past 30 years, many epidemiological studies have examined the relationship between dietary fat intake and the risk of developing many types of cancer (Bhattacharya et al., 2006; Howe et al., 1990; Hunter et al., 1996; Wahle et al., 2004). The limitations and difficulties in undertaking such studies, particularly where food recall is involved, are well recognised. Not surprisingly, conflicting results have been published that have created some confusion regarding the role of fat in the aetiology of cancer.
3.3.2
CLAs and breast cancer
In an attempt to understand further the relationships between dietary fat intake and breast cancer, two significant meta-analyses have been reported, one examining case-control studies and the other focusing on cohort studies (Howe et al., 1990; Hunter et al., 1996). Metaanalysis of case-control studies that revealed an increase in breast cancer risk was correlated with increased dietary fat intake (Howe et al., 1990). In contrast, no relationship was found when the cohort studies were analysed individually (Hunter et al., 1996). More recently, a detailed study of over 13 000 women, which overcame some of the problems associated with the previous two studies, indicated that breast cancer risk was associated with increased fat intake, in particular, saturated fat (Bingham et al., 2003). In recent years the suggestion that all types of dietary fats are associated with increased breast cancer risk and incidence have been questioned, particularly in the light of studies on animal models of the disease where tumours were either induced chemically or human breast tumour cells were transplanted (see below). Such studies have shown that certain types of fats (fatty acids) are pro-tumourigenic, whilst others are anti-tumourigenic. In the latter category, evidence for supporting the beneficial effects of fish-oil consumption and the intake of omega-3 PUFA in reducing carcinogenesis in animal models of disease is persuasive (Karmali et al., 1984). Similar studies in animals implanted with breast cancer cells and fed CLAs suggested the possibility that this type of fatty acid can also be anti-tumourigenic (see below). In contrast, publications indicating that CLAs do not inhibit mammary tumour growth in animals are also extant. Furthermore, a recent study clearly showed that trans-10, cis-12 CLA stimulated mammary tumourigenesis and metastasis in transgenic mice overexpressing the erbB2 gene in mammary epithelium (Ip et al., 2007). This is despite previous evidence to the contrary where both isomers were shown to be anti-tumourigenic and anti-metastatic in rat models of breast cancer (Ip et al., 1995, 2000, 2002). Could this be yet another example where CLAs have different, often opposing, effects in mice compared to rats and other animal models? Despite being in the minority, these reports make it difficult to form a clear consensus about the anti-cancer effects of CLAs (Wong et al., 1997). The possibility that the earlier studies showing no effect of CLAs were carried out with impure products cannot be excluded and more recent studies with clearly defined products should be given greater credence.
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
61
Because the main sources of CLA in the human diet are milk, milk products and the meat from ruminants, it is interesting to review those studies where these dietary components have been analysed separately with regard to breast cancer risk. The literature is again confusing, with some reports showing no relationship (Chajes et al., 2002; Voorrips et al., 2002), some an increased risk of breast cancer with increasing dietary intake (Aro et al., 2000; Knekt and Jarvinnen, 1999) and yet others finding that increased intake resulted in a decreased risk of breast cancer (Landa et al., 1994; Salamini et al., 1984). Reasons for such conflicting observations are not clear but could include experimental design, source of dairy products or analytical sensitivity. Milk also contains other substances known to have anti-cancer activity, such as sphingomyelin and butyric acid, all of which can vary in concentration and thereby complicate the interpretation of the findings. Sphingomyelin is the precursor of ceramide through the action of sphingomyelinase. Both ceramide and butyric acid are potent apoptotic metabolites; the latter primarily in the intestinal tract but possibly also in breast since systemic levels of butyrate can be significant in humans. Nevertheless, on the basis of these and other studies (see below), the World Cancer Research Fund concluded that at present insufficient data existed to confirm either a positive or a negative relationship between breast cancer risk and intake of milk, milk products and meat. A case-control study in Finland compared 193 women with breast cancer with a population-based control group, matched for age and the area in which they lived (Ledoux et al., 2003). The authors found that both CLA intake and serum levels of CLA were significantly lower in postmenopausal women with cancer. It was initially suggested that diets rich in CLA-containing foods may protect against breast cancer in postmenopausal women. However, on further evaluation of the data it was impossible to determine effects attributable to CLA alone and those to other components in milk in these studies (Landa et al., 1994). Another Finnish study also reported a decreased breast cancer risk in women consuming whole milk (Salamini et al., 1984) but again the findings, whilst intriguing, cannot be taken as definitive. A cohort study in the Netherlands recently determined the relationship between dietary intake of CLA and breast cancer risk (Voorrips et al., 2002). The study included 941 patients who had developed breast cancer. Their diet was determined using a 150-item food-frequency questionnaire, with its attendant errors due to recall. Follow-up was over 6 years. The foods were those containing CLA (milk, milk products, butter, cheese and meat). The analytic data (CLA content) for these food items were obtained through linking with the European TRANSFAIR study. Findings actually demonstrated a very weak, but positive, correlation between breast cancer risk and CLA intake, suggesting a possible detrimental effect of milk intake. However, no significant association between intake of CLA-containing foods and breast cancer incidence was observed. An inverse relationship between breast cancer and intake of monounsaturated and cis unsaturated fatty acids was found, indicating a possible positive benefit of these dietary fatty acids. These observations contrast with the abovementioned epidemiological studies, indicating a link between total fat intake and breast cancer incidence. Determining food-intake data and then extrapolating to CLA intake is extremely difficult because of the lack of significant data for the CLA content of foods and also because of their inherent variability in different ruminant food products from different sources and even from the same source in different seasons because of the effect of nutrition and genetics on the CLA availability (Ledoux et al., 2003). Two studies focused on the CLA content of adipose tissue in relation to breast cancer risk and also the risk of developing metastatic disease in women. In the first (Chajes et al., 2002) study, no association between breast cancer risk and CLA levels in adipose tissue
BLUK122-Dijkstra
62
September 25, 2007
20:0
Trans Fatty Acids
was apparent, but the authors did highlight the limitations of their study. In particular, there was a narrow range of CLA levels. The findings lead the authors to question the validity of CLA content in adipose tissue as a biomarker for dietary intake of CLA. The authors then determined adipose tissue CLA levels on diagnosis of breast cancer and after subsequent development of metastatic disease in 209 patients (Chajes et al., 2003). They found no relationship between CLA content in adipose tissue and various prognostic indicators, including overall survival after 7.5 years of follow-up. A recent study in breast cancer patients did find a small association between CLA intake and tumour biology in pre- but not post-menopausal women, but no association was found between CLA intake and risk of developing the disease (McCann et al., 2004). Taken together, these epidemiological/clinical studies have not established a definitive link between normal dietary intakes of CLA from dairy products, the presence of CLA in breast adipose tissue and the risk or incidence of breast cancer. The possibility that consumption of CLAs in greater concentrations than those achievable through intakes of normal dairy and meat products (i.e. in the form of nutraceuticals, functional foods or capsules) may confer benefit cannot be precluded at present. This is relevant in the light of the anti breast cancer effects observed with the relatively high concentrations of these fatty acids, compared to normal intakes, in animal models of disease and in studies with breast cancer cell lines (see below). It is very difficult to draw any firm conclusions about CLA intake, adipose CLA and breast cancer risk in human populations from the studies that are currently available. Nevertheless, the epidemiological evidence to date has neither refuted nor confirmed a positive or negative relationship between ingestion of CLA or CLA-containing foods and breast cancer in women. Human intervention studies using well-defined CLA supplements (isomer types and relative concentrations) at different levels of intake over longer periods of time and at different physiological stages of development (pre- and post-pubertal, see below) in females are needed in order to conclusively clarify these relationships.
3.3.3
CLAs and prostate cancer
3.3.3.1 In man To our knowledge, there are no published epidemiological studies relating to the intake of CLAs and prostate cancer risk or incidence in man. It can, however, be surmised that the high and increasing incidence of the disease in industrialised societies is probably linked to environmental factors, not least of which will be nutrition and particularly fat nutrition. 3.3.3.2 In animal models of disease Studies in animal models of human prostate cancer using transplanted DU145 cells showed clear anti-tumourigenic effects of dietary CLAs similar to those observed with breast cancer models when implanted into SCID mice. The effects were opposite to those observed with linoleic acid feeding that elicited pro-tumourigenic rather than anti-tumourigenic effects. Average tumour volume in the SCID mice was reduced by CLA by circa 70 and 75% when compared with control or linoleate-fed animals respectively (Cesano et al., 1998). Similar effects of linoleic acid have been found with human cancer cell proliferation in vitro (see below). Considering the high intake of linoleic acid in industrialised populations, it is tempting to suggest that these findings could offer an explanation for the high cancer incidence in these
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
63
populations. Unfortunately, two further studies where cells were inoculated into the prostate gland or subcutaneously failed to show any inhibition of prostate cancer growth in athymic mice (Scimeca, 1999). 2-Amino-1-methyl-6-phenylimidazol [4,5-b]pyridine (PhIP) is a potent mutagen and carcinogen derived from meat cooked at high temperatures that produces prostate and mammary tumours when fed to male and female rats respectively (Yang et al., 2003). PhIP feeding for 47 days at 100 ppm induced a fivefold increase in mutation frequency in the prostate of transgenic Big Blue rats. Addition of 1% CLA mixture (w/w) to rat diets 1 week prior to exposure to PhIP decreased mutagenesis by 38% and changed the mutation spectrum, decreasing –1 frameshifts and G:C to A:T transitions (Cohen et al., 2003). These findings suggested a possible use of dietary CLA as a chemopreventative in human prostate cancer. However, observations in an established rat model of implanted hormone-refractory prostate cancer (R-3327-AT-1) indicated a significant increase in tumour volume with CLA feeding compared to controls and no inhibition of growth, or development of the tumour was observed (Cohen et al., 2003). The findings suggesting enhanced tumourigenesis with CLA clearly contrast with the majority of published findings indicating anti-tumour effects in animals and cells and may relate to the use of transgenic rather than normal rats. Such contrasting findings in only a small number of experiments, mostly in mice, when compared to the wealth of published data on mammary cancer, still make it difficult to formulate an absolutely definitive conclusion regarding the effect of CLAs on prostate cancer. Observations that CLAs can inhibit angiogenesis in mammary cancer (Ip et al., 2002) (see below) indicate that these fatty acids may inhibit tumour growth through a reduced blood supply and this could apply to all tumours, not only those of the mammary. Inhibition of angiogenesis in prostate cancer patients by CLAs has not been reported but could explain the dramatic decrease in growth of transplanted tumours in animal models (Cesano et al., 1998; Scimeca, 1999). The underlying conditions and cell mechanisms relating to the possible pro-carcinogenic effects of CLAs on prostate cancer initiation and development (see above) must be investigated further if the use of these fatty acids in cancer therapy is to be considered. 3.3.3.3
In cell studies in vitro
Studies with immortalised prostate cancer cell lines in vitro tend to support the anti-cancer effects of CLAs and show that they inhibit cell proliferation, inhibit eicosanoid formation and induce apoptosis by enhancing p53 and attenuating bcl-2 expression in human prostate cancer (PC3) cell lines (Ochoa et al., 2004). The two main isomers of CLA appear to elicit different, specific effects on eicosanoid production and oncogene regulation in order to induce apoptosis. The trans-10, cis-12 isomer attenuated mainly eicosanoid formation and the LOX5 and COX-2 enzyme expression, whilst cis-9, trans-11 affected the expression of oncogenes p53, p21WAF1/CIP1 and bcl-2 in a pro-apoptotic manner. Palombo et al. (2002) also showed that both isomers of CLA had anti-proliferative and pro-apoptotic effects on human prostate cancer cells but these authors did not emphasise the specific differences between the isomers. The inhibition of proliferation and induction of apoptosis in prostate cancer cells (LNCaP) by CLAs has also been linked with positive and negative regulatory effects on specific protein kinase C (PKC) isoforms; mainly upregulation of PKC- and PKC- and downregulation of PKC- (Song et al., 2004). These are highly specific effects of CLAs on important cell signal kinases and emphasise the multifaceted role of nutrients like CLAs in cell regulation and anti-tumourigenesis.
BLUK122-Dijkstra
64
September 25, 2007
20:0
Trans Fatty Acids
Reports to date indicate that both cis-9, trans-11 and trans-10, cis-12 isomers of CLA appear to have beneficial effects in attenuating prostate cancer proliferation and progression but possibly through entirely different cellular mechanisms (lipid metabolism or oncogene expression). Further investigations into the role of CLAs in attenuating prostate cancer and identifcation of the underlying cellular mechanisms are urgently required, as this disease is increasing in the population and few therapies are available to counter it. As with breast cancer, clinical intervention studies with CLAs alone or as adjunct therapies to the classical therapies, which now include taxane and tamoxifen, are overdue, particularly as CLAs appear to have minimal side effects and do not appear to pose a significant hazard to health other than the reported oxidative formation of isoprostanes, which in cancer prevention and apoptosis may actually be beneficial in killing cancer cells.
3.3.4
CLAs in gastrointestinal cancer
3.3.4.1 Human studies Studies relating CLA intake to possible reduced risk (or increased risk) of colorectal cancer in man are greatly lacking. To our knowledge, only one very recent epidemiological study relating intake of dairy foods containing CLA with a reduction in gastrointestinal cancer risk has been published. The Swedish Mammography Cohort Study found that for each daily increment of dairy food (two servings per day increments), the risk of colorectal cancer was reduced by circa 13% but the risk of distal colon cancer was decreased by a very significant 34%. However, as in other milk and dairy food studies attempting to correlate consumption of dairy products with decreased breast cancer incidence/risk (see above), the authors conceded that it is difficult to attribute the effects entirely to CLA content of the product (Larsson et al., 2005). Clearly, these observations and those of the Finnish studies on breast cancer indicate a possible benefit in milk and dairy consumption. 3.3.4.2 Animal studies Beneficial effects of CLAs in gastrointestinal cancers have been observed mainly in chemically induced tumours in animal models. Such studies showed that CLA inhibited the benzo(a)pyrene-induced neoplasia in mouse forestomach (Ha et al., 1990). CLA also protected against 2-amino-3-methylimidazo [4,5-f]quinoline-induced colon carcinogenesis in F344 rats (Liew et al., 1995). CLA, at 1% of the diet, also reduced colon tumour incidence in 1,2-dimethylhydrazine (DMH)-treated rats (Park et al., 2001). This was the result of a 251% increase in the apoptotic index as determined by the terminal deoxynucleotide transferasemediated dUTP nick-end labelling method. The role of eicosanoids was evident because CLA also reduced mucosal levels of prostaglandin E2 (PGE2 ), thromboxane B2 and their precursor arachidonic acid. The effects were dose dependent. As with the mammary tumours induced by dietary PhIP (see above), this chemical also induced an 8–26-fold increase in mutation frequency in the distal colon of transgenic Big Blue rats, but the proximal colon and caecum were unaffected (Yang et al., 2003). Mutation frequencies were significantly reduced (14–24%) by dietary CLA supplementation in the rats. Contradictory observations have also been reported for the effects of CLAs in these as in other tumour types. In an interesting comparison with dietary fish-oil fatty acids in ApcMin mouse model of colon cancer, CLA did not reduce tumour load, whereas omega-3 LCPUFA from fish elicited significant beneficial effects (Petrik et al., 2000). This suggested that not all effects of omega-3 PUFA compare
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
65
precisely with those of CLA in animal models of the disease, but yet again, mice appear to be different to other rodents in their responsiveness to CLAs (see below). A recent study used individual diets containing one of the two main isomers of CLA at 1% (w/w) and fed them to an ApcMin mouse model of intestinal carcinogenesis. Surprisingly, the trans-10, cis-12 isomer was reported to actually promote rather than inhibit colon carcinogenesis (Rajakangas et al., 2003). It was postulated that promotion of carcinogenesis in these studies with mice was due to activation of the oxidative stress-induced nuclear factor B (NF-B) transcription factor pathway and cyclin D1 , although the authors could not demonstrate NF-B activation by increased p65 protein binding to DNA in mouse tissues. These findings contrast with the reported inhibitory effects of CLAs on NF-B activation (IB-phosphorylation; DNA binding and transfection/reporter studies) in human umbilical vein endothelial cells (HUVEC) and prostate cancer cells in vitro (see below). This group also reported adverse effects of trans-10, cis-12 CLA because of increased lipid peroxidation determined by increased isoprostane excretion in urine (see above). Unfortunately, an enhancement of carcinogenesis with the increase in trans-10, cis-12 isomer excretion that also correlated with an increase in PGE2 formation was not reported. An increase in peroxidative tone elicited by the trans-10, cis-12 isomer could enhance prostaglandin production that might be expected to elicit pro-carcinogenic effects (see above). However, most studies to date show inhibition of eicosanoid production with CLA treatment in various tissues/cells in vivo and in vitro (see below). In contrast to the above observations, a study of the effects of CLAs on DMH-induced colon carcinogenesis in Sprague Dawley rats found decreased PGE2 , TXB2 and an increased apoptotic index which suggested that the beneficial effects of CLAs on colon carcinogenesis could be mediated through cell signalling systems in the rat colonic mucosal cells (Kim et al., 2003). These observations were supported by a recent study in rats where CLA fed at 1% of the diet resulted in a decrease in implanted human colon tumour development and peritoneal metastasis that correlated with a decrease in PGE2 levels and an increase in the pro-apoptotic:anti-apoptotic Bax:Bcl-2 ratio (Park et al., 2004). 3.3.4.3 Studies with cancer cells in vitro Similar effects of CLA on the expression of the oncogenes Bax:Bcl-2 and p53,p21WAF1/CIP1 to those reported for mouse tissues above have been reported by our group in breast and prostate cancer cells in vitro (Majumder et al., 2002; Ochoa et al., 2004; Song et al., 2006; Wahle et al., 2004). In contrast to the findings in mice in vivo, where CLAs activated the NF-B pathway, our group has also shown that CLAs can actually inhibit the activation of NF-B at the stage of IB phosphorylation in human prostate cancer cells (and in HUVEC) in vitro (Song et al., 2006). In these endothelial cells, CLAs also reduced the oxidative and inflammatory stress-induced expression of adhesion molecules, the gene reporters of which are a major target for activated NF-B (Goua and Wahle, 2007; Sneddon et al., 2006). This may again reflect differences due to tissue, species (mice appear to respond differently to CLAs than other animals) or to cell versus whole animal studies. Significant anti-proliferative effects on human HT-29 colorectal cancer cells in vitro were elicited by CLA isomers through their inhibition of DNA synthesis and induction of apoptosis (Cho et al., 2003). CLA also inhibited the heregulin--induced phosphorylation of ErbB2 and ErbB3, recruitment of p85 subunit of PI3-kinase to the ErbB3 receptor, ErbB3 associated PI3-kinase activities and phosphorylation of Akt. CLA decreased ErbB2 and ErbB3 mRNA
BLUK122-Dijkstra
66
September 25, 2007
20:0
Trans Fatty Acids
and protein expression in a dose-dependent manner. Further studies suggested that the CLAassociated benefits could be related to their ability to inhibit insulin-like growth factor-II (IGF-II) expression and attenuate the kinase 1/2 pathway and IGF-receptor signalling in these cells (Kim et al., 2003). In Caco2 cells, this group showed that the effects on IGF-II regulation were isomer specific, with the trans-10, cis-12 isomer being effective but not the cis-9, trans-11 isomer (Kim et al., 2002). Similarly, it was only the trans-10, cis-12 isomer that decreased ErbB3 expression in HT29 human colon cancer cells (Cho et al., 2005). It was suggested that these inhibitory effects of CLAs were mediated through effects on IGF-II, Akt activation and the inhibition of the cell-cycle-regulatory protein p21CIP1/WAF1, the latter by physiological concentrations of the fatty acid (Cho et al., 2003; Kim et al., 2003; Lim et al., 2005). This pathway is also involved in the inhibitory effects of CLA on breast cancer and prostate cancer cells, as shown previously by our group (Majumder et al., 2002; Ochoa et al., 2004). A recent study again showed that trans-10, cis-12 but not cis-9, trans-11 or linoleic acid elicited an inhibition of cell proliferation and induced apoptosis by inducing the expression of another pro-apoptotic gene, non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) in human colorectal cancer cells (Lee et al., 2006). Further studies, both in vivo in animal models of prostate cancer and in vitro, with clearly defined CLA isomers and mixtures and varying amounts are required before the anti-carcinogenic effects of CLAs, either one or both of the isomers, on prostate cancer can be regarded as unequivocal. Suffice it to say that current findings, particularly with cells in culture, are encouraging. The reason for the distinctive differences between isomers in relation to inhibiting or promoting tumourigenesis and metastasis in rat and mice models respectively requires further elucidation.
3.3.5
CLAs and other cancers (hepatic, pancreatic and dermal)
3.3.5.1 In man Epidemiological studies on intake of CLAs and hepatic, pancreatic or epidermal cancer risk have, to our knowledge, not been reported in man. 3.3.5.2 In animals In an animal model of liver cancer, CLAs at 0.5 and 2.0% (w/w) of the diet actually enhanced the growth of transplanted rat hepatoma dRLh-84 cells in rats compared with control animals (Yamasaki et al., 2002). Surprisingly, this was despite a reduction in PGE2 and COX-2 elicited by CLA in the tumour. These effects are usually associated with decreased tumourigenesis. Similarly, CLAs did not improve body weight (inhibition of cachexia) or the nutritional status of rats implanted with the Morris 7777 hepatoma (McCarthy-Beckett, 2002). These negative effects of CLAs in rodents in vivo are not clearly understood at present. They give cause for concern regarding the possible use of these compounds in cancer therapy and require substantiation. Despite these in vivo observations, CLAs were strongly cytotoxic to the same rat dRLh-84 hepatoma cells in vitro (see above) at concentrations as low as 1M when compared to control cells, and the main active isomer was again trans-10, cis12 and not cis-9, trans-11 (Yamasaki et al., 2002). The active isomer also increased the sub-G1 population of cells, activated caspase-3 and -9 (indicators of cell-cycle inhibition and apoptosis, respectively) and elicited a time-dependent cleavage of poly(ADP-ribose) polymerase. These cytotoxic effects of CLAs were weaker in normal hepatocytes, indicating a
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
67
possible enhanced sensitivity to CLAs in cancer cells. CLAs also inhibited growth of a human hepatoma cell line (HepG2) in vitro. Effects were not due to increased lipid peroxidation in the cells but apparently to an altered fatty acid metabolism (Igarishi and Miyazawa, 2001). The trans-10, cis-12, but not the cis-9, trans-11 isomer of CLA apparently inhibited the delta-9, -6 and -5 desaturation of linoleic and -linolenic acids in human HepG2 cells (Eder et al., 2003). Authors estimated desaturase activities from the relative concentrations of precursors and products and did not determine the enzyme activity directly. This surrogate method of assessing desaturase enzyme activity can be inaccurate because of the dynamics between the reaction components being affected by other reactions like oxidation, esterification and compartmentalisation of substrates and products. Trans-10, cis-12 CLA also increased the prostaglandin production in HepG2 cells at 100 M concentrations, whilst cis-9, trans-11 was without effect. This finding correlates with the observation in vivo in implanted rat hepatoma dRLh-84 and Morris 7777 (McCarthy-Beckett, 2002; Yamasaki et al., 2002). However, these negative effects contrast significantly with a number of reports that clearly show that CLAs inhibit eicosanoid production in both cancer and normal cells, as well as with the report from the same authors which shows that the enzymatic pathway for the formation of the eicosanoid precursor arachidonic acid (ARA) is decreased (see above). Enhanced eicosanoid formation is generally regarded as a characteristic of malignancy and its reduction is a central tenet for anti-tumour effects of CLAs (Fisher, 1995). This is not the only observation of enhanced prostaglandin formation rather than inhibition in the presence of CLAs. It has also been observed in HUVEC and blood platelets when cells are treated with high concentrations of CLAs (see below in vascular section). These differences in prostaglandin formation elicited by CLAs may reflect relative isomer concentrations or total CLA concentration. Dietary CLA at 1% (w/w of diet) also induced hepatocyte proliferation as well as apoptosis in F33 rats (Lu et al., 2000) and ornithine decarboxylase activity in mouse liver, the latter through activation of hepatic peroxisome proliferator-activated receptor (PPAR) (Belury, 2002a,b). Findings contrast with those observed in many other cell types and may be a reflection of specific CLA effects on liver. The anti-carcinogenic properties of CLAs were first identified using chemical initiation of carcinogenesis in the skin of mice and its attenuation by topical application of the fatty acid (Ha et al., 1987). Induction of skin tumours in mice by phorbol esters, as determined by hyperplasia and ornithine decarboxylase activity, was not attenuated by dietary CLA, despite the observation that c-myc mRNA and prostaglandin formation (pro-carcinogenic factors) were reduced (Kavanaugh et al., 1999). Table 3.2 summarises some of the published observations, positive, negative and neutral, relating to the effects of CLAs on aspects of carcinogenesis
3.4
CELLULAR MECHANISMS OF CLAs’ ANTI-CANCER EFFECTS
Regression of an established tumour may occur because of either a decrease in cellular proliferation, an increase in programmed cell death (apoptosis) or necrosis of the tumour due to nutrient and oxygen deprivation (inhibition of tumour angiogenesis). CLAs, both the 9,11 isomer and the mixture, are capable of eliciting an increase in apoptosis in normal rat mammary epithelium in a primary culture system in addition to reducing cellular proliferation (Ip et al., 1999). Other studies assessing the effects of CLA in a rat mammary tumour cell
BLUK122-Dijkstra
68
September 25, 2007
20:0
Trans Fatty Acids
Table 3.2 Summary of some of the reported findings, positive and negative, relating to effects of CLAs on various forms of cancer. Breast cancer Human studies
No relationship between cancer risk and dairy products intake ↑ cancer risk with dairy products intake ↓ cancer risk with dairy products intake No effects on tumour growth No relationship between cancer risk and CLA intake ↓ CLA serum levels in woman with cancer No relationship between CLA content in adipose tissue and some prognostic indicators
Prostate cancer Animal models
In vitro studies
↓ tumour volume ↓ mutagenesis No inhibition of cancer growth ↓ cell proliferation and ↑ apoptosis ↑PKC- and -, ↓PKC-
Gastrointestinal cancer Human studies ↓ cancer risk Animal studies ↓ induced neoplasia Protection against induced carcinogenesis ↓ tumour incidence No effect on tumour load ↓ PGE2 , TXB2 and ↑ apoptotic index ↑ carcinogenesis (CLA t10,c12) Other cancers Animal studies
↑ growth of hepatoma cells in animal model No inhibition of cachexia in rats with hepatoma Cytotoxic effect on hepatoma cells in vitro ↑ hepatocyte proliferation and apoptosis No effect on induced skin tumour
Chajes et al. (2002); Voorips et al. (2002) Aro et al. (2002); Knekt and Jarvinnen (1999) Landa et al. (1994); Salamini et al. (1984) Wong et al. (1997) McCann et al. (2004) Ledoux et al. (2003) Chajes et al. (2003)
Cesano et al. (1998) Cohen et al. (2003) Cesano et al. (1998) Ochoa et al. (2004); Palombo et al. (2002) Song et al. (2004) Larsson et al. (2005) Ha et al. (1990) Liew et al. (1995) Park et al. (2001) Petrik et al. (2000) Kim et al. (2003); Park et al. (2004) Rajakangas et al. (2003) Yamasaki et al. (2002) McCarthy-Beckett (2002) Igarishi and Miyazawa (2001); Yamasaki et al. (2002) Lu et al. (2000) Belury (2002a,b)
line (NMU) showed an increase in apoptosis as assessed by light microscopy and a DNA laddering technique (Ip et al., 2000). This study also determined the effects of feeding rats in vivo with CLA and observing its effects on pre-malignant lesions within the mammary tissue (Ip et al., 2000). However, CLA did not stimulate apoptosis in either the alveoli or the TEB cells that are both normal components of the mammary tree. It was not possible to determine which of the isomers had the greatest effect. The finding by these authors that feeding female rats on CLA until puberty reduced the susceptibility of mammary tissue to carcinogen-induced tumour development indicated a possible beneficial, protective effect of CLA on mammary tissue development (Ip et al., 1995). This is an interesting observation indicating the possibility that CLA might influence developmental mechanisms in mammary tissue and if shown to be equally effective in human pre-pubertal females, could be exploited as a dietary preventative therapy, particularly in individuals at risk of developing the disease. Whilst these studies have focused on breast cancer, others have examined the effects of CLA on apoptosis in experimental models of colon cancer. In colon cancer cells in culture
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
69
(SW480), CLA treatment will also result in apoptosis (Miller et al., 2002). Dietary supplementation with 1% CLA (mixture of isomers) to rats resulted in a significant decrease in colon cancers induced by DMH. However, a key point to note here was that this study also examined the effects on apoptosis in ‘normal’ colonic epithelium before the tumour was actually visible. The apoptotic index more than doubled in the colonic epithelium of CLAsupplemented animals (0.5–1.5% of the diet). This may explain, in part, the effects of CLA in preventing colon cancer development in these animals. The mechanisms of these anti-tumour effects have not been clarified. However, preliminary studies have revealed some important insights that may start to explain the molecular basis for anti-tumour activity of CLAs, in particular, with regard to their effects in reducing cellular proliferation and increasing apoptosis, as described above. Recent research has focused on the molecular mechanisms underlying the control of these pathways. As mentioned previously, our group observed that, in a prostate cancer cell line (LNCaP), CLAs, whilst reducing proliferation and enhancing apoptosis, also altered the specific PKC isoform activities in cell. This was determined as an increased expression of the different isoforms in cell membranes as opposed to cytosol. There was an increased PKC-, PKC- and PKC- but a decreased PKC- level (Song et al., 2001, 2004), and this may result in inhibition of cell growth. However, others found no effect on PKC isoforms (Masso-Welch et al., 2001). These differences may be due to differences in tumour-type, species differences or the ability of the various techniques used to detect the isoforms (Wahle and Heys, 2002). The effects of CLAs on the pro- and anti-apoptotic pathways and their controlling genes have also revealed some interesting key facts. The expression of bcl-2, a key anti-apoptotic proto-oncogene, was decreased in rat mammary tumours and tumour cells by feeding or treating with CLAs; other oncogenes involved in apoptosis such as bax or bak (Banni et al., 2003; Ip et al. 1999, 2000) were either not affected or not determined (e.g. p53, p21WAF1/CIP1, bad and bcl-X). CLA was found to elicit an oncostatic, cell-cycle inhibitory effect on human, oestrogen-receptor-positive MCF-7 breast cancer cells, whereas the parent linoleic acid had the opposing effect (Durgam and Fernandes, 1997). This is another example of the pro-carcinogenic effect of the parent omega-6 fatty acid, linoleic acid, and it is tempting to speculate that high cancer incidence could be related to high linoleic intake. In contrast to the MCF-7 cells, the ER-negative MDA-MB-231 cells were unresponsive to CLA, indicating a possible involvement of the oestrogen receptors in CLA effects. The responsiveness to CLA of the two types of breast cancer cells was mirrored by a decreased expression of c-myc, a major cell-cycle-regulatory oncogene present in MCF-7 but not in MDA-MB-231 cells, which is also involved in anti-apoptosis. Our group (Majumder et al., 2002; Ochoa et al., 2004) conducted a detailed evaluation of the effects of a mix of CLAs and individual isomers on the expression of proand anti-apoptotic oncogenes in human breast cancer and prostate cancer cells. Oestrogensensitive MCF-7 and oestrogen-insensitive MDA-MB-231 breast cancer cells and androgensensitive LNCaP prostate cancer cells were studied. Expression of major oncogenes (p53, p21 WAF1/CIP1, bcl-2, Bax and bcl-Xs) were determined at the transcriptional (mRNA) and translational (protein) level, using northern- and western blotting and specific ELISAs. Treatment with CLA inhibited proliferation and induced apoptosis, and this correlated strongly with an increased expression (mRNA and protein) of pro-apoptotic p53 and p21 WAF1/CIP1 genes by circa two- to fivefold but a reduced expression of anti-apoptotic bcl-2 by circa 20–30% in MCF-7 cells. MCF-10a cells that are regarded as normal or benign cells (not malignant) were not affected. The bcl-2 protein expression in the malignant cells correlated with the expression of this protein in rat tumour tissue (Ip et al., 1995, 1999, 2000),
BLUK122-Dijkstra
70
September 25, 2007
20:0
Trans Fatty Acids
but these authors did not investigate gene (mRNA) expression in either animal or human tissues. In oestrogen-insensitive MBA-MD-231cells that express the mutant form of p53, which prevents apoptosis, p53 mRNA was unaffected by CLAs, but p21WAF1/CIP1 and the anti-apoptotic bcl-2 mRNAs were increased. The protein expression of the oncogenes largely reflected the mRNA expression. This suggested that CLAs might not be pro-apoptotic in these cells, yet they inhibited proliferation and induced apoptosis. This correlated with the inhibition of mutant p53 and an increase in p21WAF1/CIP1. Further investigation of oncogene protein expression revealed an increase in Bax and Bcl-Xs proteins. The ratio of Bcl-2 to Bax and Bcl-Xs was decreased, and this favoured apoptosis despite the reduction in Bcl2 protein. Similar effects on p53, p21WAF1/CIP1 and bcl-2 gene expression (mRNA and protein) by CLA mixture and individual isomers to the above were observed by our group in prostate cancer cells (Ochoa et al. 2004). In these studies, the cis-9, trans-12 isomer was most effective in modulating oncogene expression. The trans-10, cis-12 isomer markedly inhibited the eicosanoid production and COX gene expression; this would be expected to prevent tumour development. These observations clearly show that the two most important isomers of CLAs, in relation to nutritional and commercial CLAs, inhibit tumour growth and development through different cell pathways in prostate cancer cells. This adds support to the possible use of a mixture of isomers for maximum effects on tumour inhibition. Such findings offer a possible mechanistic explanation for the observed inhibitory effects of CLAs on transplanted human prostate cancer cells in animals (Cesano et al., 1998). Inhibition of COX and the concomitant inhibition of eicosanoid formation by CLAs in various cells/tissues have been reviewed by Belury et al. (Belury, 2002a; Belury et al., 2002; Belury and Vanden Heuvel, 1997). Effects may be due to displacement of arachidonic acid, the precursor of the two-series prostaglandins and four-series leukotrienes or attenuation of enzyme expression (COX-2 and LOX-5, -12 and -15). As mentioned above, certain concentrations of CLAs appear to enhance eicosanoid production, making it difficult to arrive at a consensus view as to their overall effects in different tissues/cells and on different diseases. It has been suggested that CLAs may exert some of their effects through metabolism of the parent isoforms to unique eicosanoids but this requires substantiation. The role of the nuclear transcription factors NF-B and PPARs in the putative beneficial effects elicited by CLAs on cell function, particularly the attenuation of stress-induced signal cascades, has been mentioned briefly (see above). NF-B activation can be inhibited by CLAs by a reduction in the level of IB phosphorylation on its serine residues and possibly reduction of binding to the B regions in respective gene promoters (see above, Fig. 3.2). We have previously postulated that CLAs (and omega-3 PUFA from fish) can induce the intrinsic redox enzymes in cells (GPx1 and GPx4) and that this may be the mechanism whereby transcription is affected (Crosby et al., 2001; Sneddon et al., 2003). It is also conceivable that CLAs elicit their effects directly on specific response elements in the affected genes or through the action of derived eicosanoids on these specific response elements. CLAs also activate the nuclear hormone receptors PPARs, particularly PPAR- , in various tissues and cell types (Belury, 2002a; Belury et al., 2002; Belury and Vanden Heuvel 1997). The ability of CLAs to activate PPAR- was reduced when delta-6 desaturase activity was inhibited by a specific inhibitor (SC-26196) in CV-1 cells. This indicates that a metabolite or metabolites of CLA, derived by desaturase, elongase and possible eicosanoid enzyme action, may be the active effector(s) of PPAR-elicited cell functions. CLAs can induce PPAR- -responsive genes and the level of the protein in vivo. Recent studies have suggested that activators of PPAR- may be protective against cancers of the mammary gland, colon and prostate (Sporn et al., 2001). Increased activation of PPARs can result in decreased activity of stress-induced
iκB
p65
p50
p65
Proteosomal degradation
p50 P
NF-κB binding
Kinase-activated phosphorylation
Nucleus
PPAR
?
Transcription
PPAR
??
GSSG
GSH
Redox enzymes
Cytokines Adhesion molecules Heat-shock proteins
GPx
CLA
September 25, 2007
Fig. 3.2 Some intracellular mechanisms whereby CLAs and fatty acids are likely to influence the expression of stress-induced genes. Stress-stimuli elicit a signal cascade which activates the inactive NF-B/IB complex in the cytoplasm that in turn releases active NF-B which translocates to the nucleus and binds specific B response elements in the promoter regions of various genes. These include genes for adhesion molecules, cytokines, redox enzymes, heat shock proteins, cyclooxygenases etc. Fatty acids like n-3 PUFA can result in increases in conjugated derivatives (CLAs) and can upregulate redox enzyme gene expression which can regulate the activation and/or nuclear binding of transcription factors like NF-B. PPAR activation by fatty acids, particularly CLAs, may also play a role in regulating NF-B activity.
Positive regulation
Negative regulation
Oxidative/inflammatory stimulus
BLUK122-Dijkstra 20:0
Conjugated linoleic acid effects 71
BLUK122-Dijkstra
72
September 25, 2007
20:0
Trans Fatty Acids
Table 3.3 apoptosis.
Summary of some reported effects, positive and negative, of CLAs on cell mechanisms and
↑ apoptosis in normal rat mammary epithelium ↑ apoptosis in rat mammary tumour cells ↑ PKC-, PKC- and PKC-, decreased PKC- No effect on PKC isoforms ↓ bcl-2 expression ↓ cell cycle of ER-positive MCF-7 breast cancer cells No effect on ER-negative MDA-MB-231 cells ↓ proliferation, ↑ apoptosis, ↑ expression of pro-apoptotic genes in MCF-7 cells No effect on MCF-10a No effect on p53 mRNA, ↑ p21 WAF1/CIP1 and blc-2 mRNA in ER-insensitive MBA-MD-231 cells and prostate cancer cells ↑ redox enzymes in cells Activation of the nuclear hormone receptors PPARs
Ip et al. (1999) Ip et al. (2000) Song et al. (2001, 2004) Masso-Welch et al. (2001) Banni et al. (2003); Ip et al. (1999, 2000) Durgam and Fernandes (1997) Durgam and Fernandes (1997) Majumder et al. (2002); Ochoa et al. (2004) Majumder et al. (2002); Ochoa et al. (2004) Ip et al. (1999, 1995, 2000); Ochoa et al. (2004) Crosby et al. (1996); Sneddon et al. (2003) Belury (2002a); Belury et al. (2002); Belury and Vanden Heuvel (1997)
NF-B, possibly through direct interaction of the two transcription factors where the PPAR resembles IB in its action (see above). It is therefore conceivable that activation of PPAR- is an important mechanism that may explain some of the anti-cancer effects of CLAs. This hypothesis, whilst appealing, requires substantiation. Table 3.3 summarises some of the published observations, both positive and negative, relating to CLA effects on cell signalling mechanisms in carcinogenesis and tumour growth.
3.4.1
Inhibition of angiogenesis
Development of new blood vessels (neovascularisation or angiogenesis) is of pivotal importance to ensure growth and maintenance of all types of tumours through adequate supply of oxygen, growth factors and nutrients. This process is also important for growth and maintenance of complex atherosclerotic plaques. Inhibition of angiogenesis would be expected to be an excellent therapeutic objective that could reduce rapid tumour growth and plaque progression. Masso-Welch et al. (2002) are, to our knowledge, the first group to show that CLA feeding reduced aspects of angiogenesis in vivo in implanted rat breast tumours when CD2/F(1) mice were fed either 1% or 2% CLA for 6 weeks. The CLA-fed mice had lower serum and mammary tissue vascular endothelial growth factor (VEGF) concentrations, an essential factor for growth of new blood vessels. A further study from this group (MassoWelch et al., 2001, 2002, 2004) again found that both isomers of CLA, when fed at 0.5 and 1% of the diet, decreased VEGF concentration and inhibited angiogenesis in vivo in the CD2/F91 mice. Surprisingly, they found that leptin, which is also a pro-angiogenic factor as well as important in energy regulation and obesity, was only decreased by the trans-10, cis-12 isomer of CLA. The mechanisms elicited by different CLAs appear to be multifactorial even when the end point is the same. These authors also observed the inhibition of angiogenesis in an in vitro model by both cis-9, trans-11 and trans-10, cis-12 isomers and
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
73
attributed these effects to the attenuation of VEGF expression and the reduction in expression of its receptor Flk-1. Fibroblasts are an essential requisite for angiogenesis to occur, possibly through the production of basic fibroblast growth factor (bFGF). CLA has been shown to inhibit bFGF-induced angiogenesis in vivo, as well as the endothelial cell proliferation and DNA synthesis induced by this growth factor in vitro (Moon et al., 2003). It is also conceivable that the effects of CLAs on the regression of atherosclerotic plaques reported by Kritchevsky’s group (Kritchevsky et al., 2004) and Toomey et al. (2006) are the result, at least in part, of a reduction in angiogenesis, but this requires substantiation. Increased angiogenesis is also a problem in diabetic retinopathy where it can result in retinal malfunction (Oettgen, 2001). CLAs have been reported to decrease hyperglycaemia and increase insulin sensitivity in diabetes (but also to elicit the opposite effect; see below). No study of the possible amelioration of neovascularisation by CLAs in retinopathy has been conducted to our knowledge. The cellular mechanisms whereby CLAs can reduce angiogenesis warrant further investigation in the light of possible preventative clinical applications in cancer, diabetic retinopathy and atherosclerosis.
3.4.2
Attenuation of cancer metastasis
Cancer involves three major stages, initiation, tumour progression/growth and metastasis, and CLAs have been implicated in the attenuation of all three, particularly with regard to mammary cancer in rodent, non-murine, models (Belury, 2002a,b; Ip et al., 1994, 1999, 2000, 2002). Two stages have been discussed in preceding sections above. The difficult stage to deal with clinically and the one with the greatest threat to life is the latter stage of metastasis since this is responsible for the spread of malignancy throughout the body and for producing multiloci in numerous tissues that are difficult to treat with conventional therapies. CLAs, both the main isomers and a mix thereof, at concentrations of 0.5 and 1% (w/w) of the diet, had a significant and dose-dependent inhibitory effect on pulmonary tumour burden, an index of metastasis, in mice with transplantable tumours (Hubbard et al., 2000). The latency period or suppression of tumours was also enhanced significantly compared to mice not receiving CLAs. Surprisingly, the efficacy of CLAs was greater than indomethacin, a recognised inhibitor of eicosanoid synthesis and suppressor of tumour growth and metastasis, indicating the recognised role of prostaglandins in the metastatic progression of many tumour types. A recent study further substantiated the anti-metastatic effects of CLAs through inhibition of peritoneal metastasis of human gastrointestinal cancer cells in an animal model (Kuniyasu et al., 2006). Similar effects in human metastatic patients would offer a novel therapy, but such studies have not been conducted. Initiation of metastasis involves increased adhesion of circulating cancer cells to the vascular endothelium of the tissue capillaries prior to extravasation and tissue invasion. This resembles the adhesion mechanism utilised by circulating monocytes during the initiation of atherogenesis (see below). We and others have shown that CLAs can reduce the expression of adhesion molecules at the level of gene expression as well as the actual adhesion of cells on monolayers of HUVEC in culture (see below). The reduced metastasis in tumourbearing animals fed CLAs could be explained by such an attenuation of adhesion molecule expression elicited by the dietary CLAs. This is further supported by observations that CLAs can attenuate the expression of the stress cascade through decreasing the activation of the NF-B, which in turn is responsible for the upregulation of adhesion molecules on vascular endothelial cells (Goua, 2003). Omega-3 LCPUFAs from fish oil have similar anti-metastatic
BLUK122-Dijkstra
74
September 25, 2007
20:0
Trans Fatty Acids
effects in animal models implanted with malignant cells (Adams et al., 1990; Karmali et al., 1984).
3.4.3
Reduction of cancer cachexia
Prevention of cachexia in cancer patients and anorexic patients would enhance their quality of life and well-being and allow more time for conventional therapies to be effective. Omega-3 PUFAs have been shown to attenuate cachexia in animal models of cancer (Wigmore et al., 2000) and in human pancreatic cancer (Barber et al., 2001) and prostate cancer patients (S.D. Heys, S. McClinton & K.W.J. Wahle, unpublished observations). The observed effects are regarded as largely due to the attenuation of the inflammatory cytokine tumour necrosis factor (TNF-) and a specific cachectic factor. CLAs also reduce TNF- production in immune cells at the level of gene expression (see below). A recent study reported a similar decrease in cachexia, in TNF- formation by macrophages and an attenuation in inflammatory cytokine formation by endotoxin-challenged splenocytes in a mouse model of cachexia treated with CLA (Yang and Cook, 2003). These observations illustrate a similarity between omega-3 PUFA and CLA effects on certain cells and tissues that could also explain in part their similarities in conferring certain health benefits. Interleukin-6 (IL-6) was also postulated to play a role in cancer cachexia induction due to its effect in reducing lipoprotein lipase activity in mice and in 3T3-L1 adipocytes (Greenberg et al., 1992). In concert with IL-1 and TNF, it is believed that IL-6 induces weight loss mainly through effects on eicosanoid production (Cook et al., 2003). The anti-cachectic effects of CLAs in animal models of the disease (Cook et al., 2003) suggest that they also inhibit IL-6, but direct evidence for this is currently lacking. In contrast, IL-6 production in rat primary adipocytes was not affected by a mixture of CLAs consisting of 36.5% cis-9, trans-11 and 56.6% trans-10, cis-12 at concentrations from 100 nM to 1 mM (Ha et al., 2003). The treatment did, however, decrease leptin production in the adipocytes, but surprisingly, TNF- formation was increased. This contrasts with the observations that CLAs attenuate inflammatory cytokine production in vivo in animals (see below) and more recently in man (Tricon et al., 2004, 2005). Why these differences occur is not apparent at present, but it highlights once again the complexity of in vivo versus in vitro responses to CLAs mentioned above. Table 3.4 summarises some of the reported variable effects of CLAs on angiogenesis, metastasis and cachexia. Table 3.4
Summary of effects of CLAs on angiogenesis, metastasis and cachexia.
Angiogenesis ↓ angiogenesis in vivo and in vitro ↓ angiogenesis and endothelial cell proliferation and DNA synthesis
Masso-Welch et al. (2002, 2004) Moon et al. (2003)
Metastasis ↓ metastasis and ↑ latency period and suppression of tumour in pulmonary tumour ↓ metastasis in human gastrointestinal cancer cells in animal models
Kuniyasu et al. (2006)
Cachexia ↓ cachexia and TNF- production by macrophages in mouse ↓ cachexia in animal model No effect on IL-6 production and ↑ TNF- in rat adipocytes ↓ inflammatory cytokines production in vivo in animals and humans
Cook et al. (2003) Cook et al. (2003) Ha et al. (2003) Tricon et al. (2004, 2005)
Hubbard et al. (2000)
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
3.5
75
EFFECT OF CLAs ON BODY COMPOSITION AND ENERGY METABOLISM IN ANIMALS AND MEN
One of the major interests in the health effects of CLAs relate to their perceived ability to regulate energy metabolism and reduce adiposity. These effects are relatively well established in various animal species, but their role in simple dietary weight reduction strategies is less clear (Bhattacharya et al., 2006; Park and Pariza, 2007; Tricon et al., 2005; Wahle et al., 2004).
3.5.1
Body composition in animals
The effect of CLA in attenuating body fat accumulation appears to be dose responsive and independent of dietary fat content (Delany et al., 1999; West et al., 1998). Dietary intake of CLAs at 0.5–2.0 g/100 g of diet clearly reduced body fat content and in some cases, increased lean body mass in growing animals, like mice, rats and pigs (Bhattacharya et al., 2006; Keim, 2003; Salas-Salvado et al., 2006; Tricon et al., 2005; Wahle et al., 2004). The proposed mechanisms to explain these effects of CLAs include increased lipolysis, enhanced fatty acid oxidation or reduced fatty acid uptake into adipocytes and decreased adipocyte size, decreased energy intake or inhibition of lipogenic enzymes. CLA upregulation of uncoupling protein-2 in white adipose tissue offered another mechanism to explain the increased energy expenditure on CLA feeding in high-fat-fed rats (Choi et al., 2004). These effects are reported to be independent of any changes in food intake. The anabolic effects appear to precede the reduction in body fat (Bhattacharya et al., 2006; Keim, 2003; Park and Pariza, 2007; Tricon et al., 2005; Wahle et al., 2004; Wang and Jones, 2004). CLA-enriched diets reduced adipocyte cell size rather than numbers in rats (Azain et al., 2000). This contrasts with findings in mice where CLA (1% wt/wt) induced apoptosis in adipocytes and reduced white adipose tissue mass (Tsuboyama-Kasaoka et al., 2000). However, in 3T3-L1 adipocytes in vitro, adipocyte proliferation and differentiation was significantly inhibited by CLA (Brodie et al., 1999). The efficacy of CLAs in changing body composition depends on the species and even the specific strain of laboratory animals. Mice are the most responsive to CLAs with levels of 0.5% of diet eliciting between circa 40 and 80% decrease in body fat (Keim, 2003). Increased lean mass and protein accretion was also observed in some studies with mice, sometimes, but not always, without any changes in body weight (Keim, 2003). Rats respond to CLAs in a similar manner to mice but accrete less body fat during active growth phase, and the magnitude of the decreased accretion is less than that observed in mice and is dependent on strain and the specific anatomical site of the adipose tissue (Azain et al., 2000; Keim 2003). CLAs as 0.5% of diet elicited a reduction of circa 25–30% in peritoneal/parametrial fat pad weight in Sprague Dawley rats, only 14% in omental fat but 44% in the epididymal fat pad of Long-Evans rats (Azain et al., 2000; Keim, 2003; Rahman et al., 2001). The effects of 0.5% dietary CLAs in Zucker rats were not as expected. A reduction in retroperitoneal fat pad in the lean phenotype but an increase in the obese phenotype when compared with its control was opposite to the expected effect (Keim, 2003; Sisk et al., 2001). The reasons for this difference are not clear at present but suggest that the genetic predisposition to fat accumulation cannot be attenuated and may even be augmented by CLAs in obese Zucker rats. It is tempting to speculate that the obese phenotype is physiologically equivalent to mature rats. Studies in adult, non-growing animals appear not to reproduce the same dramatic attenuation of fat accretion observed in young, growing animals (Bhattacharya et al., 2006; Tricon et al., 2005;
BLUK122-Dijkstra
76
September 25, 2007
20:0
Trans Fatty Acids
Wahle et al., 2004). Adult Wistar rats fed diets containing 1% of CLA mix or individual isomers in combination with moderate exercise for 6 weeks did not exhibit any effect on body composition or weight (Mirand et al., 2004). This group found that in mature, adult rats, whether sedentary or exercised, CLA isomers induced adipose tissue lipogenesis but without affecting adipose tissue weight (Faulconnier et al., 2004). However, feeding CLA mix to middle-aged C57BL/6 female mice for 10 weeks significantly decreased fat mass, prevented age-dependent loss of lean mass and maintained higher muscle weights compared to corn-oil-fed controls (Bhattacharya et al., 2006; Tricon et al., 2005; Wahle et al., 2004). Most of the earlier research on the body compositional effects of CLAs in animals used mixed isomers. Recent studies show that purified, individual isomers of CLA, cis-9, trans-11 and trans-10, cis-12, have distinct effects on lipid metabolism in these animals. Accumulating evidence suggests that the trans-10, cis-12 isomer and not the cis-9, trans-11 isomer is the one that affects body composition through decreased adipocyte size, increased fatty acid oxidation, increased oxygen consumption and inhibition of lipogenic enzymes. A CLA mix that had the highest ratio of trans-10, cis-12 than cis-9, trans-11 elicited the greatest reduction in body fat in mice and hamsters (Bhattacharya et al., 2006; Gavino et al., 2000; Park et al., 1999; Salas-Salvado et al., 2006; Tricon et al., 2005; Wahle et al., 2004). The effects of CLAs, mainly the trans-19, cis-12 isomer, in modifying body composition through reduction of adiposity seem to be reasonably well established, at least in young, growing laboratory animals if not in older animals. The reduced effect of CLAs in older animals could explain the similar lack of significant effects observed in human volunteers.
3.5.2
Body composition in man
Despite the compelling evidence that CLAs can reduce body fat content in animals, at least in young, growing animals, surprisingly few studies have been conducted to ascertain if the same applies in human volunteers. This is particularly relevant when considering the potential impact on the increasing number of obese subjects in Western populations and the increase in the accompanying diseases of the metabolic (or dysmetabolic) syndrome with its attendant health costs. However, effects of CLAs on human body composition are sparse and contradictory, and most have not shown the significant reduction in body fat observed in animal studies. Small-scale, randomised clinical trials conducted in Norway were the first to investigate the effect of CLA supplementation on body composition in humans (Blankson et al., 2000; Thom et al., 2001). Physically active men and women (ten per group) took either 1.8 g/day of a CLA mix (Tonalin, Natural, Norway) or an olive-oil-control supplement for 12 weeks. No changes in body weight were observed, but the CLA group registered a small, circa 4% decrease in body fat percentage compared to the placebo group. It was interesting that the greatest effects on body fat reduction were found with trained athletes and the suggestion was that CLAs prevented the uptake of fat into the adipocyte. This would make CLAs ideal for the prevention of weight gain common after a weight-reducing regime. A similar study from this Norwegian group was first to examine a possible dose–response relationship between CLA and body fat mass in obese and overweight volunteers (Blankson et al., 2000). Groups were assigned to either a placebo supplement or a 1.7, 3.4, 5.1 and 6.8 g/day CLA mix again for 12 weeks. Body fat mass was significantly decreased in volunteers in the 3.4 and 6.8 g/day groups, but no change in body weight was found. The 6.8 g/day group observed a significant increase in strenuous exercise compared to the other groups. Why the 6.8 g/day group should increase its exercise rate is intriguing but difficult to explain unless CLAs at this upper level of intake influenced brain functions and induced a positive
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
77
mood. It is known that omega-3 LCPUFA can elicit specific changes in brain chemistry at the level of neurotransmitters (Hibbeln et al., 2006). The authors concluded that 3.4 g/day of CLA was sufficient to cause a reduction in body fat in overweight and obese volunteers over the 12-week period. In contrast, when 17 healthy women in a residential study, using a metabolic research centre, were supplemented with CLA (3.9 g/day), no significant effect on body composition or energy expenditure was observed when compared to a sunflower oil placebo. Fat mass changes in these women were variable and ranged from a gain of 0.9 kg to a loss of 3.2 kg (Zambell et al., 2000, 2001). Similarly, an intake of 2.1 g/day of CLA mix for 45 days in sedentary young, but mature, women did not induce any changes in body composition (Petridou et al., 2003). Vessby’s group in Uppsala, Sweden, determined the effect of 4.2 g/day of CLA on body weight and composition in men and women, using a double-blind, placebo-controlled protocol (Smedman and Vessby, 2001). CLA elicited a small reduction in body fat percentage by 1.1%. (Average loss was 0.7 kg compared with 0.2 kg in placebo group.) In a similar study with middle-aged, obese males receiving 4.2 g/day of CLA for 4 weeks there was a decrease in the sagittal abdominal diameter, suggesting a reduction in visceral fat (Riserus et al., 2001). Since visceral fat is a risk factor in the metabolic syndrome, it is conceivable that even a slight reduction due to CLA supplementation might confer benefit in this disease state (see below). A study from Greece with healthy volunteers fed 0.7 g/day for 4 weeks and then 1.4 g/day for another 4 weeks showed a decrease in fat mass in these individuals compared to controls fed a placebo (Mougios et al., 2001). Another randomised placebo-controlled trial in Wisconsin-Madison University was designed to assess the long-term effect (6 months) of 2.7 g/day of CLA intake on body fat and weight loss in obese volunteers (Atkinson, 1999). Body weight and fat mass was reduced by 2.5 and 1.0 kg respectively in both control and CLA groups. No significant effect of CLA was evident and contrasts with the above studies. Some studies with overweight men and women have provided individual CLA isomers as supplements in dairy products (milk drinks and butter) at levels of 1.5, 3.0 or 4.22 g/day for 4–18 weeks but did not find any differences in fat or lean mass. Observations from Gudmundsen’s group in Norway suggest that CLA intake in healthy or overweight, obese subjects undergoing moderate-to-hard exercise have reduced body fat and enhanced lean mass. This suggested that exercise might enhance the effects of CLA in reducing fat mass (Blankson et al., 2000; Thom et al., 2001). Another factor in animal experiments compared to human experiments is that the period of supplementation is often a far greater proportion of a rodent’s life than that of human volunteers, so that the prolonged supplementation period might be required in order to more correctly reflect the animal studies. Recent studies where long-term supplementation protocols with CLA were carried out for 12 and 24 months clearly showed reduced body fat mass in healthy, overweight volunteers and that the supplements were well tolerated (Gaullier et al., 2004, 2005). Clearly, the changes in body composition in man in response to CLA differ between published clinical trials and also between these trials and observations in animals. This is most likely due to the lower dosage (g/kg body weight) of CLAs used in human compared to animal studies and also the fact that growing animals may be more responsive than mature humans. The findings with mature, adult animals suggest that age plays a significant role in the susceptibility to the fat-reducing effects of CLAs. The majority of human CLA studies to date is for non-growing, mature volunteers. Studies with growing, non-mature human volunteers are urgently needed to answer this question. Furthermore, the marked effects of CLA on body composition in rodent models could be due to activation of brown adipose tissue in young animals. This is lost in older animals and does not occur in humans (Klingenberg and
BLUK122-Dijkstra
78
September 25, 2007
20:0
Trans Fatty Acids
Huang, 1999). Body composition in humans, unlike animals, cannot be measured directly, and various prediction equations are used to estimate lean and fat content of volunteers. These predictions have inherent errors. The fact that most of the published human trials used different predictions could be another reason for the differences observed between trials (Keim, 2003). Prediction errors typically range from 1.5 to 2.0 kg for body fat mass to circa 3% for percentage body fat. Hence, the decreases reported in the human trials of about 1.0 kg and 4% in body fat mass are difficult to assess with confidence (Keim, 2003). A greater number of longer term supplementation studies (12–24 months) with growing children/adolescents or with weight-losing people predisposed to weight regain using both a CLA isomer mix of the two main isomers and the individual isomers would clearly determine if CLAs have significant effects on body composition in man. Human studies with a greater number of volunteers than hitherto reported would also give a clearer answer to the question of whether CLAs affect body composition in man.
3.5.3
Possible mechanisms underlying reported changes in body composition
As might be expected from their whole-body effects, in animals, CLAs modulate the activity of key enzymes involved in fat metabolism, both fat storage and mobilization/oxidation. Adipose tissue in mice and rats fed CLAs have a reduced lipoprotein lipase activity and increased lipolysis with enhanced palmitoyl-carnitine acyltransferase (PCAT) activity in various tissues, suggesting a generally enhanced fat mobilisation and oxidation in the aetiology of body fat reduction (Keim, 2003). This is supported by the reports of higher energy expenditure and fat oxidation in CLA-supplemented mice (Keim, 2003; Ohnuki et al., 2001; West et al., 2000). Augmented energy loss does not appear to be related to changes in the expression of mitochondrial uncoupling proteins (Keim, 2003; West et al., 2000). The reduced lipoprotein lipase activity in CLA-supplemented rodents and reduced levels of triacylglycerol and glycerol inside the cells but increased glycerol outside the cells suggest that adipocyte replenishment is impaired (see above). Available evidence suggests that CLAs reduce body fat in animals not only by altering the key enzymes of lipid storage, mobilization and oxidation but also by reducing adipocyte proliferation and differentiation and stimulating apoptosis in pre-adipocytes (Brodie et al., 1999; Keim, 2003; Miner et al., 2001; Satory and Smith, 1999). Observations that feeding mice trans-10, cis-12 isomer markedly reduced leptin and to a lesser extent, adiponectin mRNA in adipose tissue compared with mice fed control or cis-9, trans-11 isomers suggest that the trans-10, cis-12 form may elicit its effects on body composition through changes in levels of these hormones (Warren et al., 2003).
3.5.4
Efficacy of different CLA isomers in regulating body composition
CLAs are usually given as a 50:50 mixture of the two main cis-9, trans-11 and trans-10, cis-12 isomers, although in natural food sources, the cis-9, trans-11 isomer predominates by 30–70:1 (McGuire et al., 1999b; Parodi, 1997, 2003) . However, the effects of the individual isomers on body composition can vary dramatically, and the available evidence from animal and cell culture work suggests that the cis-9, trans-11 isomer is the active anabolic agent responsible for weight gain (not fat accretion), whilst the trans-10, cis-12 isomer is the
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects Table 3.5
Summary of some reported effects of CLAs on body composition in animals and man.
In animals
↓ body fat accumulation ↓ body fat content and ↑ lean body mass ↓ adipocyte size in rats ↑ adipocyte apoptosis and ↓ adipose tissue mass in mice ↓ adipocyte proliferation and differentiation in vitro ↓ body fat in mice ↑ lean mass and protein accretion in mice ↓ adipose tissue in rats No effect on body composition in exercised rats ↓ fat mass and prevention of age-dependent loss of lean mass ↓ body fat in mice and hamster
In humans
No effect on body weight and ↓ in body fat percentage in active men and women No effect on body composition and energy expenditure in healthy women ↓ body fat percentage in men and women ↓ sagittal abdominal diameter in obese men ↓ fat mass in healthy volunteers ↓ body weight and fat mass No effects on fat and lean mass in overweight men and women ↓ body fat and ↑ lean mass in exercised healthy or overweight subjects ↓ body fat mass in healthy overweight volunteers ↑ energy expenditure and fat oxidation in mice
79
Delany et al. (1999); West et al. (1998) Bhattacharya et al. (2006); Keim (2003); Tricon et al. (2005); Wahle et al. (2004) Azain et al. (2000) Tsuboyama-Kasaoka et al. (2000) Brodie et al. (1999) Keim (2003) Azain et al. (2000); Keim (2003) Azain et al. (2000); Keim (2003); Rahman et al. (2001) Mirand et al. (2004) Bhattacharya et al. (2006); Tricon et al. (2005); Wahle et al. (2004) Bhattacharya et al. (2006); Gavino et al. (2000); Park et al. (1999); Tricon et al. (2005); Wahle et al. (2004) Blankson et al. (2000); Thom et al. (2001) Zambell et al. (2000, 2001) Smedman and Vessby (2001) Riserus et al. (2001) Mougios et al. (2001) Atkinson (1999)
Blankson et al. (2000); Thom et al. (2001) Gaullier et al. (2004, 2005) Keim (2003); Ohnuki et al. (2001); West et al. (2000)
effective catabolic agent leading to increased lipolysis and fat oxidation (McGuire et al., 1999b; Parodi, 1997, 2003). The specific effect of trans-10, cis-12 compared to cis-9, trans-11 on hormones regulating energy metabolism have been mentioned (see above; Warren et al., 2003). These isomers have different, sometimes opposing, effects on other physiological systems, and this may be related to their fat-metabolising effects (see below). Table 3.5 summarises some of the reported effects of CLAs on body composition in animals and man.
3.6
OTHER REPORTED HEALTH BENEFITS OF CLAs
CLAs have been reported to elicit both beneficial and detrimental effects on a variety of other important biomarkers of disease. Again, definitive conclusions are difficult to make because of the variety of types and concentrations of the isomers and the different systems studied.
BLUK122-Dijkstra
80
September 25, 2007
20:0
Trans Fatty Acids
3.6.1
Effects on insulin resistance and diabetes
The incidences of both diabetes and its forerunner impaired glucose tolerance are increasing worldwide and are beginning to affect younger populations (Belury, 2003; Belury and Vanden Heuvel, 1999; Houseknecht et al., 1998). The potential cost to the health services of treating this disease and its attendant morbidities such as macro- and microvascular disease, including coronary heart disease, retinopathies and gangrene, is enormous. Central to this disease is obesity, and modest lifestyle changes resulting in a small reduction in body weight (circa 7%) are associated with a significant reduction in the risk of developing diabetes in people at known risk (diabetes-prevention programme). Recent observations indicating that adipose tissue produces inflammatory cytokines as well as hormones like leptin and adiponectin involved in regulation of energy metabolism suggest that adipose tissue plays an important role in normal and aberrant energy homeostasis (Hotamisligil et al., 1995; Yamasaki et al., 2003). The increased inflammatory cytokine formation attributed to adipose tissue in obese people could explain the increased risk of diabetes and cardiovascular disease in this subpopulation, as cytokines increase inflammatory processes in vasculature and increase lipolysis which can lead to insulin resistance (Belury, 2003; Belury and Vanden Heuvel, 1999; Houseknecht et al., 1998). The effect of CLAs on adipose mass in animals and men has been discussed above. The results are controversial, particularly in men, suggesting that reduced adipocity may not be the mechanism that underlies the reported beneficial effect of CLAs on glucose tolerance and insulin resistance (see below). The observations that CLAs reduce adipocytesecreted leptin levels in plasma, a hormone that regulates food intake in diabetic Zucker rats, non-diabetic mice and in humans with type 2 diabetes through hypothalamic signalling pathways (Belury, 2003; Belury and Vanden Heuvel, 1999), may indicate regulation of the most important mechanism for diabetes prevention. Although CLAs reduce food intake in some reported animal experiments, they have no effect in others and no effect in man at a level of 3 g/day, suggesting that reduced food intake may not play a role in CLAs’ effects on glucose metabolism. The reduction in leptin levels with 3 g/day CLA was only transient (see above; Belury, 2003; Belury and Vanden Heuvel, 1999). Also, the known attenuation of inflammatory cytokine production by CLAs in immune cells (Yu et al., 2002), if occurring in adipocytes, could offer another explanation for the beneficial effects of CLAs on diabetes and insulin resistance on obese subjects. Increased insulin resistance appears to be associated with increased visceral adiposity, but a clear explanation why this should be the case has not been promulgated. Although still controversial, the reduction in adipose mass observed in some experiments with human volunteers receiving CLA supplements was most apparent in the visceral region that was also associated with a significant decrease in sagittal abdominal diameter (Riserus et al., 2001). The effects of CLAs on insulin resistance and glucose homeostasis are variable and dependent on species and the type of isomer present (Kelley and Erickson, 2003; Salas-Salvado et al., 2006). Zucker rats fed diets containing a 1.5 g mix of CLA isomers (circa 42% cis9, trans-11 and trans-10, cis-12) or 0.02 g/100 g troglitazone, an anti-diabetic drug and PPAR agonist, resulted in significant reductions in fasting plasma glucose, plasma insulin, triacylglycerols, unesterified fatty acids and leptin compared with control animals. These beneficial effects on impaired glucose metabolism and insulin resistance in Zucker rats were not due solely to reduced food intake (Belury, 2003; Belury and Vanden Heuvel, 1999). In contrast to effects in diabetic rats, chronic feeding of CLA to non-diabetic swine and mice resulted in slight increases in fasting serum glucose and/or insulin (Belury, 2003; Belury and Vanden Heuvel, 1999). Similar slightly adverse effects on insulin and glucose homeostasis
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects Table 3.6
81
Summary of effects of CLAs on insulin resistance and diabetes.
↓ adipocyte-secreted leptin levels in plasma ↓ fasting plasma glucose, plasma insulin, triacylglycerols, unesterified fatty acids and leptin ↑ fasting serum glucose and insulin in non-diabetic swine and mice ↑ serum insulin in healthy women and obese men
Belury (2003); Belury and Vanden Heuvel (1999); Houseknecht et al. (1998) Belury (2003); Belury and Vanden Heuvel (1999); Houseknecht et al. (1998) Belury (2003); Belury and Vanden Heuvel (1999); Houseknecht et al. (1998) Medina et al. (2000); Riserus et al. (2001)
were observed in human volunteers. Healthy women receiving 3.9 g/day CLA mix exhibited a 20% increase in serum insulin compared with controls (Medina et al., 2000), and obese men with metabolic syndrome had a threefold increase in serum insulin compared with a placebo-control group (Riserus et al., 2001). These reported, apparently adverse, effects of CLA in animals and men appear to be largely due to the presence of the trans-10, cis-12 isomer and contrast with the reported beneficial effects of the CLA mix in enhancing insulin sensitivity in rats (see above). Table 3.6 summarises some of the reported variable effects of CLAs on insulin resistance and diabetes.
3.6.2
Modulation of immune functions
Changes in different aspects of immune-inflammatory functions due to ageing, dietary deficiencies or excesses are implicated in the aetiology of common diseases. It is now well established that alterations in the levels of fatty acids have an impact on immune function and both physiological and pathophysiological states. Understanding the molecular interactions between different fatty acids and cell responses in the immune system, especially to differentiate between physical effects and the modulation of key molecules critical to cell function, has become important in our understanding of the balance between health and disease. The major route by which the fatty acid profile of blood lipids and cells can be altered is dietary. Thus, alteration of the dietary profile of fatty acids will be reflected in the fatty acids present in blood and those incorporated into cells. This is especially important in situations that result in profoundly increased levels of free fatty acids in blood, which include trauma, stress, intense exercise and diabetes. These disease states will in turn alter specific cell responses. An especially critical response that can acutely control the balance between health and disease is the immune response to any given situation. The effect of a wide variety of saturated and PUFAs on these immune processes has been extensively studied (Bhattacharya et al., 2006; Grimble, 1998; Harbige, 2003; Tricon et al., 2005; Wahle et al., 2004). However, very little information is available on the effects of the CLAs on immune function in animals and men. The present discussion will review the mechanisms by which CLAs may influence cell function with particular emphasis on immune responsiveness. As the immune response involves many diverse components that can be subdivided into discreet response phases, the discussion will evaluate the impact of CLAs on these individual response phases. 3.6.2.1
Acute phase or inflammatory immune functions
A potential site of interaction for fatty acids is the ‘acute phase response’. The initial response of the immune system to infectious agents, such as the outer cell wall endotoxin (lipopolysaccharide, LPS) of gram-negative bacteria, is the activation of circulating monocytes or
BLUK122-Dijkstra
82
September 25, 2007
20:0
Trans Fatty Acids
tissue-resident macrophages. Monocytes are thought to play a pivotal role during the acute phase response and initiate the repertoire of immunostimulatory responses; they are critical to the overall immune response in vivo. Activated monocytes release a variety of cytokines, including IL-1 and TNF-, which are the primary initiators of the inflammatory response of immune function. This phase is also important in the coordination and maintenance of subsequent phases of the immune response (Dinarello, 1997; Suffredini et al., 1999). IL-1 and TNF- can in turn, via activation of phospholipase A2 , induce the release of PUFA from membrane phospholipids and the formation of eicosanoids, i.e. prostaglandins and leukotrienes, which are formed in many tissues and are integral parts of inflammatory-type reactions. PGE2 is particularly important, as it produces the symptoms of inflammation, such as pain, oedema and fever in a systemic reaction (Dinarello, 1999). In this sequence of reactions the role of specific PUFA is particularly important; the major precursor of prostaglandins is ARA, unless other PUFAs, like eicosapentaenoic acid, have been incorporated into membrane phospholipids. The availability of ARA to the cyclooxygenase or lipoxygenase enzymes can then be altered depending on the presence and level of other, potentially competing, unsaturated fatty acids (Dinarello, 1999). The presence of these competing PUFAs is determined by dietary intake and membrane incorporation (Wahle and Rotondo, 1999). In this context it is intriguing that CLAs are reported to decrease the production of eicosanoids, particularly prostaglandins of the II series, in vivo and in cell cultures (Iwakiri et al., 2002; Ma et al., 2002; Nakanishi et al., 2003; Ogborn et al., 2003). This is not a universal effect, and some cell studies have reported an increase in prostaglandin formation in the presence of CLA (see below). It is not clear at present if the effect of CLAs in inhibiting prostaglandin formation is due entirely to their competition with ARA for substrate in the COX reaction. CLAs are apparently also able to suppress the gene expression of the COX enzymes, indicating a fundamental effect of these fatty acids on gene regulation (Iwakiri et al., 2002). Clearly, attenuation of PGE2 formation would reduce the symptoms of fever and pain accompanying inflammation. CLAs have also been reported to suppress the release of pro-inflammatory cytokines, particularly TNF-, in animals (Akahoshi et al., 2002, 2004; Yang and Cook, 2003). In the study of Akahoshi et al. (2004), a mixture of CLA isomers was able to reduce serum TNF- levels to about 50%, compared to the serum of mice given predominantly linoleic acid. In agreement with these observations, Yang and Cook (2003) showed that feeding CLAs, especially the cis-9, trans-11 isomer, suppressed the production of TNF- in vivo following the injection of LPS compared to a corn-oil-fed group of animals. The cis-9, trans-11 isomer was also able to suppress TNF- production directly when incubated with the macrophage cell-line RAW. This indicated that the observed dietary effects of CLAs may occur directly at the level of the macrophages/monocytes that are responsible for producing the majority of inflammatory cytokines. It is not certain how CLAs, especially the cis-9, trans-11 isomer, can lead to downregulation of pro-inflammatory cytokine production. However, the prime candidates would be those mechanisms that are known to be involved in the suppression of inflammatory cytokine responses. As indicated previously, PGE2 is formed at the end of the sequence of inflammatory mediators and it is also a potent immunosuppressive prostanoid. Pro-inflammatory cytokines appear to mutually induce their own synthesis. This positivefeedback loop appears to ensure mobilisation of the response cascade, possibly to prevent immune failure. The progression of this cytokine cascade can also be limited by the increased levels of PGE2 produced at the end stage of inflammation following sufficient activation of the inflammatory process and of phospholipase A2 (Davidson et al., 2001; Rotondo et al., 1988). Inflammatory immune reactions can thus be controlled and prevented from becoming detrimental to the host by PGE2 acting as a negative-feedback regulator formed at the end of
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
83
the cascade. This is a mechanism that may also occur in vivo. The circulating levels of PGE2 can increase almost tenfold during immunoactivation, indicating a massive upregulation of biosynthesis. LPS administered i.v. can lead to an increase in PGE2 levels to almost 450– 500 pg PGE2 /mL plasma compared to levels of 30–40 pg PGE2 /mL plasma in unstimulated animals given control saline treatment (Davidson et al., 2001; Rotondo et al., 1988). There are two key pieces of evidence that support this downregulatory action of PGE2 . Firstly, in the presence of exogenously added PGE2 , less TNF- and IL-1 is produced in response to LPS. Secondly, an increased production of these cytokines is observed in the presence of inhibitors of PGE2 synthesis, indicating that endogenous prostanoids are actively suppressing cytokine production. In order for CLAs to elicit their anti-inflammatory effects through this pathway, an increase in PGE2 or other inhibitory prostanoids would have to occur. However, it has been reported that CLAs, usually but not always, reduce prostaglandin production, particularly PGE2 , in a variety of metabolic conditions and in different tissues. In a polycystic kidney disease model in rats, dietary CLAs reduced the ex vivo production of PGE2 from interstitial cells (Ogborn et al., 2003). Similarly, CLAs were shown to directly reduce PGE2 release from mammary tumour cells in vitro, which was preceded by a reduction in the availability of ARA (Ma et al., 2002). This indicated a classical interference with the flux of ARA and thus its availability for PGE2 production. Most, but not all, studies to date have indicated a suppression of prostanoids by CLA (see above). Paradoxically, this would be expected to result in increased inflammatory cytokine production according to the mechanism described above. However, very few studies have investigated the effect of CLAs on cytokine-stimulated prostanoid production. One such study has confirmed that CLAs can directly reduce the production of PGI2 from HUVEC reticulated with IL-1 (Torres-Duarte and Vanderhoek, 2003). Antigen-induced PGE2 production from guinea-pig trachea derived from animals given dietary CLA was also reduced (Whigham et al., 2001). Thus, it would seem unlikely that the actions of CLAs, in reducing the release of pro-inflammatory cytokines, are mediated via an enhancement of prostanoid levels, and it would appear that the converse is true. This could more likely be indicative of an effect of CLAs on gene expression of inflammatory cytokines, either directly through fatty acid response elements in the promoter regions of the cytokine genes or through their known effect in activating PPARs that are transcription factors (see below; Wahle et al., 2003). However, a limited number of studies have reported an increase in prostanoid production in the presence of CLAs, which suggests that the prostanoid inhibitory feedback loop cannot be entirely precluded as a regulatory mechanism for cytokine production (Davidson et al., 2001; Ogborn et al., 2003; Rotondo et al., 1988). An explanation for this is not available at present but suggests the possibility that an increase in prostanoid production cannot be entirely precluded as a factor in downregulating inflammatory cytokine formation under certain circumstances. Another potential mechanism related to lipid-induced suppression of cytokine production is via PPARs, as mentioned above. PPARs are activated by a group of structurally diverse compounds, including fatty acids, eicosanoids and drugs, such as the hypolipidaemic fibrates (Kliewer et al., 1997). PPARs can also be activated by the thiazolidinediones, a class of anti-diabetic drugs (oral hypoglycaemics), thus providing a useful tool with which to characterise their distribution and the spectrum of actions that they modulate. Specific thiazolidinediones such as troglitazone and roglitazone have been used to elucidate the role of PPAR- -activated pathways and these compounds have been shown to bind directly to the PPARs (Lehmann et al., 1995). The discovery that PPARs were activated by direct ligand binding leads to a search for the physiological ligand regulator of PPARs, especially PPAR- . A potential candidate, on the basis of binding studies and the ability to functionally
BLUK122-Dijkstra
84
September 25, 2007
20:0
Trans Fatty Acids
activate PPAR- , was 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2). It is now generally accepted that the naturally occurring activating ligand for PPAR- is 15d-PGJ2, which can be derived from prostaglandin D2 (PGD2 ). PGD2 metabolites are major products of ARA metabolism in macrophages, and PGD2 synthase, which is required for 15d-PGJ2 synthesis, is predominantly expressed in macrophages and other immune cells (Urade et al., 1989). Thus, PPAR- potentially possesses an important role in downregulating inflammatory responses by modulating the activity of macrophages/monocytes. Several studies on the role of PPAR- in macrophage functions have confirmed that its activation does indeed attenuate their activity. It has been shown that resting murine macrophages express low levels, whereas activated macrophages express high levels of PPAR- mRNA (Ricote et al., 1998). In addition, in the presence of either 15d-PGJ2 or the thiazolidinedione roglitazone, a specific PPAR- agonist, IFN- -activated macrophages retained the characteristics of resting cells (Ricote et al., 1998). This indicates that activation of PPAR- pathways is capable of halting macrophage activation and inflammation. PPAR- agonists have been shown to inhibit the production of monocyte inflammatory cytokines. In human peripheral blood mononuclear cells, the PMA-induced TNF- and IL-1 synthesis was potently inhibited by PGJ2 and 15d-PGJ2 (Jiang et al., 1998). mRNA for the inflammatory cytokines was also reduced, indicating that PPAR- pathways inhibit cytokine synthesis pre-translationally at the level of gene expression. PPARs act as transcription factors and certain genes contain PPAR response elements (PPAREs) in their promoter regions (Fruchart et al., 1999). It is therefore interesting in relation to their possible mechanisms of action that CLAs can decrease the production of both IL-1 and TNF- whilst activating PPAR- in the murine macrophage cell-line RAW (Yu et al., 2002). In the same study RAW cells were transfected with a mutation of the ligand-binding domain of PPAR- , resulting in a protein which does not lead to activation of downstream pathways. In cells transfected with this protein, CLAs failed to downregulate an inducible nitric oxide synthase (iNOS) reporter construct (Yu et al., 2002). This provides the strongest indication to date that the modulation of immune/inflammatory responses by CLA occurs via a PPAR- –dependent process. It is not clear at present if the effects of CLAs on PPAR- are direct or through some prostanoid metabolite of CLAs. Another major transcription factor that is also closely linked to the activation of the stressstimulated cell signal cascade and consequently to pro-inflammatory cytokine formation is NF-B, which exists in the cell cytosol as an inactivated complex with a specific inhibitor termed IB (Baldwin, 2001). Recent evidence from our laboratory shows that CLAs can also reduce the initial step in NF-B activation, the phosphorylation of the IB component of the inactive complex in cancer cells (Song et al., 2004). The initial IB phosphorylation leads to multiple ubiquitination of the NF-B/IB complex and its subsequent proteosomal degradation with the release of the free NF-B, which is then translocated to the nucleus where it binds to specific sites on the promoter regions of genes encoding for cytokines, adhesion molecules, heat shock proteins and other stress-induced molecules (Baldwin, 2001; Song et al., 2004; Zhang and Young, 2002). It has been suggested that PPARs and NF-B actions are integrated within the cell and that PPARs can inhibit NF-B activation by directly binding the free molecule in a similar manner to IB, thereby preventing its translocation to the nucleus (Delerive et al., 2001). However, it is not clear at present if the effects of CLAs on inflammatory cytokine formation are due to PPAR activation and subsequent NF-B sequestration and inhibition. The latter mechanism is supported by the fact that PPAR/NF-B complexes have been identified in the cytosol of PPAR-activated cells (Delerive et al., 2001). NF-B activation and binding of free NF-B to gene promoter regions is reportedly attenuated by an increase in the reductive state of cells and evidence from our laboratory indicated that
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
85
CLAs, like long-chain omega-3 PUFA, can increase the expression of redox enzymes in cells (Crosby et al., 1996; Sneddon et al., 2003). 3.6.2.2
Adaptive or specific immune functions
The initial acute phase of the immune response also involves an initial set of cytokine signals, which aids the development of a specific immune response over a period of days to weeks. This acute phase relates primarily to either T cells or B cells. These are the only cells within the body that can generate the diversity of gene combinations to provide the many antigen receptors (on T cells) or antibody variations (from B cells) to either transformed cells (infected or otherwise) or circulating foreign agents respectively. The generation of a T-cell response, i.e. the clonal expansion of a T cell whose receptor recognises an antigen presented to it via another cell, can also be linked in the majority of cases to antibody production (DeKruyff et al., 1993). This occurs as a result of the cytokines that are released from the T cell that may influence the isotype of antibody released from a B cell that can initially respond to an antigen and produce antibodies independently of other cells. However, the ‘maturation’ of an antibody response involves the actions of cytokines that can induce isotype switching within immunoglobulins, e.g. from low-affinity IgM to high-affinity IgG subclasses. Perhaps the best example of the influence of T-cell responses on antibody production is the development of B cells that produce IgE classically associated with allergy, i.e. type 1 hypersensitivity. The maturation of an IgE-producing B cell occurs in direct response to the presence of IL-4, the majority of which appears to derive from T cells which have developed a pattern of cytokine release, termed T-helper 2 (TH 2) responses (Del Prete, 1992, 1998). Much attention has focused on the development of T-helper cells that can polarise into a TH 1 response and into the pattern of cytokines that support the continuation of inflammatory responses. This is characterised by the production of IL-12 and IFN- or the production of IL-4 in a TH 2 response that is described above. It is now recognised that the presence of IgE is indicative of a TH 2 response since it is directly stimulated by IL-4 and suppressed by IFN- (Del Prete et al., 1988). Previously, it had been erroneously proposed that the inhibition of a TH 1 response occurred via IL-10 production by TH 2 cells. However, it is now recognised that much higher levels of IL-10 can be produced in response to inflammatory signals (resulting in attenuation of inflammation) in the absence of T-cell participation. It is also accepted that the definitive indicator of TH 2 polarisation is the control of IL-4 gene transcription that is spontaneously expressed in response to the transcription factor GATA-3 in the absence of inhibitory signals following at least two cell divisions (Reiner, 2001). Conversely, the presence of IL-12 inhibits IL-4 transcription and necessarily results in a TH 1 polarisation. How can CLAs influence these adaptive immune responses in a manner beneficial to human health? CLAs can decrease the ex vivo production of IL-4 from splenocytes stimulated with concanavalin A (Yang and Cook, 2003). This would tend to indicate a tendency towards a TH 1 response. This is confirmed by another study in which IgE levels in mice fed CLA were shown to be reduced (Sugano et al., 1998). However, it is unclear what effect CLAs have on the TH 1 profile of cytokines, i.e. IL-12 or indirectly IFN- . Thus, it is uncertain whether this merely reflects a generalised suppression of all immune cell activities or whether CLAs can specifically enhance particular actions. There is some evidence that CLAs can enhance some specific immune functions. For example, CLAs can elicit an enhanced production of protective immunoglobulins, i.e. IgA, IgG and IgM, whilst IgE is simultaneously reduced (Sugano et al., 1998). It has also been reported that CLAs can increase the proliferation of CD8+ T cells in pigs infected with type 2 porcine circovirus (Bassaganya-Riera et al., 2003).
BLUK122-Dijkstra
86
September 25, 2007
20:0
Trans Fatty Acids
These cells are important for an anti-viral and anti-cancer immune response and this increase in CD8+ cells correlates with a decreased morbidity in the CLA-treated animals. An increase in these cells has also been observed in the peripheral blood of pigs following vaccination; the level of CD8+ cells was greatly elevated in animals fed a CLA diet compared to those on a control diet of soya bean oil (Bassaganya-Riera et al., 2001). The authors also observed an increase in the level of natural killer (NK) cells. This suggests that CLAs can enhance the protective immune responses that eradicate intracellular pathogens, such as antibodies and cells (CD8+ and NK cells). But they suppress those responses which can be detrimental to the host animal, such as IgE production or the release of pro-inflammatory mediators. CLAs may, therefore, be useful as a supplement for specific disorders, requiring enhancement of antiviral immune mechanisms in humans. A recent randomised, double-blind, parallel dietary study was conducted with male volunteers who received the main isomers of CLA, cis-9, trans-11 or trans-10, cis-12 in their diets. The number of volunteers reaching protective antibody levels against hepatitis B was almost doubled in the group treated with CLAs in a 50:50 mixture or 80% 9/11 and 20% 10/12 mixture (Albers et al., 2003). However, none of the CLA treatments altered the ability of peripheral blood mononuclear cells to produce pro-inflammatory cytokines ex vivo following stimulation with bacterial endotoxin compared to a sunflower-oil reference group (Albers et al., 2003). This could be a reflection of the concentration of endotoxin used since a lack of cytokine response to such a stimulus could depend on the relative concentrations of both CLA and endotoxin. Another recent dietary study in humans was also not able to show any effect of CLAs on a wide variety of cytokines ex vivo (Kelley et al., 2001). This appears to indicate that the actions of CLAs on the human immune system are limited and that the effects on gross outcomes such as increased protective antibody levels may not be related to effects on cytokines. However, recent observations from our laboratory (Song et al., 2005) contrast with previous reports on the effects of CLAs on immune function in human volunteers in that the pro-inflammatory cytokines TNF- and IL-1 were significantly reduced in those receiving a 50:50 mix of CLAs compared to those receiving placebo. C-reactive protein (CRP) levels in plasma, an indicator of general inflammation, were not significantly altered by CLAs in this study, but it appeared as if the volunteers consisted of responders and non-responders, with some in the CLA group showing decreased CRP levels. IgE levels were also significantly reduced (Song et al., 2005). A lack of any stimulating effect of CLA on CRP has also been reported by others (Tricon et al., 2005), but this contrasts with the increased CRP when trans-10, cis-12 isomer was given to patients (Riserus et al., 2002). This would suggest that the responses in man were not dissimilar to those observed in some, but not all, animal experiments (see above). A study using different mixtures of the two isomers (50:50 and 80:20 of cis-9, trans-11 and trans-10, cis-12) reported a marked increase in proliferation of blood lymphocytes with the 50:50 mix and an opposite decrease with the 80:20 mix in response to phytohaemagglutinin stimulation. This suggested that the greater cis-9, trans-11 isomer content promoted the cellmediated immune response and the trans-10, cis-12 has the opposite effect (Roche et al., 2001). Tricon et al. (2005) reported a lack of effect of either of the common isomers of CLA on PBMNC subsets and inflammatory cytokine production ex vivo, but they showed a dose-dependent reduction in T-lymphocyte activation (assessed by CD69 surface expression, which was inversely proportional to the content of the isomers in the cell lipids). In contrast to the findings by Roche et al. (2001), these authors did not observe any isomer-specific effects on lymphocyte proliferation. CLAs appear to be able to alter immune functions, albeit to a small extent, in animals and men, although published results differ for both within and between species and whether both
BLUK122-Dijkstra
September 25, 2007
20:0
Conjugated linoleic acid effects
87
or only one of the isomers is the effective modulator (Roche et al., 2001; Song et al., 2005; Tricon et al., 2005). In general, the two main isomers of CLAs appear to have similar effects on immune function, although isomer-specific effects have been reported (see above). This contrasts with their different and specific effects on body composition (Tricon et al., 2005). Their effects are not necessarily mediated via an alteration of ARA metabolism or consequent modification of eicosanoid production. CLAs appear to elicit their effects directly or by the modulation of intracellular regulatory pathways, such as PPARs (Roche et al., 2001; Song et al., 2005) and possibly NF-B and AP-1. 3.6.2.3
CLAs and inflammation
The previous section has mentioned the effects of CLAs on inflammatory processes. Again, the evidence in animals appears to be fairly strong but much less so in man (see above). Pharmacological PPAR- agonists inhibited the peripheral blood mononuclear cell synthesis of inflammatory cytokines TNF-, IL-1 and IL-6 at the level of mRNA expression. Since CLAs are known ligands for PPARs, it is conceivable that the observed reduction in inflammatory cytokines with CLAs in the animal studies (see above) and in the human volunteer study of Song et al. (2005) could be due to PPAR activation. However, the precise relationship between CLAs and cellular signal mechanisms in immune cell function requires further detailed investigation before the role of PPARs, other transcription factors and CLAs can be clearly defined. The effect of CLAs on CRP expression, a predictor of CVD, is also controversial (see above). Some authors report increased CRP, especially with the trans-10, cis-12 isomer, and others find no effect or a decrease (Bhattacharya et al., 2006; Riserus et al., 2002; Roche et al., 2001; Song et al., 2005; Tricon et al., 2005; Wahle et al., 2004). This may reflect differences in responsiveness to CLAs between young, healthy volunteers and older, obese subjects and the specific isomer used. Table 3.7 summarises some of the variable effects of CLAs on immune-inflammatory functions reported in the literature.
3.6.3
Effects of CLAs on biomarkers of cardiovascular disease
Cardiovascular disease is regarded as a complex disease with a strong lipid metabolic and inflammatory component targeted on the vascular endothelium. The inflammatory response of the cells in the vascular wall initiate the upregulation of adhesion molecules and the extravasation of lymphocytes and monocytes into the intimal space culminating in foam cell formation and atherogenesis (Bhattacharya et al., 2006; Tricon et al., 2004, 2005; Wahle et al., 2004; Wahle and Rotondo, 1999). Feeding a CLA mix or individual isomers has been shown to reduce the severity of cholesterol-induced atherosclerotic lesions in aortic arch and thoracic aorta in both rabbits and hamsters (Kritchevsky, 1999; Nicolosi et al., 1997). Even when fed at levels as low as 0.1% of the diet, the aortic arch and thoracic aorta atherosclerosis was reduced by 28 and 41% respectively. This was enhanced with increasing dosage of CLAs, such that 0.5% CLA lowered severity of aortic atherosclerosis by 60% and 56% in the arch and thorax respectively (Kritchevsky et al., 2002). The positive effects at the lower levels of dietary CLA intake indicate that levels of CLAs that may be beneficial in preventing heart disease can be achieved in human diets. It is not known what effect long-term ingestion of low levels of CLAs will have on incidence of atherosclerosis in man. The individual isomers of CLA
BLUK122-Dijkstra
88
September 25, 2007
20:0
Trans Fatty Acids
Table 3.7
Summary of effects of CLAs on immune functions.
Acute phase or inflammatory immune response ↓ pro-inflammatory cytokines release in animals ↓ PGE2 production in polycystic kidney disease model rats ↓ PGE2 production in mammary tumour cells ↓ PGE2 production in HUVEC ↓ PGE2 in guinea-pig trachea ↓ IL-1 and TNF- production whilst activating PPAR- in murine macrophages ↓ NF-B activation in cancer cells Adaptive or specific immune response ↓ ex vivo production of IL-4 from splenocytes ↓ IgE levels in mice ↑ production of protective Ig (IgA, IgG and IgM) ↑ proliferation of CD8+ T cells in pigs ↑ proliferation of CD8+ T-cells and NK-cells level ↑ level of protective antibody against hepatitis B in humans No effect on pro-inflammatory cytokines production ex vivo in humans ↓ TNF- , IL-1 production and IgE levels in human ↑ proliferation of blood lymphocytes with 50:50 mix and decrease with 80:20 No effect on PBMNC subsets and inflammatory cytokine production ex vivo Dose dependent ↓ in T-lymphocyte activation
Akahoshi et al. (2002, 2004); Yang and Cook (2003) Ogborn et al. (2003) Ma et al. (2002) Torres-Duarte and Vanderhoek (2003) Whigham et al. (2001) Yu et al. (2002) Song et al. (2004) Yang and Cook (2003) Sugano et al. (1998) Sugano et al. (1998) Bassaganya-Reira et al. (2003) Bassaganya-Reira et al. (2001) Albers et al. (2003) Albers et al. (2003); Kelley et al. (2001) Tricon et al. (2004) Roche et al. (2001) Song et al. (2005); Tricon et al. (2005) Song et al. (2005); Tricon et al. (2005)
had similar effects on atherosclerosis to that observed with the CLA mix that contrasts with the effects of individual isomers on body composition, insulin sensitivity (see above) and some, but not all, cancer studies (see below). An important aspect of the role of CLAs in atherogenesis is the observation that feeding rabbits with pre-established atherosclerotic plaques resulted in plaque regression, an important process that had not been previously reported for dietary fatty acids (Kritchevsky et al., 2004). A similar regression of pre-established atherosclerotic lesions was recently observed in apoE knockout mice fed CLAs (Toomey et al., 2006). This indicates that CLAs may be affecting the lipid transfer out of the plaque. They could, therefore, be of value in treatment of established vascular disease in man. To date, no clinical nutritional studies using CLA treatment have, to our knowledge, been conducted in human volunteers, either on plaque initiation or on regression. The positive, beneficial effects of CLA on atherogenesis described above contrast with the effects reported earlier in C57BL/6 mice fed an atherogenic diet (Munday et al., 1999). Despite dietary CLA eliciting a favourable lipoprotein profile by increasing the HDL:total cholesterol ratio and decreasing the triacylglycerol concentration in serum (both supposed beneficial effects with regard to CVD risk) compared to controls, the CLA increased the development of aortic fatty streaks. Earlier studies with cholesterol-fed rabbits also did not show any effect of feeding 0.5 g/day CLA on fatty streak lesions (Lee et al., 1994). The reasons for these contrasting findings